### An Online Application to Explain Community Immunity with Personalized Avatars: A Randomized Controlled Trial

Hina Hakim, Julie A Bettinger, Christine T. Chambers, S. Michelle Driedger, Eve Dubé, Teresa Gavaruzzi, Anik Giguere, Noah M. Ivers, Anne-Sophie Julien, Shannon E. MacDonald,
Magniol Noubi, Rita Orji, Elizabeth Parent, Beate Sander, Aaron M. Scherer, Kumanan Wilson,
Daniel Reinharz, Holly O. Witteman

### Authors information:

Hina Hakim Title: Dr. Role : Research Associate Qualifications: B.D.S, M.Sc, PhD Affiliated institute: Department of Family and Emergency Medicine, Laval University, Quebec City, QC, Canada VITAM Research Centre for Sustainable Health & Research Centre of the CHU de Québec-Université Laval. Institutional address: 1050 avenue de la Médecine, Pavillon Ferdinand-Vandry 4204, Université Laval, Québec City, Québec, G1V 0A6, Canada, Email: <u>hina.hakim.1@ulaval.ca</u> ORCID: 0000-0003-0517-2621

Dr. Julie A Bettinger Title : Dr. Role : Professor Qualifications: MPH PhD Affiliated institute: Vaccine Evaluation Center, BC Children's Hospital, University of British Columbia Institutional address: 950 West 28th Ave, Vancouver, BC V5Z 4H4 Email:jbettinger@bcchr.ubc.ca ORCID:0000-0002-2118-4174

Christine T. Chambers Title (Dr., Ms., Prof., etc.): Dr. Role : Professor & Canada Research Chair Qualifications (BSc, M.Sc, PhD, etc.): PhD Affiliated institute: Departments of Psychology and Neuroscience and Pediatrics, Dalhousie University, Halifax, NS, Canada Institutional address: IWK Health Centre, Centre for Pediatric Pain Research, 5850/5980 University Avenue, Halifax, Nova Scotia, B3K 6R8 Canada Email:<u>christine.chambers@dal.ca</u> ORCID: 0000-0002-7138-916X

S. Michelle Driedger Title: Dr. Role: Professor Qualifications (BSc, M.Sc, PhD, etc.): PhD Affiliated institute: Department of Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada

Institutional address: S113-750 Bannatyne Avenue, Winnipeg, MB, R3E 0W3 Email: <u>Michelle.Driedger@umanitoba.ca</u> ORCID: 0000-0003-3769-5785

Eve Dubé Title: Dr. Role: Adjunct Professor Qualifications (BSc, M.Sc, PhD, etc.): PhD Affiliated institute: Department of Anthropology, Laval University Quebec City, QC, Canada Institutional address: 1030 Avenue des Sciences Humaines Email: <u>eve.dube@ant.ulaval.ca</u> ORCID: 0000-0003-1336-1510

Teresa Gavaruzzi Title: Dr. Role : Assistant Professor Qualifications (BSc, M.Sc, PhD etc.): PhD Affiliated institute: Department of Medical and Surgical Sciences, University of Bologna, Italy Institutional address: PSYMED c/o Policlinico S. Orsola - Malpighi - PAD 21, 2° Piano Via Massarenti 9 - 40138 Bologna- Italy Email: teresa.gavaruzzi@unibo.it ORCID: 0000-0001-6389-2550

Anik Giguere Title: Dr Role: Professor Qualifications (BSc, M.Sc, PhD, etc.): PhD Institutional address: VITAM Research Centre for Sustainable Health & Research Centre, 2480, chemin de la Canardière, bureau #139 Québec QC G1J 0A4 Email: anik.giguere@fmed.ulaval.ca ORCID:0000-0001-9928-7395

Noah M. Ivers Title: Dr Role: Associate Professor Qualifications (BSc, M.Sc, PhD, etc.): MD, PhD, CCFD Institutional address: , Department of Family & Community Medicine, University of Toronto, 76 Grenville Street Toronto, ON M5S 1B2, Canada Email: <u>Noah.Ivers@wchospital.ca</u> ORCID: 0000-0003-2500-2435

Anne-Sophie Julien Title: Ms Role: Statistical Consultant Qualifications (BSc, M.Sc, PhD, etc.): M.Sc Institutional address: Université Laval, Pavillon Adrien-Pouliot, local 3102, 1050 avenue de la Médecine, Québec (QC), Canada, G1V 0A6 Email: <u>Anne-Sophie.Julien@mat.ulaval.ca</u>

ORCID:0000-0002-5578-1399

Shannon E. MacDonald Title: Dr. Role: Associate Professor Qualifications: PhD, RN Affiliated institute: Faculty of Nursing, University of Alberta, Edmonton, AB, Canada Institutional address: Faculty of Nursing, University of Alberta, Edmonton, AB T6G 1C9 Email: <u>smacdon@ualberta.ca</u> ORCID: 0000-0003-4675-4433

Magniol Noubi Title: Mr. Role : Research technician Qualifications (BSc, M.Sc, PhD, etc.): Affiliated institute: Department of Family and Emergency Medicine, Laval University, Quebec City, QC, Canada Institutional address: 1050 avenue de la Médecine, Pavillon Ferdinand-Vandry 2881, Université Laval, Québec City, Québec, G1V 0A6, Canada Email: <u>magniol.noubi.1@ulaval.ca</u> ORCID: 0000-0002-3040-0326

Rita Orji Title: Dr Role: Professor Qualifications (BSc, M.Sc, PhD, etc.): PhD Affiliated institute: Faculty of Computer Science, Dalhousie University, Halifax, NS, Canada Institutional address: 6050 University Ave. Halifax, NS, B3H 4R2, Canada Email: <u>rita.orji@dal.ca</u> ORCID: 0000-0001-6152-8034

Elizabeth Parent Title: Ms. Role : Research professional Qualifications (BSc, M.Sc, PhD, etc.): M.A. Affiliated institute: Department of Family and Emergency Medicine, Laval University, Quebec City, QC, Canada Institutional address: 1050 avenue de la Médecine, Pavillon Ferdinand-Vandry 2881, Université Laval, Québec City, Québec, G1V 0A6, Canada Email: <u>elizabeth.parent@fmed.ulaval.ca</u> ORCID: 0000-0001-8332-9538

Beate Sander Title : Dr. Role : Senior Scientist and Professor Qualifications (BSc, M.Sc, PhD, etc.): RN MBA MEcDev PhD Affiliated institute: Institutional address: University Health Network, Toronto General Hospital, Eaton Building, 10th Floor, Room 247, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada

Email: <u>beate.sander@uhnresearch.ca</u> ORCID: 0000-0003-2128-9133

Aaron M. Scherer Title: Dr. Role: Assistant Professor of Internal Medicine Qualifications (BSc, M.Sc, PhD, etc.): PhD Affiliated institute: University of Iowa Institutional address: 200 Hawkins Dr., Department of Internal Medicine, Iowa City, IA 52242 Email: <u>aaron-scherer@uiowa.edu</u> ORCID: 0000-0002-4134-9300

Kumanan Wilson Title: Dr. Role: Senior Scientist and Professor Qualifications (BSc, M.Sc, PhD, etc.): MD, MSc, FRCP(C) Affiliated institute: Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada Bruyere Research Institute, Ottawa, Ontario, Canada Email: <u>kwilson@toh.ca</u> ORCID: 0000-0002-1741-7705

Daniel Reinharz Title: Dr Role: Professor Qualifications (BSc, M.Sc, PhD, etc.): MD, PhD Affiliated institute: Department of Social and Preventive Medicine, Laval University, Quebec City, QC, Canada Institutional address: 1050 avenue de la Médecine, Pavillon Ferdinand-Vandry, Université Laval, Québec City, Québec, G1V 0A6, Canada Email: daniel.reinharz@fmed.ulaval.ca ORCID: 0000-0003-4433-059X

Holly O. Witteman Title: Dr. Role: Professor Qualifications (BSc, M.Sc, PhD, etc.): PhD Affiliated institute: VITAM Research Centre for Sustainable Health & Research Centre of the CHU de Québec-Université Laval. Department of Family and Emergency Medicine, Laval University, Quebec City, QC, Canada Institutional address: 1050 avenue de la Médecine, Pavillon Ferdinand-Vandry 4482, Université Laval, Québec City, Québec, G1V 0A6, Canada Email: holly.witteman@fmed.ulaval.ca ORCID: 0000-0003-4192-0682

#### **Corresponding author:**

Holly O. Witteman, 1050 avenue de la Médecine, Pavillon Ferdinand-Vandry, Université Laval, Québec City, Québec, G1V 0A6, Canada, telephone: 418.656.2131, fax: 418-656.2465, email: holly.witteman@fmed.ulaval.ca

**Keywords:** Community immunity; Herd immunity; Vaccination; Vaccination Hesitancy; Visualization; Data Visualization; Digital Health; Randomized Controlled Trial

# Abstract

Background: To evaluate the effects of a web-based, personalized avatar intervention conveying the concept of community immunity (herd immunity) on risk perception (perceptions of the risk of infection spreading (to self, family, community, and vulnerable individuals)) and other cognitive and emotional responses across 4 vaccine-preventable disease contexts: measles, pertussis, influenza, and an unnamed "vaccine-preventable disease."

Methods: Through a robust user-centered design process, we developed a web application, "herdimm," showing how community immunity works. In our application, people personalize a virtual community by creating avatars (themselves, 2 vulnerable people in their community, and 6 other people around them; e.g., family members or co-workers.) Herdimm integrates these avatars in a 2-minute narrated animation showing visually how infections spread with and without the protection of community immunity. The present study was a 2x4 factorial randomized controlled trial to assess herdimm's effects. We recruited 3883 adults via Qualtrics living in Canada who could complete an online study in English or French. We pre-registered our study, including depositing our questionnaire and pre-scripted statistical code on Open Science Framework (https://osf.io/hkysb/). The trial ran from March 1 to July 1, 2021. We compared the web application to no intervention (i.e. control) on primary outcome risk perception, divided into objective risk perception (accuracy of risk perception) and subjective risk perception (subjective sense of risk), and on secondary outcomes-emotions (worry, anticipated guilt), knowledge, and vaccination intentions-using analysis of variance for continuous outcomes and logistic regression for dichotomous outcomes. We conducted planned moderation analyses using participants' scores on a validated scale of individualism and collectivism as moderators.

Results: Overall, herdimm had desirable effects on all outcomes. People randomized to herdimm were more likely to score high on objective risk perception (58.0%, 95% confidence interval 56.0%-59.9%) compared to those assigned to the control condition (38.2%, 95%) confidence interval 35.5%-40.9%). Herdimm increased subjective risk perception from a mean of 5.30 on a scale from 1 to 7 among those assigned to the control to 5.54 among those assigned to *herdimm*. The application also increased emotions (worry, anticipated guilt) (F(1,3875)=13.13, p<0.001), knowledge (F(1,3875)=36.37, p<0.001) and vaccination intentions (Chi-squared(1)=9.4136, p=0.002). While objective risk perception did not differ by disease (Chi-squared(3)=6.94, p=0.074), other outcomes did (subjective risk perception F(3,3875) =5.6430, p<0.001; emotions F(3,3875)=78.54, p<0.001; knowledge (F(3,3875)=5.20, p=0.001); vaccination intentions Chi-squared (3)=15.02, p=0.002). Moderation models showed that many findings were moderated by participants' individualism and collectivism scores. Overall, whereas outcomes tended not to vary by individualism and collectivism among participants in the control condition, the positive effects of herdimm were larger among participants with more collectivist orientations and effects were sometimes negative among participants with more individualist orientations.

Conclusions: Conveying the concept of community immunity through a web application using personalized avatars increases objective and subjective risk perception and positively influences intentions to receive vaccines, particularly among people who have more collectivist worldviews. Including prosocial messages about the collective benefits of vaccination in public health campaigns may increase positive effects among people who are more collectivist while possibly backfiring among those who are more individualistic.

# Introduction

Many vaccines protect against disease by not only preventing infection in those receiving the vaccine but also preventing the infection from being transmitted from one person to another [1,2]. Such transmission prevention can occur because the vaccines confer sterilizing immunity, because they lower viral load and therefore partially prevent transmission, and/or because, by lowering infection risk, they decrease the number of people within a population who are infected and thus lower the chances of interacting with an infectious individual [3].

The concept of community immunity, also known as herd immunity, refers to the indirect protection of unvaccinated or undervaccinated people by increasing the number of people around them who have immunity. Such an increase in immunity can break the chain of transmission by decreasing the overall probability of contact with an infectious agent, thereby preventing the spread of infectious agents within susceptible populations [1].

Despite the success of vaccines and immunization programs as public health measures, some people perceive such measures as unsafe or even unnecessary [4,5]. The reasons behind such perceptions include concerns about vaccine safety, a mistrust in healthcare agencies or pharmaceutical companies, unfamiliarity with vaccine-preventable diseases, and inaccurate mental models that ignore community immunity [6–9]. Providing accurate education about community immunity may be useful for increasing willingness to vaccinate, generating benefits both to individuals and communities, although the success of these efforts may depend on the extent the population of interest is more collectivist or more individualist [10,11].

The COVID-19 pandemic provided a salient example of the challenge of ensuring public understanding of individual and collective benefits of vaccines. On top of already-existing public health communication challenges regarding established vaccines, there was uncertainty about community immunity thresholds due to fluctuating estimates of the disease's reproductive number [12], new variants reducing vaccine effectiveness [13], the lack of sterilizing immunity offered by available vaccines, and evolving hybrid immunity due to widespread infection [14]. The Covid-19 pandemic therefore highlighted both the importance and the difficulty of communication strategies emphasizing individuals' roles in reducing transmission and protecting vulnerable people within communities [13].

In a previous systematic review, we identified graphic visualization as a potentially promising approach for achieving effective communication about community immunity [15]. Visualization is a powerful communication mechanism that uses pre-attentive processing to communicate large amounts of information rapidly in understandable and compelling ways [16]. While some visualizations about community immunity existed, few had been evaluated for their effects on vaccination intentions and uptake nor on vaccine uptake's precursors, namely knowledge, attitudes, beliefs and emotions. Furthermore, none had been evaluated in multiple disease contexts [15]. Because disease transmission dynamics and community immunity parameters (for example, vaccine effectiveness) differ across vaccine-preventable diseases, ideally, an effective means of conveying the concept of community immunity should be usable across multiple diseases. Finally, no existing visualizations used personalized avatars. Studies of the Proteus Effect have shown that people identify with a personalized avatar to the point that they change their behaviour according to their avatar's characteristics [17–19], suggesting that personalized avatars in a community immunity visualization may reinforce people's sense of actually being part of the community. This sense of community would ideally make the

visualization more salient and personally relevant, thus influencing risk perception, a key antecedent of vaccine uptake. [20,21]

Risk perception refers to the perceived severity and likelihood of an adverse event. Risk perception may draw on an individual's comprehension of the objective likelihood of events, and also on an individual's subjective feelings about the severity and likelihood of events. This latter subjective dimension of risk perception is referred to as the 'risk as feelings' framework [22] which aligns with observations of people's reactions to danger as instinctive and intuitive [23,24]. When people receive information about health risks, they may translate it intuitively into feelings of anxiety, worry, or distress, or a more vague feeling of 'badness' associated with the risk [25,26]. Risk perception influences vaccine decisions and behavior by shaping how individuals perceive and weigh the risks of vaccination against the risks of not getting vaccinated [27,28]. Therefore, when seeking to understand the impact of an educational intervention about community immunity, its effects on risk perception are of particular interest.

# Objective

Our study objective was to evaluate a previously-developed web application, hereafter referred to as *herdimm*. The main purpose of *herdimm* was to clearly convey the concept of community immunity to people from various backgrounds, including varying levels of education. We developed it with attention to its potential effects on people's feelings relevant to their role in community immunity [29]. In the web application, people personalize a virtual community by creating avatars representing themselves, 2 vulnerable people in their community, and 6 other people around them; for example, family members or co-workers. The web application integrates these avatars in a 2-minute narrated animation explaining how community immunity works [30,31].

In this study, we aimed to evaluate the effects of *herdimm* on risk perception (that is, perceptions of the risk of spreading infection to oneself, one's family, one's community, and vulnerable individuals within one's community), and on known antecedents of decisions to get vaccinated across four vaccine-preventable disease contexts. Our research questions were therefore:

- 1. Does *herdimm* influence risk perception (meaning vaccine-preventable disease risk to oneself, family, community and vulnerable people) compared to a control (no intervention)?
- 2. Does *herdimm* influence other outcomes (vaccination intentions, emotion, knowledge, and trust in information) compared to a control (no intervention)?

# Methods

# Study design

We conducted a 2 (visualization: *herdimm*, no education about community immunity) x 4 (disease: measles, pertussis, flu, unnamed "vaccine-preventable disease" hereby referred to as "generic") factorial randomized controlled trial among adults in Canada using Qualtrics, an online survey platform. The study arms differed by the two independent variables (visualization and disease). In other words, participants in different arms saw either no intervention (control) or the herdimm intervention (*herdimm*) for one of four possible vaccine-preventable diseases. For efficient data collection, the present 2x4 trial (8 study arms) conducted in both English and

French was complemented by a head-to-head comparison of existing available interventions about community immunity, most of which were available only in English and none of which offered different versions for different diseases. This complementary study added 5 arms to the larger study and will be reported separately.

## Interventions

The main intervention was the application named *herdimm*, developed in our previous study [29]; web development code available on GitHub (https://github.com/Witteman-Lab/herdimm). A version of *herdimm* (measles/generic, English) is shown here on YouTube for illustration: [30]. Links to sample visualizations of all possible *herdimm* versions are available in <u>Appendix 1</u>.

In the current study, we assessed the effects of *herdimm* across four possible diseases (measles, pertussis, flu/influenza, and generic). We tested the intervention across multiple diseases because disease transmission varies (including the number of new infections caused by the first infected person in a population) and community immunity parameters differ across vaccine-preventable diseases. Among other differences, for some diseases such as measles, a high vaccination rate can achieve a sufficient level of community immunity. For other diseases such as influenza, vaccines must be complemented by other protective measures to optimize protection of all members of a community. Therefore, it was important to assess whether any potential effects would be robust and would generalize across infectious diseases with different transmission characteristics. For the "generic" condition, we used the visualization for measles, but did not specify the disease and merely referred to, "a vaccinepreventable disease," in all questions. For example, participants assigned to the measles condition were asked to indicate their level of agreement or disagreement with the statement, "I am worried about getting measles," while the equivalent item for those assigned to the generic disease was, "I am worried about getting a vaccine preventable disease." We developed herdimm in both official languages of Canada (English and French), and the trial was conducted in both languages.

## **Randomization and allocation**

We used computerized randomization within Qualtrics [32] to automatically assign participants to study arms randomly. Each study arm was accessible in both languages and we pre-specified our sampling parameters such that 75% of the sample for each study arm would be people who elected to participate in English and 25% in French, based on the percentage of spoken languages within the Canadian population [33]. This was a single-blinded study because we could not mask participants to the fact that they have been randomized to a computer application including a visualization. However, participants did not know the purpose of the study arm to which they were assigned, and investigators were blinded to the study arm during the data collection and in the pre-scripted statistical code.

# Ethics and trial registration

This study was approved by the ethics committee of Laval University. We pre-registered the trial at ClinicalTrials.gov (NCT04787913). We pre-planned all statistical analyses by developing our statistical code prior to beginning the trial using simulated data with the support of a statistician (ASJ). This pre-scripted statistical code was also peer-reviewed by an external

statistician. We pre-registered all study materials (protocol, study questionnaire, data dictionary, and pre-scripted statistical code) on Open Science Framework on February 26, 2021 (<u>https://osf.io/hkysb/</u>). We report the trial following the CONSORT guidelines [34]. The trial began on March 1, 2021 and ended on July 1, 2021.

# **Study participants**

We conducted the online randomized controlled trial in Qualtrics among adults living in Canada. Participants were recruited using established survey panels subcontracted in Qualtrics. Participants were eligible if they were 18 years and above, residing in Canada, able to use a computer, could read and understand at least one of French or English, and were able to provide consent. Those who did not meet this criteria were excluded from the study. We used sampling quotas in an effort to represent key characteristics of the Canadian population in the most recent national census [35]. Specifically, we required that the overall sample population for the study consisted of 50% people who identified as female, 49% as male, and 1% as other (e.g., non-binary, two spirit). Regarding age, 30.5% of the study population were required to be within the age group 18-34 years old, 34.4% within 35-49 years old, and 35.2% within the group aged 50 years and older. For education level, we specified that 25-35% of the study population must report their highest education level as elementary school (completed or not) or high school diploma, 10-15% as apprenticeship or trade certificate or diploma, 20-25% as college or polytechnical school certificate or diploma, and 30-40% as university degree or above. Finally, we required a minimum of 22% of the study population to report their racial identity as other than white, and 25% of the study population to be French speakers. A small incentive (typically \$1-1.50, depending on panel) was offered to the participants to complete the survey.

# Outcomes

Our primary outcome was risk perception. We chose this as our primary outcome as people's decisions regarding vaccination depend on their perception of risks associated with diseases and vaccines, including vaccine safety and potential side effects. Such risk perceptions may be formed long before they are presented with a decision to vaccinate or not, suggesting that interventions that shape such perceptions may be important upstream influences on subsequent vaccine acceptance. High risk perception of vaccines, science and effective communication can alleviate risk perception and increase vaccination intentions [36]. We defined risk perception for this study as the participants' sense of risk posed by a vaccine-preventable disease to an individual, their family, their community, and vulnerable people in their community. Secondary outcomes were measures of emotions (worry, anticipated guilt), knowledge about community immunity, and vaccination intentions.

## Measures

We measured our primary outcome using questions developed and pre-tested to assess risk perception (6 items, Figure 1 and Table 1). Based on this pre-testing, we were concerned that the first item might be measuring a different construct than the other five items. Our pre-scripted analyses (written prior to starting data collection, with this potential difference in mind) suggested this was indeed the case. Specifically, the scatter plot and Bland-Altman test (see Figures S1 S2 in <u>Appendix 2</u>) showed that the first item did not measure the same construct as the second through sixth items. We therefore divided the six items into *objective risk* 

*perception* (Figure 1; item 1, which assessed how people perceived risk compared to actual risk) and *subjective risk perception* (Table1; items 2 to 6, which assessed people's subjective feelings of risk.) The Cronbach alpha for subjective risk perception was 0.76, which is acceptable for combining 5 items into a single measure.

### Figure 1. Objective risk perception (condition: measles)

Imagine there are two groups of 100 people each. In one group, there is 1 UNvaccinated person surrounded by 99 vaccinated people. In the other group, there is 1 vaccinated person surrounded by 99 UNvaccinated people. Who is at higher risk of getting infected with measles?

The 1 UNvaccinated person surrounded by 99 vaccinated people is at higher risk.

They are both equally at risk.

The 1 vaccinated person surrounded by a group of 99 UNvaccinated people is at higher risk.

### Table 1. Subjective risk perception

Please indicate the extent to which you agree or disagree with the following statements. (Response options: 1 = strongly disagree, 2 = moderately disagree, 3 = slightly disagree, 4 = neutral, 5 = slightly agree, 6 = moderately agree, 7 = strongly agree)

A person's decision to be vaccinated or not against {{measles/pertussis/the flu/a vaccine preventable disease}}\* affects only them, individually.

People who are vaccinated against {{measles/pertussis/the flu/a vaccine preventable disease}} are less likely to pass it on to others.

My decision to be vaccinated against {{measles/pertussis/the flu/a vaccine preventable disease}} has no impact on anyone else's chances of catching {{measles/pertussis/the flu/that vaccine preventable disease}}

My decision NOT to be vaccinated against {{measles/pertussis/the flu/a vaccine preventable disease}} has no impact on anyone else's chances of catching {{measles/pertussis/the flu/that vaccine preventable disease}}

If I get vaccinated against {{measles/pertussis/the flu/a vaccine preventable disease}}, it lowers the risk of vulnerable people in my community (babies, young children, older people, cancer patients) getting sick.

\*{{measles/pertussis/the flu/a vaccine preventable disease}} indicates all four possible conditions. Each participant in the study was randomly assigned to view the entire study, including all questions, with only one of these four.

We measured emotions by asking participants to indicate their level of agreement using a 7-point Likert-type scale from strongly agree to strongly disagree with 5 items including, for

example, "I am worried about people in my life (family, friends) getting {{measles/pertussis/flu/a vaccine preventable disease}}, " and "I would feel guilty if someone in my life (a family member, a friend) got {{measles/pertussis/flu/a vaccine preventable disease}} from me". We measured knowledge about community immunity by asking participants to respond to 15 items with response options that were either multiple choice or true/false/I don't know. Items included, for example, "A vaccine preventable disease can spread from one person to another person," and, "Unvaccinated people in a population can be protected from infections when enough people in their community are vaccinated." We measured vaccination intentions by asking people to indicate their likelihood of getting a free vaccine against the disease in question on a 100-point slider labeled "extremely unlikely, I would definitely NOT be vaccinated" at one end and "extremely likely, I would definitely BE vaccinated" at the other end. Specifically, the wording of the question was, "If you were eligible to receive a free vaccine against measles/pertussis/flu/a vaccine preventable disease, how likely would you be to get vaccinated?" <u>Appendix 3</u> provides the complete questionnaire.

## **Covariates and Moderating Variables**

### Individualism and collectivism

We used validated measures of individualism and collectivism from the cultural orientation scale [37] as moderating variables. This scale measures four dimensions of individualism and collectivism: horizontal individualism, vertical individualism, horizontal collectivism, and vertical collectivism. Horizontal Individualism is about, "seeing the self as fully autonomous, and believing that equality between individuals is the ideal." Vertical Individualism is about, "seeing the self as fully autonomous, but recognizing that inequality will exist among individuals [and] accepting this inequality." Horizontal Collectivism is about, "seeing the self as part of a collective but perceiving all the members of that collective as equal", while Vertical Collectivism is about, "seeing the self as a part of a collective and being willing to accept hierarchy and inequality within that collective." [38] All questions are answered on a 9-point Likert-type scale, where 1 indicates, "never or definitely no," and 9 indicates, "always or definitely yes." We included this scale to assess whether a person's orientation towards individualism or collectivism might change the effects that *herdimm* might have on their risk perception, emotions, knowledge, and vaccination intentions.

### **Demographics**

We used socio-demographic variables as covariates: born in Canada, age, gender, ethnicity, education level, income, disability, and preferred language. (All question wordings in English and French are available in <u>Appendix 3</u>.)

## Sample size

To determine the sample size for a  $2^*4$  factorial randomized controlled trial using a two-way analysis of variance, assuming a small effect size (Cohen's f=0.10), power of 80% (beta = 0.80), 5% type 1 error (alpha = 0.05), we determined that we required n=302 participants per group. We increased this to n=320 per group to allow for a secondary analysis (study reported separately) in which we would be comparing five groups in a one-way analysis of variance using only the English-speaking participants. The sample size of *herdimm* arms was then doubled to enable an embedded study (secondary to this work, not reported in this manuscript) of male versus female voice for the narration. This enabled more precise estimates of the

effects of the herdimm intervention. We estimated the sample size by using G\*power, version 3.1.9.2 [39] for a continuous outcome.

## **Statistical analysis**

To determine the effects of *herdimm* compared to control, we performed a two-way analyses of variance using the two independent variables (visualization, disease) and their interaction (visualization\*disease) for continuous outcomes (subjective risk perception, knowledge, emotions) and logistic regression for dichotomous outcomes (objective risk perception, vaccination intentions.)

As planned in our pre-scripted statistical analyses written prior to collecting data, we transformed outcomes from continuous to dichotomous whenever the distribution did not respect the assumptions of the models described below; for example, if there were ceiling effects. This was the case for two variables: objective risk perception and vaccination intentions. For objective risk perception, we had set a minimum value of 80 out of 100 as a cutoff indicating high risk perception because our pre-testing had suggested that we might observe ceiling effects on this variable. For vaccination intentions, we had pre-scripted a median threshold in the event of model assumption violations. We therefore dichotomized vaccination intentions as being at/above the median or below the median.

We analyzed 3 models for each outcome. We chose our primary model to examine overall effects, and subsequent models to examine the robustness of results when adjusted for covariates or in the presence of moderators. Accordingly, we first determined the effects of factors (visualization and disease) without any covariates on each outcome (Model 1). For Model 2, we first examined our planned covariates and collapsed categories containing less than 5% of participants (that is ethnicity, language, education levels, and disability.) We used Model 2 to determine the effects of factors (visualization and disease) with adjustment for covariates (socio-demographic characteristics, individualism and collectivism.) Next, we determined the moderating effects of individualism and collectivism with adjustment for socio-demographic covariates (Model 3). Our overall 3-model approach is summarized in table 2 below.

Model	Analytical goal			
Model 1 (primary model)	Check for effects of factors without any covariates			
Model 2	Check for effects of factors with adjustment for covariates (individualism and collectivism born in Canada, age, gender, ethnicity, education level, income, disability, and preferred language)			
Model 3	Check for moderating effects of individualism & collectivism with adjustment for other covariates (born in Canada, age, gender,			

### Table 2. Models used for analysis

ethnicity, education level, income, disability,
and preferred language)

For simplicity here, we report only Model 1 results when these results remained consistent after adjusting for covariates in Model 2. When inclusion of covariates affected the results, we also report the adjusted (Model 2) results. We report results from Models 3 when these showed statistically-significant interactions. We report group-based means with 95% confidence intervals for continuous variables (i.e., subjective risk perception, knowledge, emotions) and probabilities of being at or above the median with 95% confidence intervals for the dichotomous variables (i.e., objective risk perception, vaccination intentions.)

To address missing outcome data, we also repeated all the primary models after using data imputation for any missing outcome values. To do this, fifteen multiple imputation datasets were generated. The primary author (HH) and a statistician (ASJ) compared results, examining whether results from analyses of the imputed datasets replicated or contradicted analyses from the original dataset.

We performed all analyses using R version 4.1.0 [40]. We used the package *psych* (version 1.9.12.31) [41] for descriptive analyses, the packages *stats*, *car* (version 3.0-8) [42] and *emmeans* [43] for the analyses of variance and logistic regressions, and the package *mice* (version 3.11.0) [44] for multiple imputation. We developed statistical code with the support of a statistician (ASJ), using simulated data prior to collecting study data. An external statistician peer reviewed the R code prior to conducting the study. We preregistered the statistical code in Open Science Framework on February 26th, 2021 (<u>https://osf.io/hkysb/</u>).

## **Data collection methods**

The trial ran from March 1 to July 1, 2021. After providing consent, each participant was randomized into a single study arm. All participants completed the same post-intervention questionnaire containing questions about risk perception, emotion, knowledge, vaccination intentions (see <u>Appendix 3</u> for the complete questionnaire.)

## Data management

In order to be considered as contributing valid data, participants randomly allocated to intervention arms were required to spend a predetermined amount of time viewing and/or interacting with the intervention. These time requirements were set based on the minimum time possible for each intervention: control = no minimum restrictions; *herdimm* = minimum 206 seconds. To determine the minimum length of time, we calculated the shortest possible interaction time with the narrated animation, assuming very high internet speed and near-instantaneous transitions between the survey and the web application. Participants whose timestamps on the survey page were less than the predetermined minimum were excluded from the dataset. All the information we collected was kept confidential and used for research purposes only. Data was stored on Qualtrics servers located in Canada and subject to Canadian data privacy laws. Anonymized data are available at Université Laval's Dataverse, Boréalis: <a href="https://doi.org/10.5683/SP3/41MWKO">https://doi.org/10.5683/SP3/41MWKO</a>.

# Results

Of 18509 participants who started the study, 3883 participants were eligible for the analysis. Most excluded participants (n=10724) were excluded because their timestamps showed that they did not view the complete *herdimm* intervention. Figure 2 shows the CONSORT flow diagram.



\*Excluded due to lack of clicking/going through Herdimm website or not completing the study

### Figure 2. CONSORT flow diagram

Note: Non-applicable elements of the CONSORT template were removed. There was no time interval between intervention allocation and follow-up.

We collapsed covariate categories containing less than 5% of the total sample within that covariate. For example, when the people identifying as a particular ethnicity comprised less than 5% of the total sample, we collapsed that category with the closest other category within that covariate to facilitate analysis. Specifically, the covariate *ethnicity* (in which participants could select multiple options) was planned to have grouped categories Asian, Black, Indigenous, Maghrebian/Middle Eastern, white, and others (e.g., Latin American, self-reported "other"). However, because the Black, Indigenous, and Maghrebian/Middle Eastern groups each represented <5% of the total sample, categories were reduced to Asian, white, and others. Along the same lines, to account for low counts in some of the seven *education levels*, we recoded this covariate as *college degree and above* and *no college degree* (elementary

school, high school diploma, or apprenticeship or trade certificate or diploma.) Similarly, due to low counts of people identifying as having a disability that specifically affects their ability to use technology like computers, we merged this covariate with the larger group of people identifying as having any disability. In the new, merged covariate *disability*, anyone indicating a disability of any kind (technical or other) was coded as having a disability. When no other category was available or when merging with another category would be inappropriate, as was the case for *gender identity*, we coded those data as missing rather than assigning those participants to a larger gender group. Similarly, the covariate *language* was planned to include French, English and other languages, but due to low counts for other languages, only the French and English categories remained.

Of 3883 participants, 50% identified as female, 49% as male. Eighty-one percent were comfortable communicating in English with their healthcare professional, and 24% in French. Eighty-two percent of the participants identified themselves as white, a category including white North American and white European. Ten percent identified themselves as Asian, a category including East, Central, South, Southeast Asian. Twenty-three percent participants reported a disability, while 75% reported no disability. Sixty-one percent of the participants reported higher education (college degree or higher) and 39% lower education (no college degree). Eighty-five percent of participants indicated their place of birth as in Canada. Table 3 shows details of participants' characteristics across the study. Results per arm are shown in <u>Appendix 4</u>. Full results of all analyses using all models are available in <u>Appendix 5</u>.

Characteristic		Study population*
Age: median (IQR)		42 (32-57)
Gender identity: n (%)		
	Male	1914 (49%)
	Female	1934 (50%)
	Not available**	35 (1%)
Language(s) spoken: n (%)		
English	Yes	3144 (81%)
	No	734 (19%)
	Not available	5 (0)
French	Yes	937 (24%)
	No	2946 (76%)
	Not available	-
Ethnicity: n (%)		

Table 3. Participants' characteristics (N=3883)

White	Yes	3172 (82%)
	No	645 (17%)
	Not available	66 (2%)
Asian	Yes	385 (10%)
	No	3432 (88%)
	Not available	66 (2%)
Other	Yes	269 (7%)
	No	3548 (91%)
	Not available	66 (2%)
Disability: n (%)	Yes	883 (23%)
	No	2924 (75%)
	Not available	76 (2%)
Education levels: n (%)		
	College degree and above	2361 (61%)
	No college degree (elementary school, high school, apprenticeship or trade certificate)	1497 (39%)
	Not available	25 (1%)
Born in Canada: n (%)	Yes	3303 (85%)
	No	536 (14%)
	Not available	44 (1%)
Individualism and collectivism: mean (SD)	Vertical individualism (e.g., "It is important that I do my job better than others.")	5.12 (1.65)
	Horizontal individualism (e.g., "I rely on myself most of the time, I rarely rely on others.")	7.22 (1.16)
	Vertical collectivism (e.g., "It is important to me that I respect the decisions made	6.83 (1.39)

by my groups.")	
Horizontal collectivism (e.g., "I feel good when I cooperate with others.")	6.85 (1.33)

\*Percentages may add up to +/-100% because of rounding.

\*\*Data could be not available due to participants choosing another option (e.g., gender-nonconforming), choosing, "I prefer not to answer," or leaving the question unanswered.

## Primary outcome (risk perception)

### **Objective risk perception**

Compared to participants in the control condition, those in the *herdimm* condition had significantly higher odds of providing a correct objective risk perception response (Chi-squared (1) = 134.54, p < 0.001). More specifically, people who were assigned to *herdimm* were more likely to understand that 1 unvaccinated person surrounded by 99 vaccinated people is more protected from infection than 1 vaccinated person surrounded by 99 unvaccinated people (58.0%, 95% confidence interval 56.0%-59.9%) compared to those assigned to the control condition (38.2%, 95% confidence interval 35.5%-40.9%). There was no main effect of disease (measles, pertussis, flu, generic vaccine-preventable disease) (Chi-squared (3) = 6.94, p = 0.074), and no statistically-significant interaction between intervention and disease (Chi-squared (3) = 1.19, p = 0.755). These results did not change when including covariates (Model 2) or when testing for moderation effects (Model 3).

### Subjective risk perception

Participants assigned to the *herdimm* condition had higher subjective risk perception compared to those assigned to the control condition (F(1,3875) = 28.7856, p < 0.001). Subjective risk perception also differed whether the disease was presented as measles, pertussis, flu, or a generic "vaccine preventable disease" (F(3,3875) = 5.6430, p < 0.001). We also observed an interaction between intervention and disease on subjective risk perception. More specifically, subjective risk perception was higher among people who were assigned to *herdimm* compared to those assigned to the control. Differences estimates for each disease showed that this effect was likely driven by the larger difference among people assigned to the flu condition (difference estimate = 0.456, standard error = 0.0869, t(3875) = -5.243, p < 0.0001; all difference estimates available in <u>Appendix 5</u>). Table 4 shows means and 95% confidence intervals for subjective risk perception for each combination of intervention and disease.

	Intervention						
Disease	Control: mean (95% confidence interval)	Herdimm: mean (95% confidence interval)					
Generic	5.31 (5.17-5.45)	5.46 (5.36-5.56)	F(3,3875) = 5.6430, p				
Measles	5.44 (5.30-5.58)	5.61 (5.51-5.71)	< 0.001				

Table 4. 7	<mark>Гwo</mark> way	analysis	of	variance	of	subjectiv	ve risk	perce	ption
------------	----------------------	----------	----	----------	----	-----------	---------	-------	-------

Pertussis	5.39 (5.25-5.54)	5.56 (5.46-5.66)	
Flu	5.06 (4.92-5.20)	5.52 (5.42-5.62)	
	F(1,3875) = 28.7856, p	0 < 0.001	F(3,3875) = 2.8324, p = 0.037

Abbreviations: p, p-value; F, F-statistic

Our second model showed that intervention and disease interaction continued to demonstrate the same effects on subjective risk perception after adjustment for covariates, and is driven by the effects of the *herdimm* intervention among participants assigned to measles, pertussis and flu. The third model suggested that the increase in subjective risk perception for *herdimm* versus control was somewhat driven by the responses of people who scored low on vertical individualism (i.e., who disagreed with statements like, "It is important that I do my job better than others,") (see Figure 3) and low on horizontal collectivism (i.e., people who disagreed with statements like, "I feel good when I cooperate with others.") The third model further suggested that the relationship between participants' horizontal individualism scores (i.e., their agreement with statements like, "I rely on myself most of the time, I rarely rely on others,") and subjective risk perception was negative among those randomized to the flu condition while it was positive among those randomized to other diseases.



# Figure 3. Subjective risk perception for *herdimm* versus control by participants' vertical individualism

### Secondary outcomes

For our second research question we assessed the effects of the *herdimm* intervention on other outcomes (namely, emotions, knowledge and vaccination intentions) compared to a control of no intervention.

### Emotions

The primary model showed a statistically significant main effect of the intervention (*herdimm* or control) (F(1,3875) = 13.13, p < 0.001), main effect of disease (measles, pertussis, flu, generic vaccine-preventable disease) F(3,3875) = 78.54, p < 0.001), and no statistically significant interaction between intervention and disease on emotions F(3,3875) = 1.49, p = 0.216. More specifically, people who were assigned to *herdimm* reported stronger emotional responses (mean 5.07, 95% confidence interval 5.02-5.13) compared to those assigned to control (mean 4.90, 95% confidence interval 4.83-4.98). In other words, they were more likely to indicate higher levels of agreement with statements like, "I am worried about people in my life (family, friends) getting a vaccine-preventable disease," and "I would feel guilty if someone in my life (a family member, a friend) got a vaccine-preventable disease from me." People assigned to the generic 'vaccine-preventable disease' condition (mean 5.48, 95% confidence interval 5.39-5.57) had a higher mean score on emotions than those assigned to any specific diseases. People assigned to the measles (mean 4.59, 95% confidence interval 4.50-4.68) and pertussis conditions (mean 4.70, 95% confidence interval 4.6-4.79) had lower mean emotions than those assigned to flu (mean 5.18, 95% confidence interval 5.09-5.27).

The second model showed that inclusion of planned covariates, which required excluding 419 participants due to missing covariates, changed the results. The effect of the intervention became not significant (F(1,3440) = 2.93, p = 0.087) and the effect of disease remained significant (F(3,3440) = 75.47, p < 0.001), while the interaction between intervention and disease remained not significant. The third model suggested that the higher mean on emotions for *herdimm* was driven by the responses of people who scored low on horizontal collectivism (i.e., people who disagreed with statements like, "I feel good when I cooperate with others") in the generic disease and who scored high on horizontal collectivism (i.e., people who agreed with the above statement) for measles and pertussis.

### Knowledge

The primary model showed a statistically significant main effect of the interventions (F(1,3875) = 36.37, p < 0.001), main effect of disease (measles, pertussis, flu, generic vaccine-preventable disease) (F(3,3875) = 5.20, p = 0.001), and no statistically significant interaction between intervention and disease on knowledge (F(3,3875) = 2.54, p = 0.055). More specifically, people assigned to *herdimm* had higher mean knowledge (mean 9.12, 95% confidence interval 9.02-9.22) compared to those assigned to the control (mean 8.58, 95% confidence interval 8.44-8.73). People who were assigned to the generic vaccine-preventable disease had higher mean knowledge than those assigned to measles (difference estimate = 0.410, standard error = 0.127, t(3875) = 3.239, p = 0.007) and pertussis (difference estimate = 0.337, standard error = 0.128, t(3875) = 2.631, p = 0.042). Those assigned to disease flu also had higher mean knowledge than those assigned to measles (difference estimate = 0.357, standard error = 0.125, t(3875) = 2.861, p = 0.022).

The second model showed that, after inclusion of planned covariates (thus excluding 419 participants with missing covariate data), the effect of the interaction between intervention and disease became significant as well (F(3,3440) = 3.2962, p = 0.0196). After adjusting for covariates, people assigned to *herdimm* had higher mean knowledge than those assigned the control when they were also assigned to measles (difference estimate = 0.844, standard error = 0.182, t(3440) = 4.627, p < 0.001), pertussis (difference estimate = 0.508, standard error = 0.187, t(3440) = 2.725, p = 0.007) or flu (difference estimate = 0.680, standard error = 0.182, t(3440) = 2.725, p = 0.007) or flu (difference estimate = 0.680, standard error = 0.182, t(3440) = 2.725, p = 0.007) or flu (difference estimate = 0.680, standard error = 0.182, t(3440) = 2.725, p = 0.007) or flu (difference estimate = 0.680, standard error = 0.182, t(3440) = 2.725, p = 0.007) or flu (difference estimate = 0.680, standard error = 0.182, t(3440) = 0.182, t(3440) = 0.007) or flu (difference estimate = 0.680, standard error = 0.182, t(3440) = 0.182, t(3440) = 0.007) or flu (difference estimate = 0.680, standard error = 0.182, t(3440) = 0.182, t(3440) = 0.007) or flu (difference estimate = 0.680, standard error = 0.182, t(0.001), the transport explanate error = 0.182, t(0.001), the transport error explanate error = 0.182, t(0.001), the transport error explanate error = 0.182, t(0.001), the transport error e

t(3440) = 3.743, p < 0.001) but not when they were assigned to generic vaccine-preventable disease (difference estimate = 0.076, standard error = 0.184, t(3440) = 0.413, p = 0.680).

The third model suggested that the higher mean knowledge for *herdimm* was driven by the responses of people who scored low on vertical individualism (i.e., who disagreed with statements like, "It is important that I do my job better than others.") To explore whether people who scored differently on individualism and collectivism subscales might have paid more or less attention to the information in *herdimm*, we conducted additional exploratory posthoc analyses on time spent away from the Qualtrics survey, when participants were supposed to be viewing *herdimm*. Overall, differences appeared to be minimal (<u>Appendix 6</u>)

### Vaccination intentions

The primary logistic regression model showed a statistically significant main effect of the intervention (*herdimm* or control) (Chi-squared (1) = 9.41, p = 0.002), main effect of disease (measles, pertussis, flu, generic vaccine-preventable disease) (Chi-squared (3) = 15.02, p = 0.002), and no statistically significant interaction between intervention and disease on vaccination intentions (Chi-squared (3) = 3.72, p = 0.293). More specifically, people assigned to *herdimm* were more likely to score high on vaccination intentions (52.1%, 95% confidence interval 50.1%-54.0%) compared to those assigned to the control (46.9%, 95% confidence interval 44.1%-49.6%). People who were assigned to the flu (45.8%, 95% confidence interval 42.5% - 49.1%) were less likely to score high on vaccination intentions compared to those assigned to a generic 'vaccine-preventable disease' (52.7%, 95% confidence interval 49.3%-56.1%) and measles (52.9%, 95% confidence interval 49.5%-56.1%). Those assigned to measles were also more likely to score high on vaccination intentions compared to those assigned to pertussis (46.6%, 95% confidence interval 43.2%-49.9%).

The second model showed that inclusion of planned covariates (and its according exclusion of 419 participants who did not provide sociodemographic information) changed the results. The effect of the intervention became not significant (Chi-squared (1) = 2.69, p=0.10). The covariates with statistically significant effects at the 5% level on vaccination intentions were age (Chi-squared (1) = 56.646, p<0.001), collective horizontalism (Chi-squared (1) = 46.271, p<0.001), income (Chi-squared (3) = 42.401, p<0.001), disability (Chi-squared (1) = 19.7276, p<0.001), vertical individualism (Chi-squared (1) = 6.422, p= 0.011), horizontal individualism (Chi-squared (1) = 4.261, p= 0.04), and education level (Chi-squared (1) = 4.141, p= 0.042). The third model suggested that the relationship between participants' vertical individualism scores (i.e., their agreement with statements like, "I rely on myself most of the time, I rarely rely on others,") and vaccination intentions was positive among those randomized to the flu condition while it was negative among those randomized to other diseases. In addition to moderation model results available above and in <u>Appendix 5</u>, <u>Appendix 6</u> presents graphs of all outcome data, including vaccination intentions, by Collectivism and Individualism subscales.

### Impact of missing outcome data

Comparing results from analyses with multiple imputation on missing outcome data to the analyses without, we observed no notable differences. Some outcomes (subjective risk perception, knowledge, and emotion) had no missing values, and there were no changes from original results for the primary model. The lack of missing data might be because these variables are a function of several items, and therefore, even if some items were missing, a mean or sum could still be calculated. For the other outcomes measured by a single item

(objective risk perception, vaccination intention) the rate of missing data was approximately 1%. After imputing these missing data points, there were no changes to the results of any analyses.

# Discussion

This study offers 4 key findings. First, compared to the control condition of no education, the *herdimm* web app improved objective risk perception, increased subjective risk perception, improved knowledge about how herd immunity or community immunity works, increased emotions such as concern for vulnerable people, and increased intentions to receive vaccines. People often perceive risk based on their impressions of overall disease prevalence and severity [45,46]. By presenting epidemiological evidence about how vaccines protect whole communities in a way that allowed people across backgrounds, education levels, and disability statuses to understand it, the *herdimm* intervention led to improved understanding of levels of risk (objective risk perception) and increased subjective risk perception and associated emotions, indicating higher levels of concern for others in one's community and vulnerable people within it. This finding is consistent with the previous research in which risk perception and emotions influenced vaccine decisions [47–49] and similar web-based interventions improved vaccine knowledge, attitudes, and intentions to receive vaccines [10,50–52]. Our study therefore adds to previous research suggesting that communicating population-level benefits of vaccination may help encourage vaccine uptake, at least in some populations.

Second, our study showed that people with more collectivist orientations are more responsive to messages demonstrating collective benefits of widespread vaccination than people with more individualist orientations. Previous work by Betsch and colleagues analyzed the effects of a similar intervention across countries demonstrating more individualist and collectivist orientations at the population level. They found that their intervention had larger effects in encouraging vaccination intentions in countries with higher overall individualist scores (United States, Germany and the Netherlands) than in collectivist countries with higher overall collectivist scores (South Korea, Vietnam and Hong Kong) because baseline vaccine uptake was already high in the second group, and there was therefore less room for change [10]. Our study built on this finding by incorporating a validated scale of individualism and collectivism [37] to assess whether a person's orientation towards individualism or collectivism moderated how they responded to the intervention. Our study was conducted in Canada, a multicultural, Western country that was not represented in Betsch and colleagues' study but would typically be grouped with the United States, Germany and the Netherlands, rather than with South Korea, Vietnam and Hong Kong. Overall, our findings suggested that people with more collectivist orientations were more responsive to the community immunity idea than those with more individualist orientations. In other words, by conducting within-country rather than between-country analyses, we found that some people are more collectivist while others are more individualist, and these individual differences may influence how people respond to public health appeals to protect others. Other research by Amin and colleagues has similarly shown that individuals' orientations toward purity and liberty as moral foundations are associated with vaccine hesitancy, while the moral foundations of harm and fairness that are more commonly emphasized in messaging around vaccines were not associated with vaccine hesitancy or uptake [53]. Taken together, such findings emphasize the importance of potentially tailoring approaches to vaccine messaging according to individuals' broader values. worldviews, and orientations towards self and others [54].

Third, although most findings were consistent across the four disease conditions we used in our study, we did observe signals of potential disease-specific findings that offer potential implications or avenues for future work. One such signal occurred on the outcome of subjective risk perception, which was higher overall among people who were assigned to the herdimm intervention compared to those assigned to the control condition, but particularly so among people assigned to the influenza condition due to lower baseline subjective risk perception among people who completed the study in the context of influenza. Specifically, people assigned to the control condition in the context of influenza indicated lower subjective risk perception, meaning they were less likely to agree with statements like, "If I get vaccinated against the flu, it lowers the risk of vulnerable people in my community (babies, young children, older people, cancer patients) getting sick," compared to those asked to indicate their level of agreement with those same statements but with terms measles, pertussis, or a vaccinepreventable disease in place of, "the flu." This is consistent with lower uptake of influenza vaccines in many jurisdictions compared to uptake of vaccines against measles, pertussis, and many other diseases. Among those assigned to the *herdimm* intervention, however, subjective risk perception was similar across diseases. This may imply that helping people understand how community immunity works may be particularly useful in the context of influenza, a condition for which vaccine uptake is often lower, especially among those at lower risk of severe influenza [55].

Fourth and finally, our study also offers some methodological lessons for future evaluations of similar digital health interventions that may be useful to other research groups. Participants in our study assigned to the herdimm condition had to answer sociodemographic questions in Qualtrics, click on a link to visit a university-based website hosting the *herdimm* intervention, then return to their Qualtrics questionnaire to answer questions making up the outcome measures. We observed very high dropout rates due to people either abandoning the study at the point of visiting the university-based website, or completing the outcome questions with insufficient time in between to have actually visited the *herdimm* website. A related study our group conducted in which we adapted the *herdimm* intervention to show why social distancing was being recommended to help reduce COVID-19 transmission showed that the largest proportion of people who abandoned the university-based website in that study did so at the step of creating 8 additional avatars to represent the people around the individual [56]. For future research, we therefore added the option for people to auto-generate additional avatars. Additionally, rather than simply instructing participants to visit an external site and return to the questionnaire to complete the study, in future studies in which we need to ask participants to visit an external site, we plan to use individualized links containing the anonymized Qualtrics respondent IDs as parameters within the link, then provide an individualized link back to their Qualtrics questionnaire. Although this is a more complex procedure, it will ensure better intervention fidelity as well as allow the collection of data about people's behaviour at the website (for example, time spent on each step, choice of avatars, etc.) for analysis. Additionally, our planned analyses for this study included plans for multiple imputation to account for missing outcome data. However, we did not pre-plan similar imputation for missing sociodemographic data, meaning that our adjusted analyses removed about 11% of participants while also adding variables, and therefore had lower statistical power. Future studies should include plans for addressing missing data among covariates to avoid such diminished statistical power.

# **Strengths and Limitations**

Our study had five key limitations. First, some outcomes were evaluated with items developed specifically for this study due to the lack of validated scales in the context of communication about community immunity. While we pre-tested our measures and examined standard psychometric indicators of validity such as Cronbach alpha, full validation studies were outside the scope of this work. Second, as noted above, we observed high dropout rates in herdimm arms, likely because people had to visit the *herdimm* website in the middle of the questionnaire and then come back to finish the study. This means that the effects of the *herdimm* intervention may be either overestimated or underestimated. To explore this issue, we examined sociodemographic differences between people who did and did not complete the study. The largest difference we observed was among participants who self-identified as white, who were more populous among the group who completed the study (80% among completes versus 62% among incompletes.) Identifying as white was also associated with higher knowledge. This means that the observed effects of *herdimm* on knowledge may be overestimated because, in the final dataset, there were more people with a characteristic associated with higher knowledge in the intervention arms. Alternatively, effects may be underestimated if the higher knowledge scores are attributable to pre-existing knowledge. Third, some identity elements (e.g., some racial and ethnic groups) had to be merged due to low numbers. As a result, we do not know the influence of specific groups, e.g., Black Caribbean, as a covariate on our outcomes. This may be a limitation if such covariates are influential on our outcomes. However, given that the racial and ethnic groups that we did retain had little influence as covariates, it is unlikely that collapsing groups would have had a substantial influence. Fourth, the distribution of data on a number of continuous or quasicontinuous outcomes required establishing a cutoff to perform logistic regressions. Although we prepared our statistical code before collecting data and preregistered our analyses, we had little prior data to guide our choices for such cutoffs, meaning that the cutoffs were necessarily somewhat arbitrary. Fifth and finally, our study took place during early COVID-19 vaccination campaigns in Canada. We did not add COVID-19 as a named vaccine-preventable disease in our study for a number of reasons, including that it was not yet known whether the early COVID-19 vaccines would be able to produce robust community immunity. It is possible, and perhaps likely, that participants assigned to the generic, "vaccine-preventable disease," condition may have been thinking of COVID-19 as they responded to the study questions, which may have influenced their responses in one direction or another. However, for the vast majority of our outcomes, we did not observe significant differences between people assigned to the generic disease and those assigned to measles, pertussis, and flu. This suggests that if participants were thinking of COVID-19, their responses were nonetheless similar to the responses of people thinking of other diseases.

Our study also had three key strengths. First, for methodological robustness, we preregistered the entire study, including all study materials and statistical code developed with simulated data. Such preregistration may have been particularly important for this study, given that we anticipated the need to divide risk perception into objective and subjective components and use logistic regressions for a number of continuous outcomes. Second, we evaluated the *herdimm* intervention across four disease conditions—three named diseases and an unnamed, "vaccine-preventable disease." Much research on vaccine decision making is conducted on only one vaccine-preventable disease at a time or without ever naming a particular disease, thus limiting its generalizability. People may respond differently to a situation involving an abstract, unnamed disease than they do to a known, named disease, and yet we cannot

assume that responses to messaging about one specific disease will be applicable to messaging about another specific disease. Identifying approaches that work across diseases is important for achieving broader public health goals. Studies such as ours therefore offer findings that are more robust than they would have been had we used only a single disease. Third, the *herdimm* intervention offers insights about the potential applicability of personalization and tailoring to vaccine messaging. By having people create their own avatar, the avatars of people around them, and then using those avatars in an animation, the *herdimm* intervention aimed to help people literally see how their vaccination decisions could impact others around them. This message was more impactful among people with more collectivist orientations, underlining the idea that although public health messages are often universal, delivering them differently to different people may increase their impact.

# Conclusions

Visually conveying the concept of community immunity using personalized avatars improves objective and subjective risk perception, emotions, knowledge and increases intentions to receive vaccines. Our work also contributes evidence of how community immunity messages may influence vaccine acceptance differently among people whose personal orientations are more collectivist versus those who are more individualist, which offers insights about how we might target messages to different people. Put another way, conveying the concept of community immunity in understandable ways may contribute to public health efforts to achieve adequate vaccine coverage. However, this needs to be done with care, as not everyone will respond to messages about protecting others in the same way.

# DECLARATIONS

# Ethics approval and consent to participate

This project is approved by the "Comité d'éthique de la recherche en sciences de la santé" ethics committee of Laval University (Approval No. 2017- 137 Phase II / 03-09-2019). All participants included in the study consented to participate in the study.

# **Consent for publication**

### Availability of data and materials

All study materials were pre-registered and are available on Open Science Framework (<u>https://osf.io/hkysb/</u>). Web development code is available on GitHub: https://github.com/Witteman-Lab/herdimm. Anonymized data are available at Université Laval's Dataverse, Boréalis: <u>https://doi.org/10.5683/SP3/41MWKO</u>.

### **Conflict of interest**

None

# Acknowledgments

The authors gratefully acknowledge the contributions of Mehdi Aouami and Rosalie Baker for designing the first version of our prototype, and Ali Ben Charif for constructive comments on earlier versions of this paper.

# **Authors' Contributions**

# Funding

This study was funded by the Canadian Institutes of Health Research (grant number FDN-148426, 2016-2021, PI: Witteman). The CIHR had no role in determining the study design, the plans for data collection or analysis, the decision to publish, nor the preparation of this manuscript. HOW is funded by a Tier 2 Canada Research Chair in Human-Centred Digital Health. Dr. Sander is funded by a Tier 1 Canada Research Chair in Economics of Infectious Diseases (CRC-2022-00362). Dr. Scherer was supported by the National Institute on Aging of the National Institutes of Health under Award Number K01AG065440. The content is solely the responsibility of the authors and does not necessarily represent the official views of NIH.

# Appendices

Appendix 1. Links or video of herdimm intervention

- Appendix 2. Scatterplot and bland-altman for risk perception
- Appendix 3. Herdimm survey questionnaire
- Appendix 4. Descriptive statistic per study arm
- Appendix 5. Complete results of models

Appendix 6. Outcomes and timestamp versus Individualism and Collectivism subscales

# Abbreviation

OSF Open Science Framework (IQR) Interquartile range CI, Confidence interval Df, Degree of freedom p, p-value; F, F-statistic LR Chisq, Likelihood ratio tests ANOVA, Analysis of variance

# **Figures**

Figure 1. Objective risk perception Figure 2. CONSORT flow diagram

Figure 3. Subjective risk perception for herdimm versus control

# Tables

- Table 1. Subjective risk perception
- Table 2. Model used for analysis
- Table 3. Participants characteristics across the study (N=3883)
- Table 4. Two way analysis of variance of subjective risk perception

# References

- 1. Rashid H, Khandaker G, Booy R. Vaccination and herd immunity: what more do we know? Curr Opin Infect Dis. 2012;25: 243–249.
- 2. Metcalf CJE, Ferrari M, Graham AL, Grenfell BT. Understanding Herd Immunity. Trends Immunol. 2015;36: 753–755.
- 3. Mulberry N, Tupper P, Kirwin E, McCabe C, Colijn C. Vaccine rollout strategies: The case for vaccinating essential workers early. PLOS Glob Public Health. 2021;1: e0000020.
- 4. Alfredsson R, Svensson E, Trollfors B, Borres MP. Why do parents hesitate to vaccinate their children against measles, mumps and rubella? Acta Paediatr. 2004;93: 1232–1237.
- 5. Dube E, Bettinger JA, Halperin B, Bradet R, Lavoie F, Sauvageau C, et al. Determinants of parents' decision to vaccinate their children against rotavirus: results of a longitudinal study. Health Education Research. 2012. pp. 1069–1080. doi:10.1093/her/cys088
- 6. Downs JS, de Bruin WB, Fischhoff B. Parents' vaccination comprehension and decisions. Vaccine. 2008;26: 1595–1607.
- 7. Omer SB, Salmon DA, Orenstein WA, deHart MP, Halsey N. Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med. 2009;360: 1981–1988.
- 8. Salmon DA, Dudley MZ, Glanz JM, Omer SB. Vaccine hesitancy: Causes, consequences, and a call to action. Vaccine. 2015;33 Suppl 4: D66–71.
- 9. Smith LE, Amlôt R, Weinman J, Yiend J, Rubin GJ. A systematic review of factors affecting vaccine uptake in young children. Vaccine. 2017;35: 6059–6069.
- 10. Betsch C, Böhm R, Korn L, Holtmann C. On the benefits of explaining herd immunity in vaccine advocacy. Nature Human Behaviour. 2017;1: s41562–017–0056.
- 11. Logan J, Nederhoff D, Koch B, Griffith B, Wolfson J, Awan FA, et al. "What have you HEARD about the HERD?" Does education about local influenza vaccination coverage and herd immunity affect willingness to vaccinate? Vaccine. 2018;36: 4118–4125.
- 12. Al-Hatamleh MAI, Abusalah MA, Hatmal MM, Alshaer W, Ahmad S, Mohd-Zahid MH, et al. Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. J Taibah Univ Med Sci. 2023;18: 600–638.
- 13. She J, Hou D, Chen C, Bi J, Song Y. Challenges of vaccination and herd immunity in COVID-19 and management strategies. Clin Respir J. 2022;16: 708–716.
- Skowronski DM, Kaweski SE, Irvine MA, Kim S, Chuang ESY, Sabaiduc S, et al. Serial crosssectional estimation of vaccine-and infection-induced SARS-CoV-2 seroprevalence in British Columbia, Canada. CMAJ. 2022;194: E1599–E1609.
- 15. Hakim H, Provencher T, Chambers CT, Driedger SM, Dube E, Gavaruzzi T, et al. Interventions to help people understand community immunity: A systematic review. Vaccine. 2019;37: 235–247.
- 16. Healey CG, Enns JT. Attention and visual memory in visualization and computer graphics. IEEE Trans Vis Comput Graph. 2012;18: 1170–1188.
- 17. Yee N, Bailenson J. The Proteus Effect: The Effect of Transformed Self-Representation on

Behavior. Hum Commun Res. 2007;33: 271-290.

- 18. Yee N, Bailenson JN, Ducheneaut N. The Proteus Effect: Implications of Transformed Digital Self-Representation on Online and Offline Behavior. Communic Res. 2009;36: 285–312.
- 19. Yee N, Ducheneaut N, Yao M, Nelson L. Do men heal more when in drag? conflicting identity cues between user and avatar. Proceedings of the SIGCHI Conference on Human Factors in Computing Systems. New York, NY, USA: Association for Computing Machinery; 2011. pp. 773–776.
- 20. Wakefield JRH, Khauser A. Doing it for us: Community identification predicts willingness to receive a COVID-19 vaccination via perceived sense of duty to the community. J Community Appl Soc Psychol. 2021;31: 603–614.
- 21. Paul KT, Eberl J-M, Partheymüller J. Policy-Relevant Attitudes Toward COVID-19 Vaccination: Associations With Demography, Health Risk, and Social and Political Factors. Front Public Health. 2021;9: 671896.
- 22. Loewenstein GF, Weber EU, Hsee CK, Welch N. Risk as feelings. Psychol Bull. 2001;127: 267.
- 23. Slovic P, Finucane ML, Peters E, MacGregor DG. Risk as Analysis and Risk as Feelings: Some Thoughts about Affect, Reason, Risk, and Rationality. Risk Analysis. 2004. pp. 311–322. doi:10.1111/j.0272-4332.2004.00433.x
- 24. Slovic P, Peters E. Risk Perception and Affect. Curr Dir Psychol Sci. 2006;15: 322–325.
- 25. Reyna VF. How people make decisions that involve risk a dual-processes approach. Curr Dir Psychol Sci. 2004;13: 60–66.
- 26. Peters E, Lipkus I, Diefenbach MA. The Functions of Affect in Health Communications and in the Construction of Health Preferences. J Commun. 2006;56: S140–S162.
- 27. Du M, Tao L, Liu J. Association between risk perception and influenza vaccine hesitancy for children among reproductive women in China during the COVID-19 pandemic: a national online survey. BMC Public Health. 2022;22: 385.
- 28. Marzo RR, Ahmad A, Islam MS, Essar MY, Heidler P, King I, et al. Perceived COVID-19 vaccine effectiveness, acceptance, and drivers of vaccination decision-making among the general adult population: A global survey of 20 countries. PLoS Negl Trop Dis. 2022;16: e0010103.
- 29. Hakim H, Bettinger JA, Chambers CT, Driedger SM, Dubé E, Gavaruzzi T, et al. A Web Application About Herd Immunity Using Personalized Avatars: Development Study. J Med Internet Res. 2020;22: e20113.
- 30. Lab W. Community Immunity Demo Video. Youtube; 12 May 2021 [cited 16 Nov 2022]. Available: https://www.youtube.com/watch?v=PXzqXnZ-keQ
- 31. Lab W. Herdimm application. In: Design for better health Community Immunity [Internet]. 2021. Available: http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=measles&v=male&lang=en
- 32. Online survey software. In: Qualtrics [Internet]. 30 Sep 2019 [cited 11 Sep 2023]. Available: https://www.qualtrics.com/core-xm/survey-software/
- 33. Canadian Heritage. Statistics on official languages in Canada. 26 Nov 2019 [cited 2 Jul 2021]. Available: https://www.canada.ca/en/canadian-heritage/services/official-languagesbilingualism/publications/statistics.html

- 34. The CONSORT Statement. [cited 26 Jan 2021]. Available: http://www.consort-statement.org/
- 35. Government of Canada, Canada S. Census Profile, 2016 Census Canada [Country] and Canada [Country]. 8 Feb 2017 [cited 8 Nov 2023]. Available: https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm?Lang=E&Geo1=PR&Code1=01&Geo2=&Code2=&SearchText=Canada& SearchType=Begins&SearchPR=01&B1=All&TABID=1&type=0
- 36. Osuji VC, Galante EM, Mischoulon D, Slaven JE, Maupome G. COVID-19 vaccine: A 2021 analysis of perceptions on vaccine safety and promise in a U.S. sample. PLoS One. 2022;17: e0268784.
- 37. Triandis HC, Gelfand MJ. Converging measurement of horizontal and vertical individualism and collectivism. J Pers Soc Psychol. 74: 118–128.
- 38. Fetzer Institute. INDIVIDUALISM AND COLLECTIVISM SCALE (also known as the Culture Orientation Scale). Available: https://fetzer.org/sites/default/files/images/stories/pdf/selfmeasures/CollectiveOrientation.pdf
- 39. Faul F, Erdfelder E, Lang A-G, Buchner A. G\*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39: 175–191.
- 40. R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2017. Available: https://www.R-project.org/
- 41. Revelle W. Procedures for personality and psychological research, Northwestern University, Evanston, Illinois, USA. 2017. Available: https://CRAN.R-project.org/package=psych Version = 2.0.12,.
- 42. Fox J, Weisberg S. An R Companion to Applied Regression. SAGE Publications; 2018.
- 43. Lenth RV. Emmeans: estimated marginal means, aka least-squares means. R package version 1.6. 1. 2021.
- 44. van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. Journal of Statistical Software, Articles. 2011;45: 1–67.
- 45. Durham DP, Casman EA. Incorporating individual health-protective decisions into disease transmission models: a mathematical framework. J R Soc Interface. 2012;9: 562–570.
- 46. Funk S, Salathé M, Jansen VAA. Modelling the influence of human behaviour on the spread of infectious diseases: a review. J R Soc Interface. 2010;7: 1247–1256.
- 47. Chapman GB, Coups EJ. Emotions and preventive health behavior: worry, regret, and influenza vaccination. Health Psychol. 2006;25: 82–90.
- 48. Weinstein ND, Kwitel A, McCaul KD, Magnan RE, Gerrard M, Gibbons FX. Risk perceptions: assessment and relationship to influenza vaccination. Health Psychol. 2007;26: 146–151.
- 49. Caserotti M, Girardi P, Rubaltelli E, Tasso A, Lotto L, Gavaruzzi T. Associations of COVID-19 risk perception with vaccine hesitancy over time for Italian residents. Soc Sci Med. 2021;272: 113688.
- Schmid P, Rauber D, Betsch C, Lidolt G, Denker M-L. Barriers of Influenza Vaccination Intention and Behavior – A Systematic Review of Influenza Vaccine Hesitancy, 2005 – 2016. PLOS ONE. 2017. p. e0170550. doi:10.1371/journal.pone.0170550

- 51. Vietri JT, Li M, Galvani AP, Chapman GB. Vaccinating to help ourselves and others. Med Decis Making. 2012;32: 447–458.
- 52. Kim M, Lee H, Kiang P, Aronowitz T, Sheldon LK, Shi L, et al. A Storytelling Intervention in a Mobile, Web-Based Platform: A Pilot Randomized Controlled Trial to Evaluate the Preliminary Effectiveness to Promote Human Papillomavirus Vaccination in Korean American College Women. Health Educ Behav. 2020;47: 258–263.
- 53. Amin AB, Bednarczyk RA, Ray CE, Melchiori KJ, Graham J, Huntsinger JR, et al. Association of moral values with vaccine hesitancy. Nature Human Behaviour. 2017;1: 873–880.
- 54. Hornsey MJ, Harris EA, Fielding KS. The psychological roots of anti-vaccination attitudes: A 24nation investigation. Health Psychol. 2018;37: 307–315.
- 55. Yeung MPS, Lam FLY, Coker R. Factors associated with the uptake of seasonal influenza vaccination in adults: a systematic review. J Public Health . 2016;38: 746–753.
- 56. Etienne D, Archambault P, Aziaka D, Chipenda-Dansokho S, Dubé E, Fallon CS, et al. A Personalized Avatar-Based Web Application to Help People Understand How Social Distancing Can Reduce the Spread of COVID-19: Cross-sectional, Observational, Pre-Post Study. JMIR Form Res. 2023;7: e38430.

### Appendix 1 : Links or video of herdimm intervention

Visualization	Link or video
Herdimm demo video (English)	https://www.youtube.com/watch?v=PXzqXnZ-keQ
Herdimm demo video (French)	https://www.youtube.com/watch?v=F8ZjQTcihjg
Herdimm: generic vaccine preventable disease & measles (English-Male)	http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=measles&v=male⟨=en
Herdimm: generic vaccine preventable disease & measles (English-Female)	http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=measles&v=female⟨=en
Herdimm: generic vaccine preventable disease & measles (French -Male)	http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=measles&v=male⟨=fr
Herdimm: generic vaccine preventable disease & measles (French-Female)	http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=measles&v=female⟨=fr
Herdimm- pertussis (English- Male)	http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=pertussis&v=male⟨=en
Herdimm- pertussis (English- Female)	http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=pertussis&v=female⟨=en
Herdimm- pertussis (French- Male)	http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=pertussis&v=male⟨=fr
Herdimm- pertussis (French- Female)	http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=pertussis&v=female⟨=fr
Herdimm-flu (English Male)	http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=flu&v=male⟨=en
Herdimm-flu (English Female)	http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=flu&v=female⟨=en
Herdimm-flu (French Male)	http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=flu&v=male⟨=fr

Herdimm-flu (French Female)	http://wlab.fmed.ulaval.ca/projects/herdimm/#/?d=flu&v=female⟨=fr
(Prench Pennale)	

### Appendix 2:

S1: Scatter plot to see if the item risk percep\_1 (objective risk perception) and risk percept\_2 to 6 (subjective risk perception) are all measuring the same thing

			~~~~		n						
	. ~		00000	no anno a		കര്ത്		00000			
			ത്തറ	തനത		്ത	0.00000000	0000	നെറനത		
			തനത	ഞാതാ		ത്ത	ത്താത	0 00	തതത		
		- 1	ത്തര		0000	ň		ന്ത			
	0	-	ത്തര	തനതാനത്ത		തത്ത	0,000	റത്ത		0,0000	
	-		00000	ത്തത്ത	0000	ത്താ	10 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0000		0.0000	
Q.			തത്ത	000000	000	0000		0000	0 0 0 0 0 0		
~			$\overline{\infty}$	0000		000		0000	000000		
č			000	0000	00 00	00 00	0 00000	ത്രാത്			
0	40	-	ത്താ		000	000		o ooo	<b>തന്താ</b> റ		
b			00000	0000	0000	00	0 @@@@	0.0000		0.00.00	
Ð			ത്താ	താറാത	0000	0 0 0	) (@@@@@				00000
2			താത	ായായോറ	മ തറത	000		ത്തോര			00000
e			$\infty \alpha$	ത്താ	00	ാ തത്ത	0.0000000			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
¥	4	1	@\$\$\$\$	D 00000	ത്താര						
S.			ഠഠയ	0000	000	000	രത്ത		@0@@@		
-			@@00	00	οœ	000	യായാ	@@@CCO			00000
E.			0	0		0 00		@ 000			
0			$\infty$	o o	0	0		Ø	000000	<u>ann ann</u>	
Ē	3	-	0		Ø		ത്ത	ത്ത	တကာ	00	യ
5			യ		0			°_	0	0	യാറ
at			0 0	000		12		0	0	00	· ·
O			0			0	000			00	0 00
	~ .		œ	0		യ	0000		0	യ	0
	(1	-	~ 0				0 00	~	0		0
			0				~~~~	0	υw		~
			0				000				0
				_			~				0
	-	<u> </u>	~ `				ത്താം	m			0
			~				~~~~	~			~
							- 1		8		
			1	2		2	1	5		6	7
			1	2		5	4	0	,	0	1

dat\$score\_riskpercep1\_1

S2: Bland altman to see if the item risk percep\_1 and risk percept\_2 to 6 are all measuring the same thing



ba\$means
Appendix 3: Herdimm survey quesstionnaire

# contag\_phase3b

**Start of Block: Introduction** 

Intro Project Description

# **Project Description**

## Introduction

Thank you for participating in this study. This project is a collaboration with University Laval, Public Health Ontario (PHO) and The National Institute of Public Health of Quebec (INSPQ).

In this study, we will first give you some information to do with contagious diseases and then ask you to answer some questions.

The survey will take about 15 to 20 minutes. Your name will not be recorded anywhere in this survey. Researchers will not be able to associate your name with your answers. If you choose to leave the study, you can stop at any time. You may choose not to answer any questions you don't want to answer. If, for some reason, you cannot complete the survey, you may **restart** the survey at a later time by clicking on the survey link in your email invitation. You will have to **restart** the survey from the beginning.

If you become worried about your health while taking this survey, please talk to a healthcare provider.

## About the researchers

This study is a PhD project conducted by Ms. Hina Hakim, PhD student, supervised by Holly O. Witteman, PhD, professor and researcher in the Faculty of Medicine at Laval University. Ms. Hakim is co-supervised by Dr. Daniel Reinharz, professor and researcher in the Faculty of Medicine at Laval University.

## **Purpose of the study**

The purpose of this study is to evaluate the effects of information to do with contagious diseases on risk perception, knowledge, emotions, attitudes, beliefs, and behavioural intentions.

## What your participation entails

Participating in this study will involve following:

- Answering survey questions.
- You may be asked to view or listen to information, which will require either the ability to read or hear.

• You may be asked to briefly visit another website in the middle the survey.

# **Risks and benefits**

The risks associated with participating in the study, specifically:

- Information and questions, we ask may make you feel uncomfortable or anxious. We suggest you to consult your healthcare professional, as the case may be;
- You may feel some discomfort having to focus on a computer screen.
- You may feel some fatigue from concentrating throughout the survey.

There is no personal benefit to participate in this study, however, the information we gather will help us to evaluate the effects of the information, which may help in improving the way health information is shared, and population health.

Your help means a lot to us. We thank you again for taking the time to complete this survey.

# Confidentiality and data protection

All information we collect will be confidential and used only for research purposes. In other words:

- Participant credentials will not be associated with the results of the study and no individual information will be presented in reports, publications or presentations.
- All data will be presented in aggregate form without individual identifiers.
- Data will be stored on Qualtrics servers located in Canada. When we work with data, the only people who will have access to our Qualtrics account will be the investigators and our team members who have complete and relevant ethics training. When the data is stored on our computers, each of our computers will be protected by a password. The data will be stored on a secure server, to which access is maintained and reserved for the members of the team (members of the team affiliated with Université Laval).

After the end of the study:

- Anonymized data (answers to questions in the survey including socio-demographic information) will be deposited in a public repository (Dataverse de l'Université Laval (Laval University)) which will allow data sharing with the scientific community. No information that would allow anyone to identify a person will be deposited in this public repository.
- Any other electronic data will be destroyed in June 2027.

## **Contact people**

If you have any questions about the research study, or if you experience a problem as a result of participating in the study, please contact:

Holly Witteman Laval University Tel: (418) 656-2131 ext: 403981 Email: holly.witteman@fmed.ulaval.ca

If you have concerns about your rights as a participant in this study or any complaints, you can communicate with the University Laval Ombudsman at:

Pavillon Alphonse-Desjardins 2325, rue de l'Université, Local 3320 Québec, QC G1V 0A6 Tel: 418-656-3081 Toll free: 1-866-323-2271 Email: info@ombudsman.ulaval.ca

*This project has been approved by Laval University Research Ethics Board: Approval No.* 2017-137 Phase II A-6/10-09-2020

Start of Block: Consent for participation:

 $X \rightarrow$ 

# Consent

- 1. I have been informed about the nature and purpose of this study and the research procedures.
- 2. I was informed in English which is a language I understand fluently.
- 3. I understand that my participation in this study is voluntary and that I can withdraw at any time without penalty or consequences of any kind.
- 4. I understand that the information collected is confidential and will only be used for research purposes.
- 5. I have read the project description and informed consent form and I voluntarily agree to participate in this study.

• Yes I Consent (1)

O No I do not Consent (0)

Skip To: End of Survey If I have been informed about the nature and purpose of this study and the research procedures. I wa... = No I do not Consent

t\_consent Timing First Click (1) Last Click (2) Page Submit (3) Click Count (4)

t\_consent Durée First Click (1) Last Click (2) Page Submit (3) Click Count (4)

Page Break

End of Block: Consent for participation:

Start of Block: Standard Sociodemo Canada

 $X \rightarrow$ 

#### yearofbirth In what year were you born?

▼ Prefer not to answer (888) ... 2010 (2010)

bornincanada Were you born in Canada? (Check one only.)

O Prefer not to answer (888)

O Yes (1)

○ No - What year did you arrive in Canada? (0)

Display	This	Question:
lf If	Fals	se

X-

hp Were you born outside North America? (Check one only.)

Prefer not to answer (888)
----------------------------

○ Yes (1)

 $\bigcirc$  No - What year did you arrive in North America? (0)

 $X \rightarrow$ 

language What language would you feel most comfortable speaking in with your healthcare provider? (doctor, nurse, dentist, pharmacist)? (Check all that apply.)

Prefer not to answer (888)
□English (1)
□French (2)
□Other, please specify: (3)

ethnicity Which of the following best describes your racial or ethnic group(s)? (Check all that apply.)

	Prefer not to answer (888)
	Asian - East (e.g., Chinese, Japanese, Korean) (1)
	Asian - Central (e.g., Kazakhstani, Uzbekistani) (2)
	Asian - South (e.g., Indian, Pakistani, Sri Lankan) (3)
	Asian - South-East (e.g., Malaysian, Filipino, Vietnamese) (4)
	Black - African (e.g., Ghanaian, Kenyan, Somali) (13)
	Black - Caribbean (e.g., Barbadian, Jamaican) (14)
	Black - North American (e.g., Canadian, American) (15)
	First Nations (16)
Quechua)	Indigenous or aboriginal person from outside of North America (e.g., Maori, (5)
	Inuit (8)
	Latin American (e.g., Chilean, Mexican, Salvadorian) (9)
	Metis (Metis Nation in Canada) (10)
	Middle Eastern (e.g., Egyptian, Iranian, Lebanese) (12)
	North African (e.g., Moroccan, Tunisian) (11)
	White - European (e.g., English, Italian, Portuguese, Russian) (6)
	White - North American (e.g., Canadian, American) (7)

Other, please specify: (17)

X→
disability Do you consider yourself to have a disability (e.g, physical disability, sensory disability (e.g., hearing or vision loss), chronic illness, learning disability, mental illness, developmental disability or other)? (Check one only.)
O □Prefer not to answer (888)
◯ □No disability (0)

 $\bigcirc$   $\Box$ Yes, at least one disability (1)

 $X \rightarrow$ 

techdisability Do you have a disability that limits your access to technology and computer based tools (p.ex. : computer, tablet, interactive terminal)? (Check one only.)

O □Prefer not to answer	(888)
O No (0)	

O Yes (1)

 $\mathbf{x}$ 

sexatbirth What sex were you assigned at birth, meaning on your original birth certificate? (Check one only.)

O Prefer not to answer (888)

O Female (1)

O Male (2)

X→

genderidentity Do you consider yourself: (Check one only.)

O Female (1)

O Male (2)

 $\bigcirc$  Indigenous or other cultural gender minority identity (e.g., two-spirit) (3)

O Something else (e.g. non-binary, gender fluid) (4)

O Prefer not to answer (888)

 $X \dashv$ 

income What was your total family income before taxes last year? (Check one only.)

- $\bigcirc$   $\Box$ Prefer not to answer (888)
- □24 999 or less (1)
- □25 000 to 49 999 (2)
- □50 000 to 99 999 (3)
- □ 100 000 or more (4)
- $\bigcirc$   $\Box$  Do not know (5)

 $X^{-}$ 

# supported by income How many people does this income support?

O Number of people: (1) \_\_\_\_\_\_

O Prefer not to answer (888)

 $X \dashv$ 

educationlevel What is the highest level of education you have completed? (Check one only.)

- □ Prefer not to answer (888)
- □ Elementary School (completed or not) (1)
- □ □ High School Diploma (2)
- $\bigcirc$   $\Box$  Apprenticeship or trade certificate or diploma (3)
- College or polytechnical school certificate or diploma (4)
- $\bigcirc$   $\Box$  University degree, bachelor level or below (5)
- □ University graduate degree (Master's level) (6)
- □ University graduate degree (Doctorate level) (7)
- $\bigcirc$   $\Box$  Do not know (8)

t\_sociodemographic Timing First Click (1) Last Click (2) Page Submit (3) Click Count (4)

t\_sociodemographic Durée First Click (1) Last Click (2) Page Submit (3) Click Count (4)

End of Block: Standard Sociodemo Canada

Start of Block: Individualism and Collectivism Scale - Triandis1998 - EN/FR

# ih1 Evaluate how well each of the following statements applies to you:

I'd rather depend on myself rather than others.

- $\bigcirc$  Never or definitely not =1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07(7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

ih2 I rely on myself most of the time, I rarely rely on others.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07(7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

ih3 I often do "my own thing."

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- O 4 (4)
- 05 (5)
- 06 (6)
- 07 (7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

ih4 My personal identity, independent of others, is very important to me.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07 (7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

iv1 It is important that I do my job better than others.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07(7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

iv2 Winning is everything.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- O 4 (4)
- 05 (5)
- 06 (6)
- 07 (7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

iv3 Competition is the law of nature.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07 (7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

iv4 When another person does better than I do, I get tense and aroused.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07 (7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

ch1 If a coworker gets a prize, I would feel proud.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07(7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

ch2 The well-being of my coworkers is important to me.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07(7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

ch3 To me, pleasure is spending time with others.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07 (7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

ch4 I feel good when I cooperate with others.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07 (7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

cv1 Parents and children must stay together as much as possible.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07(7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

cv2 It is my duty to take care of my family, even when I have to sacrifice what I want.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07 (7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

cv3 Family members should stick together, no matter what sacrifices are required.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07 (7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

cv4 It is important to me that I respect the decisions made by my groups.

- $\bigcirc$  Never or definitely not = 1 (1)
- 0 2 (2)
- O 3 (3)
- 0 4 (4)
- 05 (5)
- 06 (6)
- 07(7)
- 0 8 (8)
- $\bigcirc$  Always or definitely yes = 9 (9)

t\_ic Timing First Click (1) Last Click (2) Page Submit (3) Click Count (4)

t\_ic Durée First Click (1) Last Click (2) Page Submit (3) Click Count (4)

End of Block: Individualism and Collectivism Scale - Triandis1998 - EN/FR

Start of Block: media Display This Question: If viz = 0

control Now we need your answers to some questions about contagious diseases.

Display This Question: If viz = 1Or viz = 2

robertkochgeneric Now you will visit another website with some information about contagious diseases.

When you are done, please come back here to finish the survey.

Display This Question: If viz = 1 And disease = 0

And voice = 1

herdimmgenericmale Please click here to go to the other website

Display This Question: If viz = 1 And disease = 0 And voice = 2

herdimmgenericfemale Please click here to go to the other website

Display This Question: If viz = 1 And disease = 1 And voice = 1

herdimmmeaslesmale Please click here to go to the other website

Display This Question: If viz = 1 And disease = 1 And voice = 2

herdimmmeaslesfemale Please click here to go to the other website

Display This Question: If viz = 1 And disease = 2

And voice = 1

herdimmpertussismale Please click here to go to the other website

Display This Question: If viz = 1 And disease = 2 And voice = 2

herdimmpertussisfema Please click here to go to the other website

Display This Question: If viz = 1 And disease = 3 And voice = 1

herdimmflumale Please click here to go to the other website

Display This Question: If viz = 1 And disease = 3 And voice = 2

herdimmflufemale Please click here to go to the other website

Display This Question: If Q\_Language = ENAnd viz = 2

robertkoch Please click here to go to the other website

Display This Question: If Q\_Language = EN And viz = 3

sbsnewsgeneric Now we ask you to please watch the video below with some information to do with contagious diseases and then continue the survey.



guardianmeasles

Now we ask you to please watch the video below with some information to do with contagious diseases and then continue the survey.

Display This Question: If Q\_Language = ENAnd viz = 6

theotheredmundmeasle Now we ask you to please watch the video below with some information to do with contagious diseases and then continue the survey.

Display This Question: If viz = 7

publichealthagencyca Now we ask you to please watch the video below with some information to do with contagious diseases and then continue the survey.

t\_media Timing First Click (1) Last Click (2) Page Submit (3) Click Count (4)

t\_media Durée First Click (1) Last Click (2) Page Submit (3) Click Count (4)

End of Block: media

**Start of Block: Risk Perception** 

riskpercep1 Imagine there are two groups of 100 people each. In one group, there is 1 UNvaccinated person surrounded by 99 vaccinated people. In the other group, there is 1 vaccinated person surrounded by 99 UNvaccinated people. Who is at higher risk of getting infected with \${e://Field/diseasedescEN}?

	The 1 UNvaccinated person surrounded by 99 vaccinated people is at higher risk.	They are both equally at risk.	The 1 vaccinated person surrounded by a group of 99 UNvaccinated people is at higher risk.
1 ()			

X→
riskpercep2 A person's decision to be vaccinated or not against \${e://Field/diseasedescEN} affects only them, individually.

- $\bigcirc$  moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- $\bigcirc$  strongly agree (7)

riskpercep3 People who are vaccinated against \${e://Field/diseasedescEN} are less likely to pass it on to others.

- O strongly disagree (1)
- $\bigcirc$  moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- $\bigcirc$  strongly agree (7)

riskpercep4 My decision to be vaccinated against \${e://Field/diseasedescEN} has **no impact** on anyone else's chances of catching \${e://Field/diseasedescEN}.

- $\bigcirc$  moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- $\bigcirc$  strongly agree (7)

riskpercep5 My decision NOT to be vaccinated against \${e://Field/diseasedescEN} has **no impact** on anyone else's chances of catching \${e://Field/diseasedescEN}.

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- $\bigcirc$  moderately agree (6)
- $\bigcirc$  strongly agree (7)

riskpercep6 If I get vaccinated against \${e://Field/diseasedescEN}, it lowers the risk of vulnerable people in my community (babies, young children, older people, cancer patients) getting sick.

- O strongly disagree (1)
- $\bigcirc$  moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- $\bigcirc$  moderately agree (6)
- $\bigcirc$  strongly agree (7)

t-riskpercp Timing First Click (1) Last Click (2) Page Submit (3) Click Count (4)

t-riskpercp Durée First Click (1) Last Click (2) Page Submit (3) Click Count (4)

**End of Block: Risk Perception** 



 $X \rightarrow$ 

confidence1 I am completely confident that vaccines are safe.

O strongly disagree (1)

 $\bigcirc$  moderately disagree (2)

 $\bigcirc$  slightly disagree (3)

O neutral (4)

 $\bigcirc$  slightly agree (5)

moderately agree (6)

 $\bigcirc$  strongly agree (7)

## X-

confidence2 Vaccinations are effective.

 $\bigcirc$  strongly disagree (1)

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- $\bigcirc$  moderately agree (6)
- $\bigcirc$  strongly agree (7)

X-

confidence3 Regarding vaccines, I am confident that public authorities decide in the best interest of the community.

O strongly disagree (1)

moderately disagree (2)

O slightly disagree (3)

 $\bigcirc$  neutral (4)

 $\bigcirc$  slightly agree (5)

O moderately agree (6)

O strongly agree (7)

X

complacency1 Vaccination is unnecessary because vaccine-preventable diseases are not common anymore.

- moderately disagree (2)
- O slightly disagree (3)
- $\bigcirc$  neutral (4)
- $\bigcirc$  slightly agree (5)
- moderately agree (6)
- $\bigcirc$  strongly agree (7)

X

complacency2 My immune system is so strong, it also protects me against diseases.

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- $\bigcirc$  moderately agree (6)
- $\bigcirc$  strongly agree (7)

X÷

complacency3 Vaccine-preventable diseases are not so severe that I should get vaccinated.

- $\bigcirc$  moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- $\bigcirc$  moderately agree (6)
- $\bigcirc$  strongly agree (7)

X

constraints1 Everyday stress prevents me from getting vaccinated.

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- $\bigcirc$  moderately agree (6)
- $\bigcirc$  strongly agree (7)

X-

constraints2 For me, it is inconvenient to receive vaccinations.

- $\bigcirc$  moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- $\bigcirc$  moderately agree (6)
- $\bigcirc$  strongly agree (7)

X-

constraints3 Visiting the doctor's makes me feel uncomfortable; this keeps me from getting vaccinated.

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- $\bigcirc$  strongly agree (7)

X-

calculation1 When I think about getting vaccinated, I weigh benefits and risks to make the best decision possible.

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- $\bigcirc$  strongly agree (7)

X

calculation2 For each and every vaccination, I closely consider whether it is useful for me.

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- $\bigcirc$  neutral (4)
- $\bigcirc$  slightly agree (5)
- $\bigcirc$  moderately agree (6)
- $\bigcirc$  strongly agree (7)

X-

calculation3 It is important for me to fully understand the topic of vaccination, before I get vaccinated.

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- $\bigcirc$  strongly agree (7)

X

collectiverespon1 When everyone else is vaccinated, I don't have to get vaccinated, too.

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- $\bigcirc$  strongly agree (7)

X-

collectiverespon2 I get vaccinated because I can also protect people with a weaker immune system.

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- $\bigcirc$  strongly agree (7)

X

collectiverespon3 Vaccination is a collective action to prevent the spread of diseases.

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- $\bigcirc$  strongly agree (7)

t\_5Cscale Timing First Click (1) Last Click (2) Page Submit (3) Click Count (4)

t\_5Cscale Durée First Click (1) Last Click (2) Page Submit (3) Click Count (4)

End of Block: 5CScale

**Start of Block: Emotion** 

 $X \rightarrow$ 

emotion1 I am worried about getting \${e://Field/diseasedescEN}.

- $\bigcirc$  moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- $\bigcirc$  moderately agree (6)
- $\bigcirc$  strongly agree (7)

emotion2 I am worried about people in my life (family, friends) getting \${e://Field/diseasedescEN}.

- O strongly disagree (1)
- $\bigcirc$  moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- $\bigcirc$  strongly agree (7)

emotion3 I am worried about vulnerable people in my community (babies, young children, older people, cancer patients) getting \${e://Field/diseasedescEN}.

- $\bigcirc$  moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- $\bigcirc$  strongly agree (7)

emotion4 I would feel guilty if someone in my life (a family member, a friend) got the \${e://Field/diseasedescEN} from me.

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- $\bigcirc$  strongly agree (7)

emotion5 I would feel guilty if a vulnerable person (a baby, a young child, an older person, a cancer patient) got \${e://Field/diseasedescEN} from me.

O strongly disagree (1)

- moderately disagree (2)
- $\bigcirc$  slightly disagree (3)
- O neutral (4)
- $\bigcirc$  slightly agree (5)
- O moderately agree (6)
- strongly agree (7)

t\_emotion Timing First Click (1) Last Click (2) Page Submit (3) Click Count (4)

t\_emotion Durée First Click (1) Last Click (2) Page Submit (3) Click Count (4)

**End of Block: Emotion** 

Start of Block: Knowledge

 $X \rightarrow$ 

know01 When a person gets vaccinated, it can help protect: (check one)

 $\bigcirc$  The person (1)

 $\bigcirc$  The people around them (2)

○ Vulnerable people in their community (3)

 $\bigcirc$  All of the above (4)

know02 Which people are considered more vulnerable to contagious diseases, either because they can catch them more easily, or the diseases can make them sicker? (check all that apply)

People who are very old (1)
People who are very young (babies, etc.) (2)
People who are athletes (3)
People who have cancer (4)
People who are healthy adults (5)

X→

statement For the following statements, please indicate whether they are true, false, or you don't know:

	True (1)	False (0)	l don't know (77)
<pre>\${e://Field/diseasedescEN_CAP} can spread from one person to another person. (know03)</pre>	0	0	0
When you come into contact with someone who is infected with \${e://Field/diseasedescEN}, there is a chance you could get the disease. (know04)	0	0	0
The only way to get \${e://Field/diseasedescEN} is to touch someone who has the disease. (know05)	0	0	0
<pre>\${e://Field/diseasedescEN_CAP} always spread through groups of     people at the same speed.         (know07)</pre>	0	0	0
Some vaccines provide less protection than others. (know08)	0	$\bigcirc$	0
Every vaccine provides full protection from a single dose (one needle/shot, one dose of drops in the mouth, or a one spray up the nose). (know10)	0	0	0
Some vaccines only provide partial protection after one dose and require multiple doses to get protected. (know11)	0	0	0
Some vaccines become less effective over time and need booster doses. (know12)	0	0	0
Community protection (or herd immunity) means everyone in the community has been vaccinated. (know13)	0	0	0
Unvaccinated people in a population can be protected from infections when enough people in their community are vaccinated. (know14)	0	0	0

0	0	0
0	0	0
0	0	0

Every person in a community (100%) must be vaccinated to achieve community protection. (know15)

The percentage of people (that is, how many members of a community) who must be vaccinated for the community to achieve community protection depends on the disease and the vaccine. (know16)

An individual's decision to get vaccinated or not affects only that individual. (know17)

t\_know Durée First Click (1) Last Click (2) Page Submit (3) Click Count (4)

End of Block: Knowledge

**Start of Block: Trust** 

 $X \rightarrow$ 

trustinfo \${e://Field/trustq\_EN}

not at all trustworthy (1)

moderately untrustworthy (2)

 $\bigcirc$  slightly untrustworthy (3)

O neutral (4)

 $\bigcirc$  slightly trustworthy (5)

moderately trustworthy (6)

 $\bigcirc$  strongly trustworthy (7)

t\_trustinfo Timing First Click (1) Last Click (2) Page Submit (3) Click Count (4)

t\_trustinfo Durée First Click (1) Last Click (2) Page Submit (3) Click Count (4)

**End of Block: Trust** 

**Start of Block: Behavioural intentions** 



immune To the best of your knowledge, are you already immune to \${e://Field/diseasedescEN}?

O Yes (1)

O No (0)

 $\bigcirc$  I don't know (77)



Q For the next question, imagine you were **not** already immune to \${e://Field/diseasedescEN}.

vaxintention If you were eligible to receive a free vaccine against \${e://Field/diseasedescEN}, how likely would you be to get vaccinated?

Extremely unlikely, I Extremely likely, I would would definitely NOT bedefinitely BE vaccinated vaccinated



\_\_\_\_\_

t\_vaxintention Timing First Click (1) Last Click (2) Page Submit (3) Click Count (4)

 $X \rightarrow$ 

c19vax Have you already received a COVID-19 vaccine (between Dec 2020 and now)?

O Yes (1)

O No (0)

 $\bigcirc$  I don't know (77)

t\_c19vax Timing First Click (1) Last Click (2) Page Submit (3) Click Count (4) t\_c19vax Durée First Click (1) Last Click (2) Page Submit (3) Click Count (4)

Display This Question:

If Have you already received a COVID-19 vaccine (between Dec 2020 and now)? = No Or Have you already received a COVID-19 vaccine (between Dec 2020 and now)? = I don't know

c19vaxintention Assuming you will be eligible to get a COVID-19 vaccine this year, how likely are you to get the vaccine?

1 ()

Extremely unlikely, I will Extremely likely, I will definitely NOT get a definitely get a COVID-COVID-19 vaccine 19 vaccine



t\_c19vaxintention Timing First Click (1) Last Click (2) Page Submit (3) Click Count (4) t\_c19vaxintention Durée First Click (1)

Last Click (2) Page Submit (3) Click Count (4)

**End of Block: Behavioural intentions** 

Appendix 4. Descriptive analysis per anni.
--------------------------------------------

		control generic*	control measles*	control pertussis*	control flu*	herdimm generic*	herdimm measles*	herdimm pertussis*	herdimm flu*
Age: median (IQR)		45 (27)	44 (29)	45 (28)	46 (28)	40 (21)	41(25)	41(24)	40 (22)
Gender identity: n (%)	Male	158 (49)	163 (49)	156 (50)	163 (50)	289 (49)	320 (49)	320 (49)	345 (53)
	Female	164 (51)	171 (51)	156 (50)	168 (51)	304 (51)	345 (52)	335 (51)	317 (48)
	Not available**	0 (0)	1 (0)	5 (2)	2 (1)	6 (1)	6 (1)	7 (1)	8 (1)
Languag e(s) spoken: n (%)									
English	Yes	235 (73)	244 (73)	232 (74)	238 (72)	502 (85)	555 (84)	559 (85)	579 (88)
	No	86 (27)	90 (27)	83 (26)	93 (28)	92 (16)	109 (16)	98 (15)	83 (13)
	Not available	1 (0)	0 (0)	0 (0)	0 (0)	1 (0)	1 (0)	1 (0)	1 (0)
French	Yes	101 (31)	107 (32)	99 (31)	109 (33)	114 (19)	141 (21)	137 (21)	129 (20)
	No	221 (69)	227 (68)	216 (69)	222 (67)	481 (81)	524 (79)	521 (79)	534 (81)
	Not available	-	-	-	-	-	-	-	-
		control generic*	control measles*	control pertussis*	control flu*	herdimm generic*	herdimm measles*	herdimm pertussis*	herdimm flu*
------------------------------------	------------------	---------------------	---------------------	-----------------------	-----------------	---------------------	---------------------	-----------------------	-----------------
Ethnicity: n (%)									
White	Yes	235 (75)	255 (78)	248 (81)	253 (78)	490 (84)	558 (85)	570 (88)	563 (86)
	No	80 (25)	74 (22)	59 (19)	71 (22)	95 (16)	99 (15)	77 (12)	90 (14)
	Not available	7 (2)	5 (2)	8(3)	7 (2)	10 (2)	8 (1)	11 (2)	10 (2)
Asian	Yes	49 (16)	43 (13)	36 (12)	44 (14)	53 (9)	59 (9)	43 (7)	58 (9)
	No	266 (84)	286 (87)	271 (88)	280 (86)	532 (91)	598 (91)	604 (93)	595 (91)
	Not available	7 (2)	5 (2)	8 (3)	7 (2)	10 (2)	8 (1)	11 (2)	10 (2)
Other	Yes	29 (9)	36 (11)	28 (9)	29 (9)	41(7)	39 (6)	35 (5)	32 (5)
	No	286 (89)	293 (88)	279 (89)	295 (89)	544 (91)	618 (93)	612 (93)	621 (94)
	Not available	7 (2)	5 (2)	8 (3)	7 (2)	10 (2)	8 (1)	11 (2)	10 (2)
Disabilit y if any: n (%)	Yes	75 (24)	71 (22)	67( 22)	72 (22)	130 (22)	155 (24)	164 (25)	149 (23)
	No	244 (76)	253 (78)	240 (78)	251 (78)	453 (78)	501 (76)	482 (75)	500 (77)

		control generic*	control measles*	control pertussis*	control flu*	herdimm generic*	herdimm measles*	herdimm pertussis*	herdimm flu*
	Not available	3 (1)	10 (3)	8 (3)	8 (2)	12 (2)	9 (1)	12 (2)	14 (2)
Educati on levels: n (%)	College degree and above	173 (54)	158 (48)	167 (54)	174 (53)	399 (67)	440 (66)	431 (66)	419 (63)
	No college degree (elementary school, high school, apprentices hip or trade certificate)	145 (46)	171 (52)	144 (46)	155 (47)	195 (33)	224 (34)	222 (34)	241 (37)
	Not available	4 (1)	5 (2)	4 (1)	2 (1)	1 (0)	1 (0)	5 (1)	3 (1)
Place of birth (Canada): n (%)	Yes	254 (79)	280 (84)	266 (86)	274 (84)	518 (88)	573 (87)	569 (87)	569 (87)
	No	66 (21)	52 (16)	45 (14)	51 (16)	70 (12)	85 (13)	83 (13)	84 (13)
	Not available	2 (1)	2 (1)	4 (1)	6 (2)	7 (2)	7 (1)	6 (1)	10 (2)
Individual ism and	Vertical individualis	46.34 (16.43)	45.5 (17.13)	46.15 (16.69)	47.52 (17.48)	42.61 (14.58)	43.86 (15.78)	44.09 (15.26)	43.28 (15.24)

		control generic*	control measles*	control pertussis*	control flu*	herdimm generic*	herdimm measles*	herdimm pertussis*	herdimm flu*
collectivi sm: mean (SD)	m (e.g., "It is important that I do my job better than others.")								
	Horizontal individualis m (e.g., "I rely on myself most of the time, I rarely rely on others.")	7.21 (1.19)	7.25 (1.16)	7.31 (1.13)	7.2 (1.24)	7.1 (1.16)	7.28 (1.11)	7.22 (1.16)	7.2 (1.15)
	Vertical collectivism (e.g., "It is important to me that I respect the decisions made by my groups.")	6.86 (1.31)	6.84 (1.4 )	6.95 (1.45)	6.97 (1.37)	6.75 (1.36)	6.78 (1.4)	6.76 (1.37)	6.85 (1.42)
	Horizontal collectivism (e.g., "I feel good when I cooperate with others.")	6.82 (1.37)	6.69 (1.36)	6.84 (1.46)	6.95 (1.26)	6.82 (1.33)	6.86 (1.29)	6.82 (1.3)	6.92 (1.3)

\*Percentages may add up to +/-100% because of rounding. \*\*Data could be not available due to participants choosing another option (e.g., gender-nonconforming), choosing, "I prefer not to answer," or leaving the question unanswered.

Non Descriptive labels	labels
disease1	Measles
disease2	Pertussis
disease3	Flu
viz1	herdimm
language_1	English
language_2	French
edhi	We recoded this covariate as college degree and above and no college degree (elementary school, high school diploma, or apprenticeship or trade certificate or diploma.)
mean_indivhorz	Mean horizontal individualism
mean_indivvertical	Mean vertical individualism
mean_collhorz	Mean horizontal collectivism
mean_collvertical	Mean vertical collectivism

### Appendix 5: Complete results of models

### **Risk perception 1 (Objective risk perception)**

### Two-way

### Model 1: Check for direct effects of factors without any covariates ####

```
> options(contrasts=c("contr.sum", "contr.poly"))
> rlog_RP1_1 <- glm(relevel(RP1_dicho,ref="Low") ~ viz * disease,
data = datMain,family=binomial("logit"))
> options(contrasts=c("contr.sum", "contr.poly"))
> rlog_RP1_1 <- glm(relevel(RP1_dicho,ref="Low") ~ viz * disease,
data = datMain,family=binomial("logit"))
> Anova(rlog RP1 1,type="III")
```

Analysis of Deviance Table (Type III tests) Response: relevel(RP1 dicho, ref = "Low") LR Chisq Df Pr(>Chisq) 134.537 1 < 2e-16 \*\*\* viz disease 6.941 3 0.07379 . viz:disease 1.193 3 0.75470 \_\_\_ Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 `' 1 > summary(rlog RP1 1) Call: glm(formula = relevel(RP1 dicho, ref = "Low") ~ viz \* disease, family = binomial("logit"), data = datMain) Deviance Residuals: Min 1Q Median ЗQ Max -1.3974 -1.2660 0.9724 1.0755 1.4395 Coefficients: Estimate Std. Error z value Pr(>|z|)(Intercept) -0.0800911 0.0350116 -2.288 0.0222 \* -0.4011403 0.0350116 -11.457 <2e-16 \*\*\* viz1 disease1 -0.0148705 0.0610799 -0.243 0.8076

disease2 -0.0110067 0.0601345 -0.183 0.8548 disease3 -0.1158617 0.0613271 -1.889 0.0589.

viz1:disease1 0.0617254 0.0610799 1.011 0.3122 viz1:disease2 -0.0201992 0.0601345 -0.336 0.7369

viz1:disease3 -0.0007439 0.0613271 -0.012 0.9903 \_\_\_ Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1 (Dispersion parameter for binomial family taken to be 1) Null deviance: 5341.2 on 3854 degrees of freedom Residual deviance: 5196.2 on 3847 degrees of freedom (28 observations effacées parce que manquantes) AIC: 5212.2 Number of Fisher Scoring iterations: 4 > # Interpretation of model 1 > mRP1 v <- emmeans(rlog RP1 1,~viz,type = "response") #proportions NOTE: Results may be misleading due to involvement in interactions > mRP1 v response SE df asymp.LCL asymp.UCL viz 0.382 0.01355 Inf no visualization 0.355 0.409 herdimm 0.580 0.00977 Inf 0.560 0.599 Results are averaged over the levels of: disease Unknown transformation "relevel": no transformation done Confidence level used: 0.95 > plot(mRP1 v) > confint(pairs(mRP1 v,reverse = TRUE)) #Odds ratios contrast odds.ratio SE df asymp.LCL asymp.UCL

herdimm / no visualization 2.23 0.156 Inf 1.92 2.54

Results are averaged over the levels of: disease Unknown transformation "relevel": no transformation done Confidence level used: 0.95 > mRP1 d <- emmeans(rlog RP1 1, ~ disease, type = "response")</pre> #proportions NOTE: Results may be misleading due to involvement in interactions > mRP1 d SE df asymp.LCL asymp.UCL disease response Generic 0.476 0.0177 Inf 0.442 0.511 Measles 0.477 0.0172 Inf 0.443 0.511 Pertussis 0.451 0.0176 Inf 0.417 0.486 0.515 0.0172 Inf 0.482 0.549 Flu Results are averaged over the levels of: viz Unknown transformation "relevel": no transformation done Confidence level used: 0.95 > plot(mRP1 d) > confint(pairs(mRP1 d, reverse = FALSE)) #Odds ratios contrast odds.ratio SE df asymp.LCL asymp.UCL Measles / Generic 1.004 0.0993 Inf 0.749 1.26 Pertussis / Generic 0.904 0.0908 Inf 0.671 1.14 Pertussis / Measles 0.900 0.0894 Inf 0.671 1.13 Flu / Generic 1.170 0.1156 Inf 0.873 1.47

1.165 0.1137 Inf

0.873

1.46

Flu / Measles

Flu / Pertussis 1.294 0.1282 Inf 0.964 1.62 Results are averaged over the levels of: viz Unknown transformation "relevel": no transformation done Confidence level used: 0.95 Conf-level adjustment: tukey method for comparing a family of 4

### Model 2: Check for direct effects of factors with adjustment for other covariates

```
> rlog RP1 2 <-
```

estimates

```
+ glm(relevel(RP1 dicho, ref="Low") ~ viz * disease +
```

- + mean indivhorz +
- + mean indivvertical +
- + mean collhorz +
- + mean collvertical +
- + bornincanada +
- + language\_1 +
- + language 2 +
- + Asian group +
- + White group +
- + disability\_any +
- + genderidentity +
- + income +
- + edhi +
- + age,
- + data = datMain, family=binomial("logit")

+ )

```
> Anova(rlog_RP1_2, type = "III")
```

Analysis of Deviance Table (Type III tests)

Response: relevel(RP1 dicho, ref = "Low")

LR Chisq Df Pr(>Chisq)

viz	99.145	1	< 2.2e-16 ***
disease	4.503	3	0.2119784
mean_indivhorz	0.941	1	0.3319641
mean_indivvertical	0.744	1	0.3882938
mean_collhorz	14.842	1	0.0001169 ***
mean_collvertical	1.214	1	0.2704943
bornincanada	0.030	1	0.8628115
language_1	0.568	1	0.4509358
language_2	2.082	1	0.1490280
Asian_group	3.852	1	0.0496760 *
White_group	2.451	1	0.1174442
disability_any	0.000	1	0.9876937
genderidentity	2.371	1	0.1236102
income	17.023	3	0.0006991 ***
edhi	1.668	1	0.1964689
age	0.814	1	0.3669477
viz:disease	2.054	3	0.5611757

Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1

> summary(rlog RP1 2)

### Call:

glm(formula = relevel(RP1 dicho, ref = "Low") ~ viz \* disease +

mean\_indivhorz + mean\_indivvertical + mean\_collhorz +
mean\_collvertical +

bornincanada + language\_1 + language\_2 + Asian\_group +
White\_group + disability\_any + genderidentity + income + edhi + age,
family = binomial("logit"), data = datMain)

Deviance Residuals:

Min		1Q	Median	3Q	Max
-1.6602	-1.1533	C	0.8341	1.0694	1.7111

Coefficients:

Estimate Std. Error z value Pr(>|z|)

(Intercept)	-1.2372706	0.3035918	-4.075 4.59e-05 ***
viz1	-0.3843823	0.0390175	-9.852 < 2e-16 ***
disease1	-0.0040396	0.0652813	-0.062 0.950658
disease2	-0.0353700	0.0652503	-0.542 0.587772
disease3	-0.0886128	0.0664177	-1.334 0.182147
mean_indivhorz	0.0328459	0.0338591	0.970 0.332008
mean_indivvertio	cal -0.02051	22 0.023784	44 -0.862 0.388454
mean_collhorz	0.1269786	0.0331068	3.835 0.000125 ***
mean_collvertica	al 0.03533	44 0.032066	66 1.102 0.270502
bornincanadal	0.0099776	0.0577401	0.173 0.862807
language_11	-0.0616265	0.0817918	-0.753 0.451176
language_21	-0.1076321	0.0746361	-1.442 0.149277

Asian_group1	0.1715646	0.0875834	1.959 0.050128 .			
White_group1	0.1133617	0.0725047	1.564 0.117933			
disability_any1	0.0006842	0.0443622	0.015 0.987694			
genderidentity1	-0.0561817	0.0364970	-1.539 0.123719			
income1	-0.2487811	0.0840148	-2.961 0.003065 **			
income2	-0.0709786	0.0664042	-1.069 0.285121			
income3	0.0696654	0.0564833	1.233 0.217434			
edhi1	-0.0504610	0.0390503	-1.292 0.196285			
age	-0.0021782	0.0024144	-0.902 0.366961			
viz1:disease1	0.0916958	0.0651595	1.407 0.159353			
viz1:disease2	-0.0295778	0.0652268	-0.453 0.650217			
viz1:disease3	-0.0170697	0.0663730	-0.257 0.797042			
Signif. codes:	0 `***' 0.0	01 `**′ 0.01	···· 0.05 ··· 0.1 · / 1			
(Dispersion para	meter for b	inomial fami	ly taken to be 1)			
Null deviance:	4775.3 on	3447 degree	s of freedom			
Residual devianc	e: 4575.5	on 3424 deg	rees of freedom			
(435 observati	ons effacée	s parce que	manquantes)			
AIC: 4623.5						
Number of Fisher Scoring iterations: 4						
> # Interpretation of model 2						
<pre>&gt; mRP1_2_v &lt;- emmeans(rlog_RP1_2,~viz,type = "response")</pre>						

NOTE: Results may be misleading due to involvement in interactions > mRP1\_2\_v

viz	respor	nse SE	df asymp.	LCL asymp.	UCL	
no visual:	ization	0.384 0.0	0215 Inf	0.342	0.426	
herdimm		0.573 0.0	)217 Inf	0.531	0.616	
Results are language_1, genderident	e averaged o , language_2 tity, income	ver the . , Asian_ , edhi	levels of: group, Whit	disease, te_group,	bornincanada disability_a	ny,
Unknown tra	ansformation	"releve	l": no tran	nsformatio	n done	
Confidence	level used:	0.95				
> plot(mRP	1_2_v)					
> confint(p	pairs(mRP1_2	_v,rever	se = TRUE);	)		
contrast		odd	s.ratio SE	df asymp	.LCL asymp.U	JCL
herdimm /	no visualiz	ation	2.16 0.1	.68 Inf 1	.83 2.4	9
Results are language_1, genderident	e averaged o , language_2 tity, income	ver the , , Asian_ , edhi	levels of: group, Whit	disease, te_group,	bornincanada disability_a	ny,
Unknown tra	ansformation	"releve	l": no tran	nsformatio	n done	
Confidence	level used:	0.95				
> mRP1_2_d	<- emmeans(	rlog_RP1	_2, ~ dise	ease, type	= "response	e <b>"</b> )
NOTE: Resul	lts may be m	isleadin	g due to in	nvolvement	in interact	ions
> mRP1_2_d						
disease	response	SE df	asymp.LCL	asymp.UCL		
Generic	0.477 0.025	7 Inf	0.426	0.527		
Measles	0.469 0.025	8 Inf	0.418	0.520		
Pertussis	0.456 0.026	2 Inf	0.404	0.507		
Flu	0.510 0.025	8 Inf	0.459	0.560		

Results are averaged over the levels of: viz, bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

Unknown transformation "relevel": no transformation done

Confidence level used: 0.95

> plot(mRP1 2 d)

> confint(pairs(mRP1 2 d, reverse = TRUE))

contrast	odds.ratio	SE df	asymp.LCL	asymp.UCL
Measles / Generic	0.969	0.1032 Inf	0.704	1.23
Pertussis / Generic	0.919	0.0992 Inf	0.664	1.17
Pertussis / Measles	0.948	0.1022 Inf	0.686	1.21
Flu / Generic	1.141	0.1206 Inf	0.831	1.45
Flu / Measles	1.177	0.1245 Inf	0.858	1.50
Flu / Pertussis	1.242	0.1330 Inf	0.900	1.58

Results are averaged over the levels of: viz, bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

Unknown transformation "relevel": no transformation done

Confidence level used: 0.95

Conf-level adjustment: tukey method for comparing a family of 4 estimates

## Model 3: Check for moderating effects of individualism & collectivism with adjustment for other covariates

> rlog\_RP1\_3 <+ glm(relevel(RP1\_dicho,ref="Low") ~
+ viz \* disease \* mean\_indivhorz +
+ viz \* disease \* mean\_indivvertical +</pre>

```
+ viz * disease * mean collhorz +
```

```
+ viz * disease * mean_collvertical +
```

```
+ bornincanada +
```

```
+ language 1 +
```

```
+ language 2 +
```

```
+ Asian group +
```

```
+ White group +
```

```
+ disability_any +
```

```
+ genderidentity +
```

```
+ income +
```

```
+ edhi +
```

```
+ age,
```

)

```
+ data = datMain, family=binomial("logit")
```

```
+
```

```
> Anova(rlog_RP1_3, type = "III")
```

Analysis of Deviance Table (Type III tests)

```
Response: relevel(RP1 dicho, ref = "Low")
```

LR Chisq Df Pr(>Chisq)

viz	0.7868	1	0.3750784	
disease	0.3022	3	0.9596235	
mean_indivhorz	0.4402	1	0.5070139	
mean_indivvertical	0.0518	1	0.8199333	
mean_collhorz	12.8300	1	0.0003411	***
mean_collvertical	0.9290	1	0.3351292	

bornincanada	0.0279	1	0.8674032	
language_1	0.7579	1	0.3839776	
language_2	2.4752	1	0.1156556	
Asian_group	3.9343	1	0.0473122	*
White_group	2.6661	1	0.1025044	
disability_any	0.0002	1	0.9887741	
genderidentity	2.2450	1	0.1340512	
income	17.1811	3	0.0006486	***
edhi	1.5977	1	0.2062323	
age	0.9055	1	0.3413121	
viz:disease	0.3926	3	0.9417634	
viz:mean_indivhorz	0.6121	1	0.4339999	
disease:mean_indivhorz	3.1340	3	0.3714283	
viz:mean_indivvertical	1.6252	1	0.2023618	
disease:mean_indivvertical	0.9590	3	0.8111732	
viz:mean_collhorz	0.0371	1	0.8471999	
disease:mean_collhorz	0.4709	3	0.9252262	
viz:mean_collvertical	0.0134	1	0.9078471	
disease:mean_collvertical	1.1954	3	0.7540962	
viz:disease:mean_indivhorz	1.3141	3	0.7257980	
viz:disease:mean_indivvertical	1.6541	3	0.6471908	
viz:disease:mean_collhorz	1.6143	3	0.6561498	
viz:disease:mean_collvertical	1.0509	3	0.7889304	

\_\_\_

```
medRxiv preprint doi: https://doi.org/10.1101/2024.10.18.24314709; this version posted October 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license.
```

```
Signif. codes: 0 `***' 0.001 `**' 0.01 `*' 0.05 `.' 0.1 ` ' 1
> summary(rlog RP1 3)
Call:
glm(formula = relevel(RP1 dicho, ref = "Low") ~ viz * disease *
     mean indivhorz + viz * disease * mean indivvertical + viz *
     disease * mean collhorz + viz * disease * mean collvertical +
     bornincanada + language 1 + language 2 + Asian group +
White group +
     disability any + genderidentity + income + edhi + age, family =
binomial("logit"),
     data = datMain)
 Deviance Residuals:
     Min
                10
                     Median
                                30
                                      Max
-1.6729 -1.1513 0.8305 1.0642
                                     1.7068
Coefficients:
                                  Estimate Std. Error z value Pr(>|z|)
(Intercept)
                                 -1.220066 0.331571 -3.680 0.000234
* * *
                                 -0.273334
                                             0.308566 -0.886 0.375715
viz1
disease1
                                 -0.264449
                                             0.515026 -0.513 0.607624
disease2
                                  0.024359
                                             0.551847
                                                        0.044 0.964792
                                  0.193246
                                             0.549988
                                                        0.351 0.725315
disease3
mean indivhorz
                                  0.024186
                                             0.036459
                                                        0.663 0.507086
mean indivvertical
                                 -0.005925
                                             0.026027 -0.228 0.819913
                                  0.125924
                                             0.035397 3.557 0.000374
mean collhorz
***
```

mean_collvertical	0.033474	0.034761	0.963	0.335572
bornincanada1	0.009706	0.058134	0.167	0.867399
language_11	-0.071511	0.082192	-0.870	0.384274
language_21	-0.117862	0.074964	-1.572	0.115894
Asian_group1 *	0.173873	0.087836	1.980	0.047759
White_group1	0.119056	0.073001	1.631	0.102913
disability_any1	0.000629	0.044705	0.014	0.988774
genderidentity1	-0.055069	0.036764	-1.498	0.134158
income1 **	-0.252880	0.084649	-2.987	0.002814
income2	-0.072620	0.066955	-1.085	0.278099
income3	0.073967	0.056857	1.301	0.193282
edhil	-0.049780	0.039367	-1.264	0.206053
age	-0.002319	0.002437	-0.952	0.341332
viz1:disease1	0.279651	0.515453	0.543	0.587450
viz1:disease2	-0.250393	0.553360	-0.452	0.650912
viz1:disease3	0.037273	0.550251	0.068	0.945994
viz1:mean_indivhorz	-0.027963	0.035734	-0.783	0.433905
diseasel:mean_indivhorz	0.032513	0.061886	0.525	0.599329
disease2:mean_indivhorz	0.044438	0.062685	0.709	0.478382
disease3:mean_indivhorz	-0.113597	0.064417	-1.763	0.077821
viz1:mean_indivvertical	0.031819	0.024988	1.273	0.202899
diseasel:mean_indivvertical	0.022073	0.042855	0.515	0.606503

disease2:mean_indivvertical	0.012209	0.043235	0.282	0.777651
disease3:mean_indivvertical	0.006216	0.042493	0.146	0.883689
viz1:mean_collhorz	-0.006752	0.035027	-0.193	0.847143
disease1:mean_collhorz	0.025793	0.061596	0.419	0.675399
disease2:mean_collhorz	-0.032992	0.059849	-0.551	0.581464
disease3:mean_collhorz	0.019632	0.060708	0.323	0.746410
viz1:mean_collvertical	-0.003986	0.034431	-0.116	0.907833
disease1:mean_collvertical	-0.039039	0.060984	-0.640	0.522075
disease2:mean_collvertical	-0.031763	0.059356	-0.535	0.592556
disease3:mean_collvertical	0.055172	0.060415	0.913	0.361122
viz1:disease1:mean_indivhorz	-0.005886	0.061841	-0.095	0.924178
viz1:disease2:mean_indivhorz	0.069124	0.062627	1.104	0.269705
viz1:disease3:mean_indivhorz	-0.038323	0.064451	-0.595	0.552100
viz1:disease1:mean_indivvertical	-0.044082	0.042850	-1.029	0.303596
viz1:disease2:mean_indivvertical	0.042412	0.043270	0.980	0.327002
viz1:disease3:mean_indivvertical	0.014027	0.042503	0.330	0.741388
viz1:disease1:mean_collhorz	0.054583	0.061646	0.885	0.375932
viz1:disease2:mean_collhorz	-0.054661	0.059842	-0.913	0.361020
viz1:disease3:mean_collhorz	-0.031210	0.060773	-0.514	0.607563
viz1:disease1:mean_collvertical	-0.043031	0.060990	-0.706	0.480474
viz1:disease2:mean_collvertical	-0.018040	0.059462	-0.303	0.761596
viz1:disease3:mean_collvertical	0.054549	0.060450	0.902	0.366857

Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1

(Dispersion parameter for binomial family taken to be 1)

Null deviance: 4775.3 on 3447 degrees of freedom

Residual deviance: 4562.3 on 3396 degrees of freedom

(435 observations effacées parce que manquantes)

AIC: 4666.3

Number of Fisher Scoring iterations: 4

## Interpretation of model 3 : no interaction with moderator to interpret

### **Risk perception 2-6 (Subjective risk perception)**

### Two-way

### Model 1: Check for direct effects of factors without any covariates (for risk perception 2 to 6) ####

> options(contrasts=c("contr.sum", "contr.poly")) # CHANGELOG: The statement below is added to calculate properly the type III sum of squares with lm 2021-07-27

> mRP1\_2\_6 <- lm(mean\_riskperception2\_6 ~ viz \* disease, data =
datMain)</pre>

> Anova(mRP1 2 6,type="III")

Anova Table (Type III tests)

Response: mean riskperception2 6

Sum S	Sq	Df	F value	Pr(>F)	
(Intercept) 101	523	1	60871.3300	< 2.2e-16	* * *
viz	48	1	28.7856	8.558e-08	* * *
disease	28	3	5.6430	0.000743	***
viz:disease	14	3	2.8324	0.036917	*
Residuals 6463	3875				

```
___
Signif. codes: 0 `***' 0.001 `**' 0.01 `*' 0.05 `.' 0.1 ` ' 1
> summary(mRP1 2 6)
Call:
lm(formula = mean riskperception2 6 ~ viz * disease, data = datMain)
Residuals:
    Min 1Q Median 3Q
                            Max
-4.6087 -1.0622 0.2419 1.2063 1.9378
Coefficients:
          Estimate Std. Error t value Pr(>|t|)
(Intercept)
               5.41839 0.02196 246.721 < 2e-16 ***
         -0.11783 0.02196 -5.365 8.56e-08 ***
viz1
disease1 -0.03458 0.03847 -0.899 0.36875
disease2
               0.10543 0.03768 2.798 0.00517 **
disease3
              0.05746
                        0.03822
                                 1.503 0.13286
viz1:disease1 0.04147 0.03847
                                 1.078 0.28112
viz1:disease2 0.03293
                        0.03768
                                  0.874 0.38226
viz1:disease3 0.03563 0.03822 0.932 0.35135
___
Signif. codes: 0 `***' 0.001 `**' 0.01 `*' 0.05 `.' 0.1 ` ' 1
Residual standard error: 1.291 on 3875 degrees of freedom
```

Multiple R-squared: 0.01293, Adjusted R-squared: 0.01115 F-statistic: 7.25 on 7 and 3875 DF, p-value: 1.175e-08

> mRP1 2 6 vd <- emmeans(mRP1 2 6,~viz|disease)</pre>

> mRP1 2 6 vd

disease = Generic:

viz	emn	lean	SE	df ]	lower.CL	upper.CL
no visualizati	Lon	5.31	0.0720	3875	5.17	5.45
herdimm	5.4	6 0.0	529 387	5	5.36	5.56

disease = Measles:

viz	emmean	SE	df lot	wer.CL	upper.CL
no visualizatio	on 5.44 0	.0707	3875	5.30	5.58
herdimm	5.61 0.050	1 387	5	5.51	5.71
Jana Dantos					

disease = Pertussis:

viz	emmean	l	SE	df l	ower.CL	upper.CL
no visualizatio	n 5.	39 0.0	0728	3875	5.25	5.54
herdimm	5.56 0	.0503	387.	5	5.46	5.66

disease = Flu:

viz emmean SE df lower.CL upper.CL no visualization 5.06 0.0710 3875 4.92 5.20 herdimm 5.52 0.0502 3875 5.42 5.62

Confidence level used: 0.95

> pairs(mRP1\_2\_6\_vd) # Only do multiple comparisons if type 3 test is significant

disease = Generic:

contrast estimate SE df t.ratio p.value

no visualization - herdimm -0.153 0.0893 3875 -1.709 0.0875 disease = Measles: contrast estimate SE df t.ratio p.value no visualization - herdimm -0.170 0.0866 3875 -1.960 0.0500 disease = Pertussis: estimate SE df t.ratio p.value contrast no visualization - herdimm -0.164 0.0885 3875 -1.858 0.0632 disease = Flu: estimate SE df t.ratio p.value contrast no visualization - herdimm -0.456 0.0869 3875 -5.243 <.0001 > plot(mRP1 2 6 vd) > mRP1\_2\_6\_dv <- emmeans(mRP1\_2\_6,~disease|viz)</pre> > mRP1 2 6 dv viz = no visualization: SE df lower.CL upper.CL disease emmean Generic 5.31 0.0720 3875 5.17 5.45 Measles 5.44 0.0707 3875 5.58 5.30 Pertussis 5.39 0.0728 3875 5.25 5.54 Flu 5.06 0.0710 3875 4.92 5.20 viz = herdimm: disease SE df lower.CL upper.CL emmean Generic 5.46 0.0529 3875 5.36 5.56 Measles 5.61 0.0501 3875 5.51 5.71

Pertussis 5.56 0.0503 3875 5.46 5.66 5.52 0.0502 3875 Flu 5.42 5.62 Confidence level used: 0.95 > pairs(mRP1 2 6 dv) # Only do multiple comparisons if type 3 test is significant viz = no visualization: contrast estimate SE df t.ratio p.value -0.1315 0.1009 3875 -1.303 0.5607 Generic - Measles Generic - Pertussis -0.0862 0.1023 3875 -0.842 0.8343 Generic - Flu 0.2452 0.1011 3875 2.426 0.0724 Measles - Pertussis 0.0453 0.1014 3875 0.446 0.9703 0.3767 0.1002 3875 3.761 0.0010 Measles - Flu 0.3314 0.1017 3875 3.260 0.0062 Pertussis - Flu viz = herdimm: estimate SE df t.ratio p.value contrast Generic - Measles -0.1486 0.0729 3875 -2.038 0.1741 Generic - Pertussis -0.0979 0.0731 3875 -1.340 0.5375 Generic - Flu -0.0578 0.0729 3875 -0.792 0.8580 Measles - Pertussis 0.0507 0.0710 3875 0.713 0.8918 Measles - Flu 0.0908 0.0709 3875 1.281 0.5753 0.0401 0.0711 3875 0.564 0.9426 Pertussis - Flu P value adjustment: tukey method for comparing a family of 4 estimates

### Model 2: Check for direct effects of factors with adjustment for other covariates

```
> #CHANGELOG ASJ: change list of covariates after recoding and
deletion for <5% categories, 2021-08-04
>
> mRP2 2 6 <-
+
    lm(
     mean riskperception2 6 ~ viz * disease +
+
     mean indivhorz +
+
     mean indivvertical +
+
+
     mean collhorz +
     mean collvertical +
+
     bornincanada +
+
     language 1 +
+
+
     language 2 +
+
     Asian group +
     White group +
+
     disability any +
+
+
     genderidentity +
     income +
+
     edhi +
+
+
     age,
     data = datMain
+
+
    )
> Anova(mRP2 2 6, type = "III")
Anova Table (Type III tests)
```

Response: mean\_riskperception2\_6

	Sum Sq D	f	F value	Pr(>F)				
(Intercept)	1290.0	1	869.5460	< 2.2e-16	***			
viz	57.5	1	38.7881	5.295e-10	***			
disease	36.0	3	8.0840	2.302e-05	***			
mean_indivhorz	23.0	1	15.4788	8.508e-05	***			
mean_indivvertic	al 275.6	1	185.7474	< 2.2e-16	* * *			
mean_collhorz	18.5	1	12.4731	0.0004183	***			
mean_collvertica	1 12.2	1	8.1899	0.0042379	**			
bornincanada	3.8	1	2.5749	0.1086604				
language_1	4.7	1	3.2001	0.0737206	•			
language_2	2.7	1	1.7957	0.1803165				
Asian_group	0.4	1	0.2369	0.6264830				
White_group	0.3	1	0.1924	0.6609294				
disability_any	55.4	1	37.3121	1.119e-09	* * *			
genderidentity	6.4	1	4.3079	0.0380105	*			
income	36.0	3	8.0944	2.268e-05	* * *			
edhi	3.8	1	2.5492	0.1104447				
age	121.61 81	.9	744 < 2.2	e-16 ***				
viz:disease	23.6	3	5.3036	0.0012021	**			
Residuals	5103.5 344	0						
Signif. codes:	0 `***' 0.(	001	·**/ 0.0	)1 `*' 0.05	<b>`.′</b> 0	.1 `	,	1

> summary(mRP2\_2\_6)

### Call:

lm(formula = mean\_riskperception2\_6 ~ viz \* disease + mean\_indivhorz +

mean indivvertical + mean collhorz + mean collvertical +

bornincanada + language\_1 + language\_2 + Asian\_group +
White group +

```
disability_any + genderidentity + income + edhi + age, data =
datMain)
```

#### Residuals:

Min 1Q Median 3Q Max -5.3125 -0.9019 0.1312 0.9893 2.6108

### Coefficients:

	Estimate St	td. Error t	value Pr(>	t )
(Intercept)	5.252126	0.178110	29.488 < 2e	-16 ***
viz1	-0.142931	0.022950	-6.228 5.29	e-10 ***
disease1	-0.016014	0.038546	-0.415 0.67	7831
disease2	0.125488	0.038175	3.287 0.001	022 **
disease3	0.056686	0.038801	1.461 0.144	118
mean_indivhorz	0.078372	0.019920	3.934 8.51e	-05 ***
mean_indivvertio	al -0.19061	.0 0.01398	36 -13.629	< 2e-16 ***
mean_collhorz	0.068661	0.019441	3.532 0.000	418 ***
mean collvertica	l -0.05421	.2 0.01894	13 -2.862 0	.004238 **

bornincanada1	-0.054658	0.034062	-1.605 0.108660
language_11	0.086412	0.048305	1.789 0.073721 .
language_21	0.059010	0.044035	1.340 0.180316
Asian_group1	0.025106	0.051580	0.487 0.626483
White_group1	-0.018771	0.042791	-0.439 0.660929
disability_any1	0.159688	0.026143	6.108 1.12e-09 ***
genderidentity1	0.044696	0.021535	2.076 0.038010 *
income1	-0.203629	0.049311	-4.129 3.72e-05 ***
income2	0.016673	0.039208	0.425 0.670679
income3	0.140941	0.033363	4.225 2.46e-05 ***
edhi1	0.036862	0.023088	1.597 0.110445
age	0.012870	0.001421	9.054 < 2e-16 ***
viz1:disease1	0.057247	0.038468	1.488 0.136802
viz1:disease2	0.049503	0.038170	1.297 0.194755
viz1:disease3	0.044842	0.038774	1.156 0.247561

Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1

Residual standard error: 1.218 on 3440 degrees of freedom

(419 observations effacées parce que manquantes)
Multiple R-squared: 0.1369, Adjusted R-squared: 0.1312
F-statistic: 23.73 on 23 and 3440 DF, p-value: < 2.2e-16</pre>

> mRP2\_2\_6\_vd <- emmeans(mRP2\_2\_6,~viz|disease)</pre>

### > mRP2\_2\_6\_vd

```
disease = Generic:
```

viz	emmean	SE	df lot	wer.CL	upper.CL
no visualizatio	on 5.42 0	.0809	3440	5.26	5.58
herdimm	5.59 0.069	8 344	0	5.45	5.73

### disease = Measles:

viz	emmean	SE	df lov	wer.CL	upper.CL
no visualizatio	n 5.55 0	.0827	3440	5.39	5.71
herdimm	5.74 0.067	71 344	0	5.61	5.87

#### disease = Pertussis:

viz	emmean	1	SE	df lot	wer.CL	upper.CL
no visualizatio	n 5.4	8 0.0	0848	3440	5.31	5.64
herdimm	5.67 0.	0681	344	0	5.54	5.81

disease = Flu:

viz	emm	ean	SE	df	lower.CL	upper.CL
no visualizati	on	5.06	0.0822	344	0 4.90	5.22
herdimm	5.6	5 0.0	676 344	0	5.52	5.78

Results are averaged over the levels of: bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

Confidence level used: 0.95

> pairs(mRP2 2 6 vd) # Only do multiple comparisons if type 3 test is significant disease = Generic: contrast estimate SE df t.ratio p.value no visualization - herdimm -0.171 0.0897 3440 -1.910 0.0563 disease = Measles: df t.ratio p.value contrast estimate SE no visualization - herdimm -0.187 0.0887 3440 -2.106 0.0353 disease = Pertussis: estimate SE df t.ratio p.value contrast no visualization - herdimm -0.196 0.0908 3440 -2.162 0.0307 disease = Flu:estimate SE df t.ratio p.value contrast no visualization - herdimm -0.589 0.0884 3440 -6.661 <.0001 Results are averaged over the levels of: bornincanada, language 1, language 2, Asian group, White group, disability any, genderidentity, income, edhi > plot(mRP2\_2\_6\_vd) # Explore options for less ugly plot for publication/thesis > > mRP2 2 6 dv <- emmeans(mRP2 2 6,~disease|viz)</pre> > mRP2 2 6 dv

viz = no visualization:

disease	emmean	SE di	f lower.CL	upper.CL
Generic	5.42 0.0809	3440	5.26	5.58
Measles	5.55 0.0827	3440	5.39	5.71
Pertussis	5.48 0.08	348 3440	5.31	5.64
Flu	5.06 0.0822	2 3440	4.90	5.22

viz = herdimm:

disease	emmean	SE	df lower.CL	upper.CL
Generic	5.59 0.0698	3 3440	5.45	5.73
Measles	5.74 0.0673	1 3440	5.61	5.87
Pertussis	5.67 0.0	681 34	40 5.54	5.81
Flu	5.65 0.067	6 3440	5.52	5.78

Results are averaged over the levels of: bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

Confidence level used: 0.95

> pairs(mRP2\_2\_6\_dv) # Only do multiple comparisons if type 3 test is
significant

viz = no visualization:

contrast	estimate SE	df t.	ratio p	.value
Generic - Measles	-0.1338 0.1020	3440	-1.311	0.5560
Generic - Pertussis	-0.0603 0.1038	3440	-0.581	0.9378
Generic - Flu	0.3590 0.1016	3440	3.533	0.0024

Measles -	Pertussis	0.073	5 0.1042	2 3440	0.705	0.8951
Measles -	Flu	0.4927	0.1022	3440	4.820	<.0001
Pertussis	- Flu	0.4193	0.1039	3440	4.035	0.0003

viz = herdimm:

contrast	estimate SE	df t.	.ratio p	.value
Generic - Measles	-0.1492 0.0725	3440	-2.059	0.1668
Generic - Pertussis	-0.0851 0.0727	3440	-1.171	0.6452
Generic - Flu	-0.0587 0.0725	3440	-0.810	0.8499
Measles - Pertussis	0.0641 0.0705	3440	0.910	0.7995
Measles - Flu	0.0906 0.0703 3	3440	1.287	0.5710
Pertussis - Flu	0.0264 0.0705 3	3440	0.375	0.9821

Results are averaged over the levels of: bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

P value adjustment: tukey method for comparing a family of 4 estimates

# Model 3: Check for moderating effects of individualism & collectivism with adjustment for other covariates

```
> mRP3_2_6 <-
+ lm(
+ mean_riskperception2_6 ~
+ viz * disease * mean_indivhorz +</pre>
```

```
+ viz * disease * mean indivvertical +
```

```
+ viz * disease * mean collhorz +
```

```
+ viz * disease * mean collvertical +
```

```
+ bornincanada +
```

```
+ language 1 +
```

```
+ language_2 +
```

```
+ Asian group +
```

```
+ White group +
```

```
+ disability_any +
```

```
+ genderidentity +
```

```
+ income +
```

```
+ edhi +
```

```
+ age,
```

```
+ data = datMain
```

```
+ )
```

```
> Anova(mRP3_2_6, type = "III")
```

Anova Table (Type III tests)

```
Response: mean riskperception2 6
```

	Sum Sq	Df	F value	Pr(>F)	
(Intercept)	1047.	91	716.6940	< 2.2e-16	* * *
viz	3.	2 1	2.1952	0.1385346	
disease	23.	73	5.3948	0.0010573	* *
mean_indivhorz	17.	8 1	12.1958	0.0004851	* * *
mean_indivvertical	157.	91	108.0030	< 2.2e-16	***

mean_collhorz	21.5	1	14.7221	0.0001268	***
mean_collvertical	13.7	1	9.3499	0.0022472	* *
bornincanada	4.5	1	3.0785	0.0794237	•
language_1	4.8	1	3.2494	0.0715364	
language_2	2.3	1	1.5555	0.2124109	
Asian_group	0.3	1	0.1850	0.6671728	
White_group	0.0	1	0.0117	0.9137622	
disability_any	51.8	1	35.4543	2.876e-09	***
genderidentity	7.2	1	4.9324	0.0264237	*
income	36.1	3	8.2197	1.896e-05	* * *
edhi	3.0	1	2.0294	0.1543757	
age	108.5	1	74.2377	< 2.2e-16	***
viz:disease	2.9	3	0.6691	0.5709438	
viz:mean_indivhorz	5.5	1	3.7357	0.0533429	
disease:mean_indivhorz	30.6	3	6.9784	0.0001118	***
viz:mean_indivvertical	45.6	1	31.2066	2.501e-08	***
disease:mean_indivvertical	2.7	3	0.6081	0.6097023	
viz:mean_collhorz	5.6	1	3.8465	0.0499299	*
disease:mean_collhorz	1.1	3	0.2592	0.8548273	
viz:mean_collvertical	5.6	1	3.8335	0.0503207	
disease:mean_collvertical	3.1	3	0.7043	0.5493584	
viz:disease:mean_indivhorz	8.0	3	1.8299	0.1394644	
viz:disease:mean_indivvertical	6.5	3	1.4882	0.2156734	
viz:disease:mean_collhorz	6.2	3	1.4027	0.2400508	

medRxiv preprint doi: https://doi.org/10.1101/2024.10.18.24314709; this version posted October 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license. viz:disease:mean collvertical 7.3 3 1.6614 0.1731695 Residuals 4988.8 3412 \_\_\_ Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1 > summary(mRP3 2 6) Call: lm(formula = mean riskperception2 6 ~ viz \* disease \* mean indivhorz + viz \* disease \* mean indivvertical + viz \* disease \* mean collhorz + viz \* disease \* mean collvertical + bornincanada + language 1 + language 2 + Asian group + White group + disability any + genderidentity + income + edhi + age, data = datMain) Residuals: Min 10 Median 30 Max -5.5146 -0.9026 0.1188 0.9901 2.6264 Coefficients: Estimate Std. Error t value Pr(>|t|) 5.119656 0.191238 26.771 < 2e-16 (Intercept) \*\*\* viz1 -0.262906 0.177445 -1.482 0.138535 -0.207575 0.298125 -0.696 0.486307 disease1 disease2 0.018653 0.315541 0.059 0.952864 disease3 -0.890051 0.314521 -2.830 0.004684 \*\* mean indivhorz 0.073631 0.021084 3.492 0.000485

\*\*\*

<pre>mean_indivvertical ***</pre>	-0.156605	0.015069	-10.392	< 2e-16
<pre>mean_collhorz ***</pre>	0.077808	0.020279	3.837	0.000127
<pre>mean_collvertical **</pre>	-0.061468	0.020102	-3.058	0.002247
bornincanadal	-0.059627	0.033984	-1.755	0.079424
language_11	0.086694	0.048093	1.803	0.071536
language_21	0.054667	0.043832	1.247	0.212411
Asian_group1	0.022077	0.051334	0.430	0.667173
White_group1	0.004630	0.042751	0.108	0.913762
disability_any1 ***	0.155111	0.026050	5.954	2.88e-09
genderidentity1 *	0.047724	0.021489	2.221	0.026424
income1 ***	-0.204520	0.049157	-4.161	3.25e-05
income2	0.007103	0.039110	0.182	0.855887
income3 ***	0.141228	0.033260	4.246	2.23e-05
edhi1	0.032852	0.023061	1.425	0.154376
age ***	0.012247	0.001421	8.616	< 2e-16
viz1:disease1	0.084059	0.298389	0.282	0.778184
viz1:disease2	-0.368701	0.316511	-1.165	0.244144
viz1:disease3	-0.048925	0.314674	-0.155	0.876453
viz1:mean_indivhorz	-0.039969	0.020679	-1.933	0.053343
diseasel:mean_indivhorz	0.015116	0.036099	0.419	0.675428
-------------------------------------------	-----------	----------	--------	----------
disease2:mean_indivhorz	0.040223	0.036070	1.115	0.264878
disease3:mean_indivhorz *	0.094139	0.036966	2.547	0.010921
viz1:mean_indivvertical ***	0.080747	0.014455	5.586	2.50e-08
disease1:mean_indivvertical	-0.004002	0.024912	-0.161	0.872371
disease2:mean_indivvertical	0.005490	0.024827	0.221	0.824990
disease3:mean_indivvertical	-0.027332	0.024440	-1.118	0.263500
viz1:mean_collhorz *	0.039367	0.020072	1.961	0.049930
disease1:mean_collhorz	0.025438	0.035229	0.722	0.470297
disease2:mean_collhorz	-0.018287	0.034516	-0.530	0.596277
disease3:mean_collhorz	0.007966	0.034184	0.233	0.815740
viz1:mean_collvertical .	-0.038973	0.019905	-1.958	0.050321
disease1:mean_collvertical	-0.010672	0.035616	-0.300	0.764467
disease2:mean_collvertical	-0.011774	0.034393	-0.342	0.732123
disease3:mean_collvertical	0.048407	0.034326	1.410	0.158572
viz1:disease1:mean_indivhorz	-0.011523	0.036071	-0.319	0.749410
viz1:disease2:mean_indivhorz	0.013563	0.036027	0.376	0.706593
<pre>viz1:disease3:mean_indivhorz .</pre>	0.065112	0.036980	1.761	0.078370
viz1:disease1:mean_indivvertical	0.039675	0.024903	1.593	0.111205
viz1:disease2:mean_indivvertical	0.009363	0.024849	0.377	0.706335
viz1:disease3:mean_indivvertical	-0.043781	0.024448	-1.791	0.073418

•

viz1:disease1:mean_collhorz	0.053518	0.035268	1.517	0.129241
viz1:disease2:mean_collhorz	0.007187	0.034511	0.208	0.835035
<pre>viz1:disease3:mean_collhorz .</pre>	-0.061586	0.034224	-1.799	0.072033
<pre>viz1:disease1:mean_collvertical *</pre>	-0.076700	0.035625	-2.153	0.031391
viz1:disease2:mean_collvertical	0.033591	0.034451	0.975	0.329611
viz1:disease3:mean_collvertical	0.037282	0.034339	1.086	0.277695
Signif. codes: 0 `***' 0.001 `*	*' 0.01 `*'	0.05 '.' 0	.1 ` ′ 1	

Residual standard error: 1.209 on 3412 degrees of freedom

```
(419 observations effacées parce que manquantes)
Multiple R-squared: 0.1563, Adjusted R-squared: 0.1437
F-statistic: 12.4 on 51 and 3412 DF, p-value: < 2.2e-16
> > mRP3_2_6_d <- emmeans(mRP3_2_6, ~ disease)
NOTE: Results may be misleading due to involvement in interactions
> mRP3_2_6_d
```

diseaseemmeanSEdflower.CLupper.CLGeneric5.500.060734125.385.61Measles5.640.061034125.525.76Pertussis5.550.062234125.435.67Flu5.360.061134125.245.48

Results are averaged over the levels of: viz, bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

Confidence level used: 0.95

> pairs(mRP3\_2\_6\_d) # Only do multiple comparisons if type 3 test is significant

contrast	estimate SE df t	.ratio p.value
Generic - Measles	-0.1492 0.0629 3412	-2.374 0.0823
Generic - Pertussis	-0.0550 0.0635 3412	-0.866 0.8226
Generic - Flu	0.1355 0.0626 3412	2.163 0.1340
Measles - Pertussis	0.0942 0.0637 3412	1.480 0.4499
Measles - Flu	0.2847 0.0628 3412	4.533 <.0001
Pertussis - Flu	0.1905 0.0634 3412	3.003 0.0143

Results are averaged over the levels of: viz, bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

P value adjustment: tukey method for comparing a family of 4 estimates

> plot(mRP3 2 6 d)







### **Emotions**

## Two-way

### Model 1: Check for direct effects of factors without any covariates ####

```
> mEmotions_1 <- lm(mean_emotion ~ viz * disease, data = datMain)
> Anova(mEmotions_1,type="III")
Anova Table (Type III tests)
Response: mean_emotion
    Sum Sq Df F value Pr(>F)
```

(Intercept) 86042 1 45899.2910 < 2.2e-16 \*\*\* 13.1273 0.0002948 \*\*\* viz 25 1 442 3 78.5368 < 2.2e-16 \*\*\* disease 3 8 1.4856 0.2163553 viz:disease Residuals 7264 3875 \_\_\_ Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1 > summary(mEmotions 1) Call: lm(formula = mean emotion ~ viz \* disease, data = datMain) Residuals: Min 10 Median 30 Max -4.4808 -0.8808 0.1842 1.0791 2.5311 Coefficients: Estimate Std. Error t value Pr(>|t|) 0.02328 214.241 < 2e-16 \*\*\* (Intercept) 4.98820 viz1 -0.08436 0.02328 -3.623 0.000295 \*\*\* 0.04079 12.069 < 2e-16 \*\*\* disease1 0.49228 disease2 -0.39332 0.03995 -9.845 < 2e-16 \*\*\* disease3 -0.28728 0.04052 -7.089 1.59e-12 \*\*\* viz1:disease1 0.08400 0.04079 2.059 0.039518 \* viz1:disease2 -0.04166 0.03995 -1.043 0.297091 viz1:disease3 -0.03053 0.04052 -0.753 0.451277

\_\_\_

Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1 Residual standard error: 1.369 on 3875 degrees of freedom Multiple R-squared: 0.06262, Adjusted R-squared: 0.06093 F-statistic: 36.98 on 7 and 3875 DF, p-value: < 2.2e-16 > mEmotions 1 v <- emmeans(mEmotions 1,~viz)</pre> NOTE: Results may be misleading due to involvement in interactions > mEmotions 1 v viz SE df lower.CL upper.CL emmean no visualization 4.90 0.038 3875 4.98 4.83 herdimm 5.07 0.027 3875 5.02 5.13 Results are averaged over the levels of: disease Confidence level used: 0.95 > plot(mEmotions 1 v) > mEmotions 1 d <- emmeans(mEmotions 1, ~ disease)</pre> NOTE: Results may be misleading due to involvement in interactions > mEmotions 1 d disease emmean SE df lower.CL upper.CL 5.48 0.0474 3875 5.39 5.57 Generic Measles 4.59 0.0459 3875 4.50 4.68 Pertussis 4.70 0.0469 3875 4.61 4.79

5.09

5.27

Results are averaged over the levels of: viz

5.18 0.0461 3875

Confidence level used: 0.95

Flu

> pairs(mEmotions\_1\_d) # Only do multiple comparisons if type 3 test
is significant

contrast	estimate	SE	df	t.ratio	p.value
Generic - Measles	0.886	0.0660	3875	13.426	<.0001
Generic - Pertussis	0.780	0.0667	3875	11.695	<.0001
Generic - Flu	0.304	0.0661	3875	4.600	<.0001
Measles - Pertussis	-0.106	0.0656	3875	-1.616	0.3699
Measles - Flu	-0.582	0.0650	3875	-8.943	<.0001
Pertussis - Flu	-0.476	0.0657	3875	-7.234	<.0001

Results are averaged over the levels of: viz

P value adjustment: tukey method for comparing a family of 4 estimates

## Model 2: Check for direct effects of factors with adjustment for other covariates

```
> mEmotions 2 <-
```

```
+ lm(
```

+ mean emotion ~ viz \* disease +

+ mean indivhorz +

```
+ mean indivvertical +
```

+ mean collhorz +

+ mean collvertical +

```
+ bornincanada + #CHANGELOG ASJ: covariate list shortened 2021-
08-04
```

+ language 1 +

+ language\_2 +

+ Asian\_group +

+ White\_group +

```
^+
        disability any +
        genderidentity +
+
        income +
+
        edhi +
+
+
        age,
      data = datMain
+
^{+}
    )
> Anova(mEmotions 2, type = "III")
Anova Table (Type III tests)
Response: mean emotion
                   Sum Sq
                           Df F value Pr(>F)
(Intercept)
                    477.1
                             1 282.7357 < 2.2e-16 ***
                      4.9
                                 2.9305 0.087009 .
viz
                             1
disease
                    382.0
                             3
                                75.4663 < 2.2e-16 ***
mean indivhorz
                     16.0
                             1
                                9.4949 0.002077 **
     indimuntical
                     12 2
                              1
                                 25 6527 4 2026
me
```

mean_indivvertical	43.3	1	25.6527	4.302e-07	***
mean_collhorz	105.4	1	62.4423	3.663e-15	***
mean_collvertical	47.3	1	28.0367	1.265e-07	***
bornincanada	0.6	1	0.3840	0.535521	
language_1	4.1	1	2.4494	0.117661	
language_2	0.1	1	0.0365	0.848408	
Asian_group	2.4	1	1.4398	0.230253	
White_group	1.5	1	0.8640	0.352682	
disability any	40.6	1	24.0744	9.698e-07	***

```
genderidentity
                    52.9
                            1 31.3216 2.357e-08 ***
income
                     20.0
                                3.9542 0.007937 **
                            3
edhi
                     8.6
                                5.0942 0.024069 *
                            1
                                2.7296 0.098596 .
age
                     4.6
                            1
viz:disease
                      8.9
                            3
                                1.7638 0.151878
Residuals
                  5804.7 3440
___
Signif. codes: 0 `***' 0.001 `**' 0.01 `*' 0.05 `.' 0.1 ` ' 1
> summary(mEmotions 2)
Call:
lm(formula = mean emotion ~ viz * disease + mean indivhorz +
   mean indivvertical + mean collhorz + mean collvertical +
   bornincanada + language 1 + language 2 + Asian group + White group
+
   disability any + genderidentity + income + edhi + age, data =
datMain)
Residuals:
            10 Median
   Min
                            30
                                   Max
-5.0215 -0.8450 0.1745 0.9612 3.1640
Coefficients:
                   Estimate Std. Error t value Pr(>|t|)
                              0.189953 16.815 < 2e-16 ***
(Intercept)
                   3.194016
viz1
                  -0.041900
                              0.024476 -1.712 0.08701 .
disease1
                  0.497976
                              0.041109 12.114 < 2e-16 ***
                              0.040713 -9.794 < 2e-16 ***
disease2
                  -0.398729
```

disease3	-0.269408	0.041381	-6.510	8.58e-11	***
mean_indivhorz	-0.065463	0.021245	-3.081	0.00208	**
mean_indivvertical	0.075545	0.014916	5.065	4.30e-07	***
mean_collhorz	0.163841	0.020734	7.902	3.66e-15	***
mean_collvertical	0.106974	0.020203	5.295	1.26e-07	***
bornincanada1	0.022510	0.036327	0.620	0.53552	
language_11	0.080627	0.051517	1.565	0.11766	
language_21	0.008978	0.046963	0.191	0.84841	
Asian_group1	0.066008	0.055010	1.200	0.23025	
White_group1	-0.042421	0.045637	-0.930	0.35268	
disability_any1	0.136799	0.027881	4.907	9.70e-07	***
genderidentity1	0.128534	0.022967	5.597	2.36e-08	***
incomel	-0.170171	0.052590	-3.236	0.00122	**
income2	0.023860	0.041815	0.571	0.56829	
income3	0.037599	0.035581	1.057	0.29072	
edhi1	-0.055574	0.024623	-2.257	0.02407	*
age	0.002505	0.001516	1.652	0.09860	•
viz1:disease1	0.092047	0.041026	2.244	0.02492	*
viz1:disease2	-0.049539	0.040708	-1.217	0.22371	
viz1:disease3	-0.018986	0.041353	-0.459	0.64618	

Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1 Residual standard error: 1.299 on 3440 degrees of freedom

(419 observations effacées parce que manquantes)

Multiple R-squared: 0.1448, Adjusted R-squared: 0.139 F-statistic: 25.31 on 23 and 3440 DF, p-value: < 2.2e-16 > mEmotions 2 v <- emmeans (mEmotions 2,~viz) NOTE: Results may be misleading due to involvement in interactions > mEmotions 2 v emmean df lower.CL upper.CL viz SE no visualization 5.04 0.0570 3440 5.15 4.93 herdimm 5.12 0.0557 3440 5.01 5.23 Results are averaged over the levels of: disease, bornincanada, language 1, language 2, Asian group, White group, disability any, genderidentity, income, edhi Confidence level used: 0.95 > plot(mEmotions 2 v) > mEmotions 2 d <- emmeans(mEmotions 2, ~ disease)</pre> NOTE: Results may be misleading due to involvement in interactions > mEmotions 2 d disease emmean df lower.CL upper.CL SE 5.58 0.0648 3440 5.45 Generic 5.71 Measles 4.68 0.0649 3440 4.55 4.81 Pertussis 4.81 0.0662 3440 4.68 4.94 Flu 5.25 0.0649 3440 5.12 5.38

Results are averaged over the levels of: viz, bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

Confidence level used: 0.95

> pairs(mEmotions\_2\_d) # Only do multiple comparisons if type 3 test
is significant

contrast	estimate	SE	df	t.ratio	p.value
Generic - Measles	0.897	0.0668	3440	13.429	<.0001
Generic - Pertussis	0.767	0.0676	3440	11.347	<.0001
Generic - Flu	0.328	0.0666	3440	4.923	<.0001
Measles - Pertussis	-0.129	0.0671	3440	-1.928	0.2165
Measles - Flu	-0.569	0.0662	3440	-8.596	<.0001
Pertussis - Flu	-0.440	0.0670	3440	-6.565	<.0001

Results are averaged over the levels of: viz, bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

P value adjustment: tukey method for comparing a family of 4 estimates

# Model 3: Check for moderating effects of individualism & collectivism with adjustment for other covariates

```
> mEmotions 3 <-
+
    lm(
      mean emotion ~
^+
        viz * disease * mean indivhorz +
+
        viz * disease * mean indivvertical +
+
        viz * disease * mean collhorz +
+
        viz * disease * mean collvertical +
+
        bornincanada + #CHANGELOG ASJ: covariate list shortened 2021-
+
08 - 04
+
        language 1 +
+
        language 2 +
```

```
+ Asian_group +
```

```
+ White group +
```

- + disability\_any +
- + genderidentity +
- + income +
- + edhi +
- + age,
- + data = datMain
- + )

```
> Anova(mEmotions 3, type = "III")
```

```
Anova Table (Type III tests)
```

```
Response: mean emotion
```

	Sum Sq	Df	F value	Pr(>F)	
(Intercept)	435.5	1	260.4980	< 2.2e-16	***
viz	3.6	1	2.1566	0.1420470	
disease	19.3	3	3.8388	0.0093137	**
mean_indivhorz	13.3	1	7.9560	0.0048206	**
mean_indivvertical	29.2	1	17.4907	2.960e-05	***
mean_collhorz	89.0	1	53.2458	3.643e-13	***
mean_collvertical	36.9	1	22.0572	2.751e-06	***
bornincanada	0.3	1	0.2018	0.6532923	
language_1	3.4	1	2.0067	0.1566974	
language_2	0.0	1	0.0089	0.9248792	
Asian_group	2.1	1	1.2604	0.2616512	

White_group	1.8	1	1.1036	0.2935579		
disability_any	41.8	1	25.0122	5.984e-07	***	
genderidentity	55.1	1	32.9685	1.019e-08	***	
income	19.5	3	3.8955	0.0086106	**	
edhi	7.9	1	4.7368	0.0295918	*	
age	5.2	1	3.1294	0.0769792	•	
viz:disease	0.3	3	0.0691	0.9763966		
viz:mean_indivhorz	1.4	1	0.8542	0.3554259		
disease:mean_indivhorz	8.5	3	1.7030	0.1641963		
viz:mean_indivvertical	3.8	1	2.2624	0.1326437		
disease:mean_indivvertical	29.0	3	5.7740	0.0006187	***	
viz:mean_collhorz	0.2	1	0.1425	0.7058583		
disease:mean_collhorz	1.9	3	0.3885	0.7612813		
viz:mean_collvertical	1.0	1	0.6117	0.4341908		
disease:mean_collvertical	2.7	3	0.5388	0.6557366		
viz:disease:mean_indivhorz	10.5	3	2.0840	0.1001869		
viz:disease:mean_indivvertical	4.6	3	0.9163	0.4320920		
viz:disease:mean_collhorz	22.7	3	4.5229	0.0035968	* *	
viz:disease:mean_collvertical	5.3	3	1.0570	0.3661375		
Residuals	5704.5	3412				
Signif. codes: 0 `***' 0.001	`**′ 0.C	)1 `*'	0.05 `.'	0.1 ' 1	L	
<pre>&gt; summary(mEmotions_3)</pre>						

Call:

```
lm(formula = mean emotion ~ viz * disease * mean indivhorz +
    viz * disease * mean indivvertical + viz * disease * mean collhorz
+
    viz * disease * mean collvertical + bornincanada + language 1 +
    language 2 + Asian group + White group + disability any +
    genderidentity + income + edhi + age, data = datMain)
Residuals:
            10 Median
    Min
                             30
                                    Max
-4.8307 -0.8326 0.1854 0.9500 3.1323
Coefficients:
                                  Estimate Std. Error t value Pr(>|t|)
                                  3.300575
                                             0.204497 16.140 < 2e-16
(Intercept)
***
viz1
                                  0.278655
                                             0.189748
                                                        1.469 0.142047
                                                        2.325 0.020147
                                  0.741100
                                             0.318795
disease1
disease2
                                 -0.385695
                                             0.337419 -1.143 0.253088
                                             0.336328 -2.516 0.011923
disease3
                                 -0.846124
*
                                             0.022546 -2.821 0.004821
mean indivhorz
                                 -0.063594
**
                                             0.016114
                                                        4.182 2.96e-05
                                  0.067392
mean indivvertical
***
                                             0.021685
                                                        7.297 3.64e-13
mean collhorz
                                  0.158233
***
mean collvertical
                                             0.021496
                                                        4.697 2.75e-06
                                  0.100957
***
bornincanada1
                                  0.016325
                                             0.036340
                                                        0.449 0.653292
```

language_11	0.072852	0.051428	1.417	0.156697
language_21	0.004420	0.046871	0.094	0.924879
Asian_group1	0.061627	0.054893	1.123	0.261651
White_group1	-0.048025	0.045716	-1.051	0.293558
disability_any1 ***	0.139315	0.027856	5.001	5.98e-07
genderidentity1 ***	0.131940	0.022979	5.742	1.02e-08
income1 **	-0.167638	0.052565	-3.189	0.001440
income2	0.019546	0.041822	0.467	0.640265
income3	0.038619	0.035566	1.086	0.277627
edhil *	-0.053671	0.024660	-2.176	0.029592
age •	0.002689	0.001520	1.769	0.076979
viz1:disease1	-0.008251	0.319077	-0.026	0.979372
viz1:disease2	0.102371	0.338456	0.302	0.762316
viz1:disease3	-0.138933	0.336492	-0.413	0.679716
viz1:mean_indivhorz	-0.020438	0.022113	-0.924	0.355426
diseasel:mean_indivhorz	0.057945	0.038602	1.501	0.133426
disease2:mean_indivhorz	-0.050536	0.038571	-1.310	0.190216
disease3:mean_indivhorz	0.040915	0.039530	1.035	0.300720
viz1:mean_indivvertical	-0.023249	0.015457	-1.504	0.132644
diseasel:mean_indivvertical ***	-0.102503	0.026639	-3.848	0.000121

disease2:mean_indivvertical *	0.064341	0.026549	2.424	0.015423
disease3:mean_indivvertical	0.041311	0.026134	1.581	0.114034
viz1:mean_collhorz	0.008102	0.021464	0.377	0.705858
disease1:mean_collhorz	0.013902	0.037672	0.369	0.712122
disease2:mean_collhorz	-0.032382	0.036909	-0.877	0.380358
disease3:mean_collhorz	-0.009992	0.036554	-0.273	0.784610
viz1:mean_collvertical	-0.016648	0.021285	-0.782	0.434191
disease1:mean_collvertical	-0.031870	0.038086	-0.837	0.402768
disease2:mean_collvertical	0.033988	0.036777	0.924	0.355476
disease3:mean_collvertical	0.018906	0.036706	0.515	0.606545
viz1:disease1:mean_indivhorz	-0.046718	0.038572	-1.211	0.225903
viz1:disease2:mean_indivhorz	0.043263	0.038525	1.123	0.261528
<pre>viz1:disease3:mean_indivhorz .</pre>	0.065099	0.039544	1.646	0.099801
viz1:disease1:mean_indivvertical	0.011224	0.026629	0.422	0.673412
viz1:disease2:mean_indivvertical	-0.018731	0.026572	-0.705	0.480902
viz1:disease3:mean_indivvertical	-0.028146	0.026143	-1.077	0.281728
viz1:disease1:mean_collhorz **	0.117797	0.037714	3.123	0.001802
viz1:disease2:mean_collhorz **	-0.096573	0.036903	-2.617	0.008912
viz1:disease3:mean_collhorz	-0.041413	0.036597	-1.132	0.257890
<pre>viz1:disease1:mean_collvertical .</pre>	-0.063272	0.038095	-1.661	0.096824
viz1:disease2:mean_collvertical	0.043736	0.036840	1.187	0.235238

viz1:disease3:mean\_collvertical 0.010858 0.036720 0.296 0.767476
---

Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1 Residual standard error: 1.293 on 3412 degrees of freedom

(419 observations effacées parce que manquantes)
Multiple R-squared: 0.1595, Adjusted R-squared: 0.147
F-statistic: 12.7 on 51 and 3412 DF, p-value: < 2.2e-16</pre>



## Knowledge

#### Two-way

#### Model 1: Check for direct effects of factors without any covariates ####

> mKnowledge 1 <- lm(sum knowledge ~ viz \* disease, data = datMain)</pre>

```
> Anova(mKnowledge 1,type="III")
```

Anova Table (Type III tests)

Response: sum\_knowledge

```
Sum Sq
                  Df
                        F value
                                    Pr(>F)
(Intercept) 270957 1 39192.6506 < 2.2e-16 ***
                          36.3666 1.788e-09 ***
viz
              251
                    1
                    3 5.1982 0.001392 **
disease
              108
                         2.5345 0.055118 .
viz:disease
               53
                   3
Residuals 26790 3875
___
Signif. codes: 0 `***' 0.001 `**' 0.01 `*' 0.05 `.' 0.1 ` ' 1
> summary(mKnowledge 1)
Call:
lm(formula = sum knowledge ~ viz * disease, data = datMain)
Residuals:
     Min
            10 Median
                          30
                                Max
-9.2670 -1.9627 0.0015 1.9203 5.5683
Coefficients:
```

Estimate Std. Error t value Pr(>|t|)

(Intercept) 8.85194 0.04471 197.971 < 2e-16 \*\*\* -0.26964 0.04471 -6.030 1.79e-09 \*\*\* viz1 0.20002 0.07833 2.554 0.01070 \* disease1 disease2 -0.21029 0.07672 -2.741 0.00615 \*\* disease3 -0.13683 0.07782 -1.758 0.07879. viz1:disease1 0.18042 0.07833 2.303 0.02131 \* viz1:disease2 -0.16841 0.07672 -2.195 0.02822 \* viz1:disease3 -0.01373 0.07782 -0.176 0.86001 \_\_\_ Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1 Residual standard error: 2.629 on 3875 degrees of freedom Multiple R-squared: 0.01425, Adjusted R-squared: 0.01247

F-statistic: 8.003 on 7 and 3875 DF, p-value: 1.106e-09

> mKnowledge 1 v

viz emmean SE df lower.CL upper.CL no visualization 8.58 0.0729 3875 8.44 8.73 herdimm 9.12 0.0518 3875 9.02 9.22 Results are averaged over the levels of: disease Confidence level used: 0.95 > plot(mKnowledge\_1\_v) > mKnowledge\_1\_d <- emmeans(mKnowledge\_1, ~ disease)</pre>

NOTE: Results may be misleading due to involvement in interactions > mKnowledge\_1\_d

disease emmean SE df lower.CL upper.CL

Generic	9.05 0.0910 3875	8.87	9.23
Measles	8.64 0.0882 3875	8.47	8.81
Pertussis	8.72 0.0901 3875	8.54	8.89
Flu	9.00 0.0885 3875	8.83	9.17

Results are averaged over the levels of: viz

Confidence level used: 0.95

> pairs(mKnowledge\_1\_d) # Only do multiple comparisons if type 3 test
is significant

contrast	estimate SE df	t.ratio p.value
Generic - Measles	0.4103 0.127 3875	3.239 0.0066
Generic - Pertussis	0.3368 0.128 3875	2.631 0.0424
Generic - Flu	0.0529 0.127 3875	0.417 0.9756
Measles - Pertussis	-0.0735 0.126 3875	-0.583 0.9373
Measles - Flu	-0.3574 0.125 3875	-2.861 0.0220
Pertussis - Flu	-0.2839 0.126 3875	-2.249 0.1105

Results are averaged over the levels of: viz

P value adjustment: tukey method for comparing a family of 4 estimates

## Model 2: Check for direct effects of factors with adjustment for other covariates

```
> mKnowledge 2 <-
```

```
+ lm(
```

- + sum knowledge ~ viz \* disease +
- + mean indivhorz +
- + mean indivvertical +
- + mean collhorz +

```
+ mean collvertical +
```

```
+ bornincanada + #CHANGELOG ASJ: covariate list shortened 2021-08-
```

04

```
+ language 1 +
```

```
+ language 2 +
```

```
+ Asian group +
```

```
+ White group +
```

- + disability any +
- + genderidentity +
- + income +

```
+ edhi +
```

+ age,

```
+ data = datMain
```

+ )

```
> Anova(mKnowledge 2, type = "III")
```

Anova Table (Type III tests)

Response: sum knowledge

	Sum Sq Df	F value	Pr(>F)
(Intercept)	3845.9 1	613.7038	< 2.2e-16 ***
viz	195.7 1	31.2254	2.476e-08 ***
disease	101.9 3	5.4199	0.001020 **
mean_indivhorz	138.3	1 22.0	0687 2.734e-06 ***
mean_indivvertio	al 613.3	1 97.86	597 < 2.2e-16 ***
mean_collhorz	12.6	1 2.01	.19 0.156161

mean_collvertical	176.6	1 28.1776 1.177e-07 ***
bornincanada	0.2 1	0.0306 0.861181
language_1	0.5 1	0.0728 0.787382
language_2	0.1 1	0.0087 0.925645
Asian_group	29.6 1	4.7163 0.029945 *
White_group	51.6 1	8.2395 0.004124 **
disability_any	27.9 1	4.4558 0.034855 *
genderidentity	19.4	1 3.0930 0.078718.
income	154.2 3	8.2021 1.943e-05 ***
edhi	12.9 1	2.0513 0.152163
age	319.0 1	50.9008 1.179e-12 ***
viz:disease	62.0 3	3.2962 0.019652 *
Residuals 21557	.7 3440	
Signif. codes: 0 `**	*′ 0.001	`**' 0.01 `*' 0.05 `.' 0.1 `' 1
<pre>&gt; summary(mKnowledge_</pre>	2)	
Call:		
<pre>lm(formula = sum_know</pre>	ledge ~	viz * disease + mean_indivhorz +
mean_indivvertic	cal + mea	an_collhorz + mean_collvertical +
bornincanada + 1 White_group +	.anguage_	_1 + language_2 + Asian_group +
disability_any + datMain)	- genderi	identity + income + edhi + age, data
Residuals:		
Min 1Q Mec	lian 3Ç	) Max

=

-9.5302 -1.6472 0.1765 1.8945 6.0874

#### Coefficients:

	Estimate Std. Error t value Pr(> t )
(Intercept)	9.068508 0.366064 24.773 < 2e-16 ***
viz1	-0.263572 0.047168 -5.588 2.48e-08 ***
disease1	0.254299 0.079222 3.210 0.00134 **
disease2	-0.166158 0.078460 -2.118 0.03427 *
disease3	-0.185772 0.079746 -2.330 0.01989 *
mean_indivhorz	0.192331 0.040941 4.698 2.73e-06 ***
mean_indivvertic	al -0.284364 0.028744 -9.893 < 2e-16 ***
mean_collhorz	0.056675 0.039957 1.418 0.15616
mean_collvertica	1 -0.206670 0.038934 -5.308 1.18e-07 ***
bornincanada1	-0.012243 0.070006 -0.175 0.86118
language_11	0.026779 0.099279 0.270 0.78738
language_21	0.008447 0.090504 0.093 0.92565
Asian_group1	0.230226 0.106011 2.172 0.02995 *
White_group1	0.252449 0.087948 2.870 0.00412 **
disability_any1	0.113416 0.053730 2.111 0.03486 *
genderidentityl	-0.077839 0.044259 -1.759 0.07872 .
incomel	-0.414060 0.101348 -4.086 4.50e-05 ***
income2	-0.056751 0.080582 -0.704 0.48132
income3	0.132385 0.068569 1.931 0.05360.
edhi1	-0.067962 0.047451 -1.432 0.15216
age	0.020844 0.002922 7.134 1.18e-12 ***

```
viz1:disease1 0.225499 0.079063 2.852 0.00437 **
              -0.158270 0.078450 -2.017 0.04373 *
viz1:disease2
viz1:disease3 0.009383 0.079691 0.118 0.90628
___
Signif. codes: 0 `***' 0.001 `**' 0.01 `*' 0.05 `.' 0.1 ` ' 1
Residual standard error: 2.503 on 3440 degrees of freedom
  (419 observations effacées parce que manguantes)
Multiple R-squared: 0.08506, Adjusted R-squared: 0.07894
F-statistic: 13.9 on 23 and 3440 DF, p-value: < 2.2e-16
> mKnowledge 2 vd <- emmeans(mKnowledge 2,~viz|disease)</pre>
> mKnowledge 2 vd
disease = Generic:
viz
                         SE df lower.CL upper.CL
               emmean
no visualization 9.13 0.166 3440 8.80
                                           9.45
herdimm
             9.20 0.144 3440 8.92 9.48
disease = Measles:
viz
               emmean SE
                            df lower.CL upper.CL
no visualization 8.32 0.170 3440 7.99 8.66
             9.17 0.138 3440 8.90 9.44
herdimm
disease = Pertussis:
viz
               emmean SE df lower.CL upper.CL
no visualization 8.47 0.174 3440 8.13 8.81
herdimm 8.98 0.140 3440 8.70 9.25
```

disease = Flu:

viz emmean SE df lower.CL upper.CL no visualization 8.67 0.169 3440 8.34 9.00 9.35 0.139 3440 9.08 9.62 herdimm Results are averaged over the levels of: bornincanada, language 1, language 2, Asian group, White group, disability any, genderidentity, income, edhi Confidence level used: 0.95 > pairs(mKnowledge 2 vd) # Only do multiple comparisons if type 3 test is significant disease = Generic: estimate SE df t.ratio p.value contrast no visualization - herdimm -0.0761 0.184 3440 -0.413 0.6797 disease = Measles: contrast estimate SE df t.ratio p.value no visualization - herdimm -0.8437 0.182 3440 -4.627 <.0001 disease = Pertussis: contrast estimate SE df t.ratio p.value no visualization - herdimm -0.5084 0.187 3440 -2.725 0.0065 disease = Flu: contrast estimate SE df t.ratio p.value no visualization - herdimm -0.6804 0.182 3440 -3.743 0.0002 Results are averaged over the levels of: bornincanada, language 1, language 2, Asian group, White group, disability any, genderidentity, income, edhi > plot(mKnowledge 2 vd) > mKnowledge 2 dv <- emmeans(mKnowledge 2,~disease|viz)</pre>

> mKnowledge\_2\_dv

viz = no visualization:

disease	emmean	SE	2 df	lower.CL	upper.CL
Generic	9.13	0.166	3440	8.80	9.45
Measles	8.32	0.170	3440	7.99	8.66
Pertussis	8.47	0.174	3440	8.13	8.81
Flu	8.67	0.169	3440	8.34	9.00

viz = herdimm:

disease	emmean	SE	df df	lower.CL	upper.CL
Generic	9.20	0.144	3440	8.92	9.48
Measles	9.17	0.138	3440	8.90	9.44
Pertussis	8.98	0.140	3440	8.70	9.25
Flu	9.35	0.139	3440	9.08	9.62

Results are averaged over the levels of: bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

Confidence level used: 0.95

> pairs(mKnowledge\_2\_dv) # Only do multiple comparisons if type 3 test
is significant

viz = no visualization:

 contrast
 estimate
 SE
 df t.ratio p.value

 Generic - Measles
 0.8042
 0.210
 3440
 3.835
 0.0007

 Generic - Pertussis
 0.6562
 0.213
 3440
 3.076
 0.0113

 Generic - Flu
 0.4588
 0.209
 3440
 2.197
 0.1243

 Measles - Pertussis
 -0.1480
 0.214
 3440
 -0.691
 0.9004

Measles - Flu	-0.3454 0.210 3440 -1.644 0.3540
Pertussis - Flu	-0.1974 0.214 3440 -0.924 0.7919
viz = herdimm:	
contrast	estimate SE df t.ratio p.value
Generic - Measles	0.0367 0.149 3440 0.246 0.9948
Generic - Pertussis	0.2240 0.149 3440 1.499 0.4380
Generic - Flu	-0.1454 0.149 3440 -0.976 0.7630
Measles - Pertussis	0.1873 0.145 3440 1.293 0.5675
Measles - Flu	-0.1821 0.145 3440 -1.260 0.5886
Pertussis - Flu	-0.3694 0.145 3440 -2.549 0.0528

Results are averaged over the levels of: bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

P value adjustment: tukey method for comparing a family of 4 estimates

## Model 3: Check for moderating effects of individualism & collectivism with adjustment for other covariates

```
> mKnowledge 3 <-
+
    lm(
     sum knowledge ~
+
+
     viz * disease * mean_indivhorz +
     viz * disease * mean indivvertical +
+
     viz * disease * mean collhorz +
+
+
     viz * disease * mean collvertical +
     bornincanada + #CHANGELOG ASJ: covariate list shortened 2021-08-
+
04
+
     language 1 +
```

```
+ language_2 +
```

```
+ Asian_group +
```

```
+ White group +
```

```
+ disability_any +
```

```
+ genderidentity +
```

```
+ income +
```

+ edhi +

+ age,

)

```
+ data = datMain
```

```
+
```

```
> Anova(mKnowledge 3, type = "III")
```

Anova Table (Type III tests)

Response: sum knowledge

	Sum Sq	Df F value Pr(>F)
(Intercept)	3098.9	1 496.4341 < 2.2e-16 ***
viz	14.2 1	2.2730 0.1317400
disease	48.8 3	2.6083 0.0499439 *
mean_indivhorz	113.91	18.2538 1.986e-05 ***
mean_indivvertical	379.41	60.7743 8.437e-15 ***
mean_collhorz	15.5 1	2.4797 0.1154176
mean_collvertical	144.81	23.1948 1.528e-06 ***
bornincanada	0.1 1	0.0091 0.9241715
language_1	0.3 1	0.0472 0.8281107
language_2	0.0 1	0.0074 0.9312850

Asian_group	29.0 1 4.6501 0.0311214 *
White_group	60.4 1 9.6746 0.0018837 **
disability_any	24.1 1 3.8588 0.0495671 *
genderidentity	16.4 1 2.6291 0.1050123
income	165.23 8.8199 8.012e-06 ***
edhi	12.2 1 1.9594 0.1616648
age	291.31 46.6646 9.933e-12 ***
viz:disease	77.4 3 4.1346 0.0061797 **
viz:mean_indivhorz	10.2 1 1.6331 0.2013679
disease:mean_indivhorz	22.8 3 1.2169 0.3019200
viz:mean_indivvertical	69.3 1 11.1059 0.0008697 ***
disease:mean_indivvertical	15.0 3 0.8009 0.4932355
viz:mean_collhorz	9.0 1 1.4338 0.2312218
disease:mean_collhorz	13.6 3 0.7286 0.5348361
viz:mean_collvertical	2.1 1 0.3386 0.5606861
disease:mean_collvertical	20.1 3 1.0740 0.3588160
viz:disease:mean_indivhorz	10.9 3 0.5827 0.6263226
viz:disease:mean_indivvertica	1 5.8 3 0.3082 0.8194584
viz:disease:mean_collhorz	2.4 3 0.1260 0.9447159
viz:disease:mean_collvertical	43.9 3 2.3466 0.0708305 .
Residuals 21	299.1 3412

\_\_\_

Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1
> summary(mKnowledge\_3)

```
Call:
lm(formula = sum knowledge ~ viz * disease * mean indivhorz +
     viz * disease * mean indivvertical + viz * disease *
mean collhorz +
     viz * disease * mean collvertical + bornincanada + language 1 +
     language 2 + Asian group + White group + disability any +
     genderidentity + income + edhi + age, data = datMain)
Residuals:
              10 Median
                           30
     Min
                                 Max
-9.4256 -1.6255 0.1538 1.8771 5.9932
Coefficients:
                                Estimate Std. Error t value Pr(>|t|)
                                8.804181 0.395147 22.281 < 2e-16
(Intercept)
* * *
                                -0.552772
                                          0.366648 -1.508 0.131740
viz1
disease1
                                0.832961
                                           0.616002
                                                      1.352 0.176399
disease2
                                -0.315740
                                           0.651989 -0.484 0.628224
                                -1.546495
                                            0.649880 -2.380 0.017383
disease3
mean indivhorz
                                0.186130
                                           0.043565
                                                      4.272 1.99e-05
***
                                -0.242735
                                           0.031137 -7.796 8.44e-15
mean indivvertical
***
                                0.065982
                                           0.041901 1.575 0.115418
mean collhorz
                                -0.200044
                                           0.041537 -4.816 1.53e-06
mean collvertical
***
bornincanada1
                                -0.006684
                                            0.070220 -0.095 0.924171
```

language_11	0.021578	0.099373	0.217 0.828111
language_21	-0.007810	0.090567	-0.086 0.931285
Asian_group1	0.228727	0.106069	2.156 0.031121 *
White_group1 **	0.274759	0.088335	3.110 0.001884
disability_any1	0.105735	0.053826	1.964 0.049567 *
genderidentity1	-0.071995	0.044402	-1.621 0.105012
income1 ***	-0.424961	0.101570	-4.184 2.94e-05
income2	-0.068079	0.080812	-0.842 0.399601
income3	0.139800	0.068723	2.034 0.042004 *
edhil	-0.066700	0.047650	-1.400 0.161665
age ***	0.020063	0.002937	6.831 9.93e-12
vizl:diseasel ***	2.089741	0.616548	3.389 0.000708
viz1:disease2	-0.989636	0.653993	-1.513 0.130316
viz1:disease3	-1.043932	0.650197	-1.606 0.108463
viz1:mean_indivhorz	-0.054603	0.042728	-1.278 0.201368
diseasel:mean_indivhorz	-0.111898	0.074590	-1.500 0.133661
disease2:mean_indivhorz	0.067611	0.074531	0.907 0.364387
disease3:mean_indivhorz	0.090626	0.076382	1.186 0.235517
viz1:mean_indivvertical ***	0.099532	0.029867	3.333 0.000870
disease1:mean_indivvertical	0.053314	0.051474	1.036 0.300395
disease2:mean_indivvertical	0.027883	0.051299	0.544 0.586793

disease3:mean_indivvertical	-0.013011	0.050499	-0.258 0.796700
viz1:mean_collhorz	0.049663	0.041475	1.197 0.231222
diseasel:mean_collhorz	-0.022577	0.072792	-0.310 0.756457
disease2:mean_collhorz	-0.085513	0.071319	-1.199 0.230604
disease3:mean_collhorz	0.027768	0.070632	0.393 0.694245
viz1:mean_collvertical	-0.023932	0.041129	-0.582 0.560686
disease1:mean_collvertical	0.015869	0.073592	0.216 0.829289
disease2:mean_collvertical	0.016401	0.071064	0.231 0.817494
disease3:mean_collvertical	0.082808	0.070927	1.168 0.243082
viz1:disease1:mean_indivhorz	-0.083871	0.074531	-1.125 0.260538
viz1:disease2:mean_indivhorz	0.075909	0.074442	1.020 0.307943
viz1:disease3:mean_indivhorz	0.014277	0.076409	0.187 0.851791
viz1:disease1:mean_indivvertical	-0.032055	0.051455	-0.623 0.533344
viz1:disease2:mean_indivvertical	0.031742	0.051344	0.618 0.536473
<pre>viz1:disease3:mean_indivvertical</pre>	0.024596	0.050516	0.487 0.626364
viz1:disease1:mean_collhorz	0.006155	0.072873	0.084 0.932690
viz1:disease2:mean_collhorz	-0.021965	0.071308	-0.308 0.758081
viz1:disease3:mean_collhorz	-0.023475	0.070717	-0.332 0.739945
<pre>viz1:disease1:mean_collvertical *</pre>	-0.166587	0.073610	-2.263 0.023692
viz1:disease2:mean_collvertical	0.040229	0.071185	0.565 0.572025
<pre>viz1:disease3:mean_collvertical *</pre>	0.142723	0.070954	2.011 0.044353

\_\_\_

Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1

Residual standard error: 2.498 on 3412 degrees of freedom

(419 observations effacées parce que manquantes)
Multiple R-squared: 0.09603, Adjusted R-squared: 0.08252
F-statistic: 7.107 on 51 and 3412 DF, p-value: < 2.2e-16</pre>



Vax intention

Two-way

Model 1
```
medRxiv preprint doi: https://doi.org/10.1101/2024.10.18.24314709; this version posted October 18, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license.
   > options(contrasts=c("contr.sum", "contr.poly"))
   > rlog vi 1 <- glm(vaxintentRel ~ viz * disease, data =</pre>
   datMain, family=binomial("logit"))
   > Anova(rlog vi 1,type="III")
   Analysis of Deviance Table (Type III tests)
   Response: vaxintentRel
                   LR Chisq Df Pr(>Chisq)
                  9.4136 1
                                  0.002154 **
   viz
                  15.0225 3 0.001798 **
   disease
   viz:disease
                      3.7223 3 0.293055
    ___
   Signif. codes: 0 `***' 0.001 `**' 0.01 `*' 0.05 `.' 0.1 ` ' 1
   > summary(rlog vi 1)
   Call:
   glm(formula = vaxintentRel ~ viz * disease, family =
   binomial("logit"),
           data = datMain)
   Deviance Residuals:
       Min
                   10 Median
                                        30
                                                 Max
   -1.303 -1.161 1.057
                                   1.194
                                               1.279
   Coefficients:
                         Estimate Std. Error z value Pr(>|z|)
    (Intercept) -0.021170 0.034217 -0.619 0.53612
                  -0.104892 0.034217 -3.066 0.00217 **
   viz1
```

disease1 0.128075 0.059932 2.137 0.03260 \*
disease2 0.135581 0.058819 2.305 0.02116 \*
disease3 -0.116625 0.059511 -1.960 0.05003 .
viz1:disease1 -0.039518 0.059932 -0.659 0.50965
viz1:disease2 -0.070144 0.058819 -1.193 0.23305
viz1:disease3 0.006676 0.059511 0.112 0.91068
----

Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1 (Dispersion parameter for binomial family taken to be 1) Null deviance: 5362.1 on 3867 degrees of freedom Residual deviance: 5327.2 on 3860 degrees of freedom

(15 observations effacées parce que manquantes) AIC: 5343.2

Number of Fisher Scoring iterations: 3

> # Interpretation of model 1

> mvi\_1\_v <- emmeans(rlog\_vi\_1,~viz,type = "response") #proportions
NOTE: Results may be misleading due to involvement in interactions
> mvi\_1\_v

viz prob SE df asymp.LCL asymp.UCL no visualization 0.469 0.01388 Inf 0.441 0.496 herdimm 0.521 0.00991 Inf 0.501 0.540 Results are averaged over the levels of: disease Confidence level used: 0.95 Intervals are back-transformed from the logit scale

```
> plot(mvi_1_v)
```

> confint(pairs(mvi 1 v,reverse = TRUE)) #Odds ratios

contrast	odds.ratio S	E df	asymp.LCL	asymp.UCL
herdimm / no visualizati	on 1.23 0.0844	Inf	1.08	1.41

Results are averaged over the levels of: disease

Confidence level used: 0.95

Intervals are back-transformed from the log odds ratio scale

```
> mvi_1_d <- emmeans(rlog_vi_1, ~ disease, type = "response")
#proportions</pre>
```

NOTE: Results may be misleading due to involvement in interactions

> mvi 1 d

	disease	prob	SE	df	asymp.LCL	asymp.	UCL		
	Generic	0.527	0.0173	Inf	0.493	0	.561		
	Measles	0.529	0.0169	Inf	0.495	0	.561		
	Pertussis	0.466	0.0171	Inf	0.432	0.	499		
	Flu	0.458	0.0168	Inf	0.425	0	.491		
F	Results are	e avera	aged ove	er th	e levels c	f: viz			
C	Confidence	level	used: (	).95					
]	Intervals a	are bac	ck-trans	sform	ed from th	e logit	scale		
>	> plot(mvi_	_1_d)							
>	> pairs(mvi	1_d,1	reverse	= TR	UE,type =	"respor	ise")		
	contrast		00	lds.ra	atio	SE df	null z.ra	atio p.va	lue
	Measles /	Generi	Lc	1	.008 0.097	78 Inf1	0.077	0.9998	

Pertussis / Generic	0.783	0.0766	Inf1	-2.500	0.0600
Pertussis / Measles	0.777	0.0750	Inf1	-2.613	0.0445
Flu / Generic	0.759	0.0737	Inf1	-2.836	0.0237
Flu / Measles	0.754	0.0721	Inf1	-2.955	0.0165
Flu / Pertussis	0.970	0.0936	Inf1	-0.315	0.9892

Results are averaged over the levels of: viz

P value adjustment: tukey method for comparing a family of 4 estimates Tests are performed on the log odds ratio scale

> confint(pairs(mvi 1 d, reverse = TRUE)) #Odds ratios

contrast	odds.ratio	SE df	asymp.LCL	asymp.UCL
Measles / Generic	1.008	0.0978 Inf	0.785	1.293
Pertussis / Generic	0.783	0.0766 Inf	0.609	1.007
Pertussis / Measles	0.777	0.0750 Inf	0.606	0.996
Flu / Generic	0.759	0.0737 Inf	0.592	0.974
Flu / Measles	0.754	0.0721 Inf	0.590	0.964
Flu / Pertussis	0.970	0.0936 Inf	0.757	1.243

Results are averaged over the levels of: viz

Confidence level used: 0.95

Conf-level adjustment: tukey method for comparing a family of 4 estimates

Intervals are back-transformed from the log odds ratio scale

#### Model 2: Check for direct effects of factors with adjustment for other covariates

> rlog vi 2 <-

+ glm(vaxintentRel ~ viz \* disease +

```
+ mean indivvertical +
```

```
+ mean collhorz +
```

- + mean collvertical +
- + bornincanada +
- + language 1 +
- + language 2 +
- + Asian group +
- + White\_group +
- + disability any +
- + genderidentity +
- + income +
- + edhi +
- + age,
- + data = datMain,family=binomial("logit")
- + )

```
> Anova(rlog vi 2, type = "III")
```

```
Analysis of Deviance Table (Type III tests)
```

Response: vaxintentRel

LR Chisq Df Pr(>Chisq)

viz	2 693	1	0 100809
V 1 2	2.095	<b>T</b>	0.100000

- disease 15.778 3 0.001259 \*\*
- mean indivhorz 4.261 1 0.039000 \*

mean_indivvertical	6.422	1	0.011274 *
mean_collhorz	46.271	1	1.030e-11 ***
mean_collvertical	0.018	1	0.894372
bornincanada	1.294	1	0.255327
language_1	0.177	1	0.673708
language_2	3.476	1	0.062282 .
Asian_group	1.005	1	0.316029
White_group	0.321	1	0.571114
disability_any	19.727	1	8.935e-06 ***
genderidentity	0.524	1	0.469012
income	42.401	3	3.299e-09 ***
edhi	4.141	1	0.041860 *
age	56.646	1	5.217e-14 ***
viz:disease	1.170	3	0.760313
Signif. codes: 0 `**;	* 0.001	L <b>\</b> *>	*' 0.01 `*' 0.05 `.' 0.1 ` ' 1
<pre>&gt; summary(rlog_vi_2)</pre>			
Call:			
glm(formula = vaxinter	ntRel ~	viz	* disease + mean_indivhorz +
mean_indivvertic	al + me	an_c	ollhorz + mean_collvertical +

bornincanada + language\_1 + language\_2 + Asian\_group + White group +

disability\_any + genderidentity + income + edhi + age, family = binomial("logit"),

data = datMain)

Deviance Residuals:

Min	1Q	Median	ЗQ	Max
-1.8868	-1.1331	0.6937	1.0939	2.1065

#### Coefficients:

	Estimate S	td. Error z	<pre>value Pr(&gt; z )</pre>
(Intercept)	-2.626498	0.311119	-8.442 < 2e-16 ***
viz1	-0.064457	0.039289	-1.641 0.10088
disease1	0.114874	0.065946	1.742 0.08152 .
disease2	0.174135	0.065398	2.663 0.00775 **
disease3	-0.098568	0.066185	-1.489 0.13642
mean_indivhorz	0.070515	0.034187	2.063 0.03915 *
mean_indivvertic	cal -0.06056	64 0.02393	32 -2.531 0.01138 *
mean_collhorz	0.226951	0.033798	6.715 1.88e-11 ***
mean_collvertica	al 0.00431	0.03252	25 0.133 0.89437
bornincanadal	0.066158	0.058170	1.137 0.25541
language_11	-0.034958	0.083058	-0.421 0.67384
language_21	-0.141268	0.075946	-1.860 0.06287 .
Asian_group1	0.088213	0.088028	1.002 0.31630
White_group1	0.041390	0.073103	0.566 0.57126
disability_any1	0.200115	0.045293	4.418 9.95e-06 ***
genderidentity1	0.026611	0.036750	0.724 0.46900
incomel	-0.463243	0.086078	-5.382 7.38e-08 ***

income2	0.082026	0.067168	1.221 (	0.22201
income3	0.011847	0.057075	0.208 (	0.83556
edhi1	-0.080337	0.039490	-2.034	0.04191 *
age	0.018277	0.002451	7.457 8	.83e-14 ***
vizl:diseasel	-0.017027	0.065787	-0.259	0.79577
viz1:disease2	-0.056351	0.065360	-0.862	0.38860
viz1:disease3	0.021626	0.066135	0.327 (	0.74368
Signif. codes:	0 `***' 0.0	)01 `**′ 0.0	)1 `*′ 0.	05 '.' 0.1 ' ' 1
(Dispersion para	ameter for h	oinomial fam	nily take	en to be 1)
Null deviance:	4786.9 on	3453 degre	ees of fr	reedom
Residual deviand	ce: 4529.3	on 3430 de	egrees of	freedom
(429 observati	ons effacée	es parce que	e manquan	ites)
AIC: 4577.3				
Number of Fisher	r Scoring it	erations: 4	1	
> # Interpretati	on of model	2		
> mvi_2_v <- emn	neans(rlog_v	vi_2,~viz,ty	ype = "re	esponse")
NOTE: Results ma	ay be mislea	ading due to	o involve	ement in interactions
> mvi_2_v				
viz	prob SE d	lf asymp.LCI	asymp.U	CL
no visualizatio	on 0.480 0.0	)228 Inf	0.436	0.525
herdimm	0.513 0.02	23 Inf	0.469	0.556
Results are aver	aged over t	the levels o	of: disea	se, bornincanada,

language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

Confidence level used: 0.95 Intervals are back-transformed from the logit scale > plot(mvi 2 v) > confint(pairs(mvi 2 v, reverse = TRUE)) contrast odds.ratio SE df asymp.LCL asymp.UCL herdimm / no visualization 1.14 0.0894 Inf 0.975 1.33 Results are averaged over the levels of: disease, bornincanada, language 1, language 2, Asian group, White group, disability any, genderidentity, income, edhi Confidence level used: 0.95 Intervals are back-transformed from the log odds ratio scale > mvi 2 d <- emmeans(rlog vi 2, ~ disease, type = "response") NOTE: Results may be misleading due to involvement in interactions > mvi 2 d SE df asymp.LCL asymp.UCL disease prob Generic 0.525 0.0259 Inf 0.474 0.576 Measles 0.540 0.0259 Inf 0.489 0.590 Pertussis 0.472 0.0264 Inf 0.421 0.524 0.449 0.0258 Inf 0.399 0.500 Flu Results are averaged over the levels of: viz, bornincanada, language 1, language 2, Asian group, White group, disability any, genderidentity, income, edhi Confidence level used: 0.95 Intervals are back-transformed from the logit scale > plot(mvi 2 d) > confint(pairs(mvi 2 d, reverse = TRUE))

contrast	odds.ratio	SE df	asymp.LCL	asymp.UCL
Measles / Generic	1.061	0.1138 Inf	0.806	1.398
Pertussis / Generic	0.808	0.0875 Inf	0.612	1.067
Pertussis / Measles	0.761	0.0819 Inf	0.578	1.004
Flu / Generic	0.737	0.0787 Inf	0.560	0.969
Flu / Measles	0.694	0.0738 Inf	0.529	0.912
Flu / Pertussis	0.912	0.0976 Inf	0.693	1.201

Results are averaged over the levels of: viz, bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

Confidence level used: 0.95

Conf-level adjustment: tukey method for comparing a family of 4 estimates

Intervals are back-transformed from the log odds ratio scale

> pairs(mvi 2 d,reverse=TRUE,type="response")

contrast	odds.ratio	SE df	null z.ra	atio p.value
Measles / Generic	1.061	0.1138 Inf1	0.553	0.9459
Pertussis / Generic	0.808	0.0875 Inf1	-1.971	0.1992
Pertussis / Measles	0.761	0.0819 Inf1	-2.536	0.0545
Flu / Generic	0.737	0.0787 Inf1	-2.860	0.0220
Flu / Measles	0.694	0.0738 Inf1	-3.433	0.0033
Flu / Pertussis	0.912	0.0976 Inf1	-0.858	0.8263

Results are averaged over the levels of: viz, bornincanada, language\_1, language\_2, Asian\_group, White\_group, disability\_any, genderidentity, income, edhi

P value adjustment: tukey method for comparing a family of 4 estimates

Tests are performed on the log odds ratio scale

# Model 3: Check for moderating effects of individualism & collectivism with adjustment for other covariates

```
> rlog_vi_3 <-</pre>
```

```
+ glm(vaxintentRel ~
```

+ viz \* disease \* mean\_indivhorz +

+ viz \* disease \* mean indivvertical +

+ viz \* disease \* mean collhorz +

+ viz \* disease \* mean collvertical +

```
+ bornincanada +
```

- + language 1 +
- + language 2 +
- + Asian group +
- + White\_group +
- + disability any +
- + genderidentity +
- + income +

```
+ edhi +
```

```
+ age,
```

```
+ data = datMain,family=binomial("logit")
```

+ )

```
> Anova(rlog_vi_3, type = "III")
```

```
Analysis of Deviance Table (Type III tests)
```

```
Response: vaxintentRel
```

#### LR Chisq Df Pr(>Chisq)

viz	0.073	1	0.7867666
disease	4.314	3	0.2294804
mean_indivhorz	4.417	1	0.0355838 *
mean_indivvertical	5.727	1	0.0167020 *
mean_collhorz	44.802	1	2.181e-11 ***
mean_collvertical	0.301	1	0.5830358
bornincanada	0.908	1	0.3405692
language_1	0.059	1	0.8084048
language_2	2.835	1	0.0922474 .
Asian_group	0.916	1	0.3383970
White_group	0.322	1	0.5702079
disability_any	20.025	1	7.643e-06 ***
genderidentity	0.676	1	0.4110133
income	42.826	3	2.680e-09 ***
edhi	4.128	1	0.0421857 *
age	57.220	1	3.897e-14 ***
viz:disease	1.451	3	0.6936517
viz:mean_indivhorz	0.119	1	0.7299379
disease:mean_indivhorz	2.670	3	0.4452902
viz:mean_indivvertical	0.005	1	0.9419263
disease:mean_indivvertical	16.801	3	0.0007764 ***
viz:mean_collhorz	0.939	1	0.3325764
disease:mean_collhorz	2.031	3	0.5659568

```
viz:mean collvertical
                               3.667 1 0.0555092 .
disease:mean collvertical
                                3.033 3 0.3865716
viz:disease:mean indivhorz
                                0.840 3 0.8399763
viz:disease:mean indivvertical 2.481 3 0.4786469
viz:disease:mean collhorz
                                0.129 3 0.9881121
viz:disease:mean collvertical 1.471 3 0.6890145
___
Signif. codes: 0 `***' 0.001 `**' 0.01 `*' 0.05 `.' 0.1 ` ' 1
> summary(rlog vi 3)
Call:
glm(formula = vaxintentRel ~ viz * disease * mean indivhorz +
     viz * disease * mean indivvertical + viz * disease *
mean collhorz +
     viz * disease * mean collvertical + bornincanada + language 1 +
     language 2 + Asian group + White group + disability any +
     qenderidentity + income + edhi + age, family = binomial("logit"),
     data = datMain)
Deviance Residuals:
     Min
               10
                   Median
                                30
                                        Max
-2.0072 -1.1176 0.6401 1.0911 2.2031
Coefficients:
                                Estimate Std. Error z value Pr(>|z|)
                                -2.579532
                                          0.339262 -7.603 2.89e-14
(Intercept)
* * *
                                0.084661 0.312834 0.271 0.78668
viz1
```

diseasel	0.736750	0.523299	1.408 0.15916
disease2	-0.757207	0.565249	-1.340 0.18038
disease3	-0.524349	0.556100	-0.943 0.34573
mean_indivhorz	0.077555	0.036947	2.099 0.03581 *
<pre>mean_indivvertical *</pre>	-0.062966	0.026352	-2.389 0.01688
<pre>mean_collhorz ***</pre>	0.237841	0.036120	6.585 4.56e-11
mean_collvertical	-0.019425	0.035406	-0.549 0.58326
bornincanada1	0.056059	0.058825	0.953 0.34060
language_11	-0.020293	0.083708	-0.242 0.80845
language_21	-0.128395	0.076417	-1.680 0.09292
Asian_group1	0.084929	0.088768	0.957 0.33869
White_group1	0.041991	0.073990	0.568 0.57036
disability_any1 ***	0.203942	0.045822	4.451 8.56e-06
genderidentity1	0.030525	0.037130	0.822 0.41101
incomel ***	-0.469615	0.087148	-5.389 7.10e-08
income2	0.075218	0.067879	1.108 0.26781
income3	0.016099	0.057684	0.279 0.78018
edhil *	-0.081161	0.039957	-2.031 0.04223
age ***	0.018615	0.002484	7.493 6.75e-14
viz1:disease1	-0.184935	0.523603	-0.353 0.72394

viz1:disease2	-0.471708	0.566570	-0.833	0.40509
viz1:disease3	0.597600	0.556309	1.074	0.28272
viz1:mean_indivhorz	0.012505	0.036233	0.345	0.72999
disease1:mean_indivhorz	0.057972	0.063535	0.912	0.36153
disease2:mean_indivhorz	0.037503	0.063299	0.592	0.55354
disease3:mean_indivhorz	-0.007697	0.065240	-0.118	0.90608
viz1:mean_indivvertical	-0.001844	0.025310	-0.073	0.94193
disease1:mean_indivvertical **	-0.124739	0.043899	-2.842	0.00449
disease2:mean_indivvertical	0.015600	0.043446	0.359	0.71954
disease3:mean_indivvertical	-0.044564	0.042916	-1.038	0.29909
viz1:mean_collhorz	0.034582	0.035764	0.967	0.33357
disease1:mean_collhorz	-0.022534	0.062831	-0.359	0.71986
disease2:mean_collhorz	0.077252	0.061773	1.251	0.21109
disease3:mean_collhorz	0.006502	0.061534	0.106	0.91585
viz1:mean_collvertical .	-0.066983	0.035049	-1.911	0.05599
disease1:mean_collvertical	-0.036034	0.063185	-0.570	0.56848
disease2:mean_collvertical	0.005388	0.060436	0.089	0.92896
disease3:mean_collvertical	0.095008	0.060594	1.568	0.11690
viz1:disease1:mean_indivhorz	0.044599	0.063497	0.702	0.48244
viz1:disease2:mean_indivhorz	0.017629	0.063222	0.279	0.78037
viz1:disease3:mean_indivhorz	-0.026671	0.065266	-0.409	0.68279
viz1:disease1:mean_indivvertical	0.014022	0.043861	0.320	0.74919
viz1:disease2:mean_indivvertical	-0.011519	0.043491	-0.265	0.79111

-0.054534	0.042933	-1.270	0.20401
0.003405	0.062885	0.054	0.95682
-0.016792	0.061754	-0.272	0.78569
0.018311	0.061609	0.297	0.76630
-0.038982	0.063198	-0.617	0.53735
0.067116	0.060529	1.109	0.26751
-0.035333	0.060604	-0.583	0.55988
	-0.054534 0.003405 -0.016792 0.018311 -0.038982 0.067116 -0.035333	-0.0545340.0429330.0034050.062885-0.0167920.0617540.0183110.061609-0.0389820.0631980.0671160.060529-0.0353330.060604	-0.0545340.042933-1.2700.0034050.0628850.054-0.0167920.061754-0.2720.0183110.0616090.297-0.0389820.063198-0.6170.0671160.0605291.109-0.0353330.060604-0.583

Signif. codes: 0 `\*\*\*' 0.001 `\*\*' 0.01 `\*' 0.05 `.' 0.1 ` ' 1 (Dispersion parameter for binomial family taken to be 1) Null deviance: 4786.9 on 3453 degrees of freedom Residual deviance: 4491.9 on 3402 degrees of freedom

(429 observations effacées parce que manquantes)

AIC: 4595.9

Number of Fisher Scoring iterations: 4

# Interpretation of model 3

> emmip(rlog\_vi\_3, disease ~ mean\_indivvertical, cov.reduce = range, type = "response")

NOTE: Results may be misleading due to involvement in interactions



### Appendix 6: Outcomes versus Individualism and Collectivism subscales

### **Objective risk perception (risk percep\_1)**

### S1: objective risk perception vs mean horizontal individualism

Objective risk perception vs mean\_indivhorz



### S2: objective risk perception vs mean vertical individualism



### S3: objective risk perception vs mean vertical collectivism



### Objective risk perception vs mean\_collhorz 100 75 disease Objective risk perception • Generic Measles Pertussis Flu + 50 studyarm Control Herdimm 25 0 2 3 5 6 7 8 9 1 4 mean\_collhorz

### S4: objective risk perception vs mean horizontal collectivism

# Subjective risk perception (risk percept\_2 to 6)

### S5: subjective risk perception vs mean horizontal individualism

Subjective risk perception vs mean\_indivhorz



### S6: subjective risk perception vs mean vertical individualism



Subjective risk perception vs mean\_indivvertical





Subjective risk perception vs mean\_collvertical





Subjective risk perception vs mean\_collhorz

# Emotions

### S9: emotions vs mean horizontal individualism

Emotions vs mean\_indivhorz



### S10: emotions vs mean vertical individualism

Emotions vs mean\_indivvertical



### S11: emotions vs mean vertical collectivism





### S12: emotions vs mean horizontal collectivism

# Knowledge

### S13: knowledge vs mean horizontal individualism

Knowledge vs mean\_indivhorz





### S14: knowledge vs mean vertical individualism



### S15: knowledge vs mean vertical collectivism



### S16: knowledge vs mean horizontal collectivism

**Vaccine intentions** 



### S17: vaccine intentions vs mean horizontal individualism

### S18: vaccine intentions vs mean vertical individualism



Vaccine Intentions vs mean\_indivvertical








## Timestamp for *herdimm* versus Individualism and Collectivism subscales (for participants assigned to *herdimm*)

Timestamp = seconds between reaching the page in which participants were directed to the *herdimm* intervention and returning to the page and clicking submit

## S21: Timestamp submitted for *herdimm* versus mean vertical individualism



Media Page Submit Time vs mean\_indivvertical







## S23: Timestamp submitted for *herdimm* versus mean vertical collectivism



## S24: Timestamp submitted for *herdimm* versus mean horizontal collectivism